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Abstract  
Introduction 
The objectives of this thesis are to: (1) examine how ambulatory blood pressure 
monitoring (ABPM) refines office blood pressure (BP) measurement; (2) determine 
if absolute ambulatory BP or dipping status is better associated with target organ 
damage (TOD); (3) explore the association of isolated nocturnal hypertension (INH) 
with TOD; and (4) investigate the association of night-time BP with ultrasound 
markers of cardiovascular damage.  
Methods 
Data from the first screen of the Mitchelstown Cohort Study was analysed to 
examine how ABPM refines office BP measurement and investigate if absolute 
ambulatory BP or dipping status are better associated with left ventricular 
hypertrophy (LVH) documented by electrocardiogram (ECG) Cornell Product 
Voltage and microalbuminuria documented by an albumin:creatinine ratio (ACR)     
≥ 1.1 mg/mmol. A systematic review of the literature was carried out to explore the 
association of INH and TOD. In addition analysis of the baseline data from the 
Mitchelstown Cohort Study examined the association of INH with ECG LVH and 
microalbuminuria. After 3.9 years of follow-up, a sample of the Mitchelstown 
Cohort who underwent ABPM in the initial wave of data collection were invited to 
have an echocardiogram for speckle tracking analysis and carotid ultrasound to 
further investigate the association of night-time systolic BP with subclinical 
cardiovascular disease.  
Results 
Chapter 2 demonstrates that at an individual level ABPM reclassifies approximately 
a quarter of patients with prevalence rates of white coat and masked hypertension 
of 11% and 13% respectively in untreated individuals. Chapter 3 finds night-time 
systolic BP to be better associated with ECG LVH and microalbuminuria than 
daytime systolic BP and dipping level. In multi-variable models each 10 mmHg rise 
in night-time systolic BP increased the odds of TOD - odds ratio (OR) LVH 1.4 (95% 
12 
 
CI 1.1 -1.8) and OR ACR ≥ 1.1 mg/mmol 1.5 (95% CI 1.2 – 1.8). Chapter 4 finds the 
evidence for the association of INH with TOD to be inconclusive. Chapter 6 
demonstrates night-time systolic BP to be significantly associated with global 
longitudinal strain (GLS) (beta coefficient 0.85 for every 10 mmHg rise, 95% CI 0.3 – 
1.4) and carotid plaques (OR 1.9 for every 10 mmHg rise, 95% CI 1.1 – 3.2) in 
univariable models. The findings persist for GLS in sex and age adjusted analysis but 
are attenuated in fully adjusted models.   
Discussion 
Hypertension cannot be effectively managed at the individual level without using 
ABPM. Using ABPM to examine the full twenty four hour BP profile is the way 
forward in guiding hypertension treatment decisions. The absolute night-time 
systolic BP seems to be better associated with TOD than the daytime systolic BP 
and dipping level and may be a better therapeutic target in future studies. However 
the results of large prospective studies are necessary before chronotherapy can be 
adopted into guidelines and routine clinical practice.   
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1. Introduction 
1.1. Hypertension 
“The great importance of arterial hypertension or the conditions associated with it, 
as a widespread and apparently increasing cause of disability and death, is a self-
evident incentive to investigation. At the same time it must be recognized that our 
knowledge of the subject is in a very confused state, as respects its phases of 
etiology, mechanism and treatment”. (1) This quotation from the Journal of the 
American Medical Association in 1920 demonstrates the challenges that 
hypertension posed to physicians at the time. Even today in the era of evidence 
based medicine many of these same challenges still exist. 
Hypertension can be defined as the level of blood pressure at which investigation 
and treatment do more benefit than harm. (2) Most guidelines use a systolic 
threshold of 140 mmHg and a diastolic threshold of 90 mmHg as this level. (3-5) 
However blood pressure is a continuous risk factor (6) and one half of the disability 
adjusted life-years (DALYs) burden attributable to blood pressure occur below the 
140/90 mmHg threshold. (7) 
In 1961 the Framingham investigators reported on the association of hypertension 
and other risk factors with the development of coronary heart disease. (8) Today 
hypertension is one of the leading risk factors for cardiovascular mortality. In 2009 
the World Health Organisation estimated that raised blood pressure caused 51% of 
stroke deaths and 45% of coronary heart disease deaths worldwide. (9) Globally 
reducing hypertension prevalence would account for the greatest risk reduction in 
cardiovascular mortality by 2025. (10) However, control rates remain low nationally 
and internationally. (11, 12)  
1.2. Blood pressure measurement 
Traditionally blood pressure is measured in the clinical setting by a trained 
professional and a diagnosis of hypertension is made based on this office blood 
pressure. Guidelines recommend measurements should be made using 
standardised methods with the patient in a seated position for 3 to 5 minutes 
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before beginning. At least 2 measurements should be made 1 to 2 minutes apart 
with additional measurements if the first two are very different. In addition a 
diagnosis of hypertension should be made based on at least 2 visits with at least 2 
measurements per visit. (4)  
Out of office measurement allows blood pressure to be measured away from the 
clinical setting. This can be achieved either through home blood pressure 
monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM). For HBPM 
the patient should carry out their own blood pressure measurements over 7 days. A 
validated upper arm device with an appropriate cuff size should be used. Two 
morning and 2 evening readings should be taken 1-2 minutes apart with the patient 
sitting in a quiet room with their back and arm supported after 5 minutes of rest. 
With the exception of the first day all of the values should be averaged. (13)  
ABPM measures blood pressure at 15 to 30 minute intervals over a 24 or 48 hour 
period and so provides information on blood pressure during activity and sleep. 
Rather than a single measurement ABPM more accurately reflects true blood 
pressure as it gives a blood pressure profile over a prolonged period. ABPM was 
first introduced in the 1960s. (14-16) The prognostic relevance of ambulatory blood 
pressure began to be recognised in the 1980s. (17) Subsequent studies 
demonstrated ambulatory blood pressure to be better than office blood pressure at 
predicting cardiovascular mortality. (18-20) The use of ABPM has gained steady 
momentum in recent years. It allows identification of white coat and masked 
hypertension. White coat hypertension is the condition in which blood pressure is 
elevated in the office and normal when measured out of the office. Masked 
hypertension is the situation whereby blood pressure is normal in the office but 
elevated when measured out of the office. The early morning surge can be 
examined. The presence of nocturnal hypertension and information on nocturnal 
dipping can also be gleaned. In addition episodes of hypotension may be identified. 
Thresholds for hypertension based on HBPM and ABPM are lower than the office 
blood pressure threshold. Table 1.1. 
15 
 
A systematic review and meta-analysis on the relative effectiveness of office blood 
pressure measurements and HBPM compared to ABPM concluded that treatment 
decisions based on office or HBPM alone might result in over-diagnosis of 
hypertension. (21) A subsequent modelling study examining cost-effectiveness 
found that ABPM would reduce misdiagnosis and save costs from better targeted 
treatment if used to confirm the diagnosis of hypertension in primary care. (22) In 
2011, the National Institute for Health and Care Excellence in the United Kingdom 
(UK) recommended the use of ABPM if the office blood pressure is 140/90 or higher 
to confirm the diagnosis of hypertension. (3) Recently the United States Preventive 
Services Task Force made a similar recommendation. (23) The 2013 European 
Society of Hypertension/European Society of Cardiology guidelines for arterial 
hypertension state that office blood pressure remains the ‘’gold standard’ but out-
of-office blood pressure measurement should be considered in cases of suspected 
white coat or masked hypertension, in cases of considerable office blood pressure 
variability, to detect hypotensive episodes or resistant hypertension and to assess 
nocturnal blood pressure. (4)  
There are a number of methodological considerations for ABPM. An independently 
validated device and appropriately sized cuff should be used. (24) The device is 
usually worn on the non-dominant arm. The patient should be instructed to engage 
in normal activity and to stop moving and talking and keep the arm straight at the 
level of the heart when the cuff inflates. (4) Inaccuracies can arise in those with 
atrial fibrillation as automated devices can lead to overestimates of the diastolic 
blood pressure in these patients. (25) A software programme that processes the 
raw data and produces a standardised report appropriate for the intended clinical 
or research use is also necessary.  
Table 1.1. Thresholds for hypertension by office and out-of-office blood pressure 
measurements 
Blood Pressure  Systolic (mmHg) Diastolic (mmHg) 
Office  140 90 
Home  135 85 
24 hour  130 80 
Daytime  135 85 
Night-time  120 70 
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1.3. Nocturnal blood pressure  
ABPM allows measurement of blood pressure throughout the 24 hour period. Blood 
pressure has a circadian or diurnal rhythm that varies over a 24 hour period which 
was described in the 1970s. (26) There are generally 2 peaks of blood pressure 
during the day, one shortly after we awaken and the second in the late afternoon or 
early evening. (27) Blood pressure generally falls at night and reaches its lowest 
point from 3am to 6am or 1 to 3 hours before we awaken. (28)  
Defining the night-time blood pressure window can be done using fixed clock 
intervals or patient diaries. Research using actigraphy to document sleep/activity 
cycles has shown that either approach is reasonable. (29) For fixed clock intervals 
large or narrow intervals can be chosen. For large fixed clock intervals no interval is 
used between day and night. For narrow fixed clock intervals periods between day 
and night are excluded as they are subject to inter patient variations in activity and 
retiring time. (30) For example the period from 1 am to 6 am is used as the night-
time window as this is the time that most people will be asleep or at least cease 
activity and the period from 9 am to 9 pm is taken as the daytime window. (24) 
Patients may also provide diaries of the time they go to bed and get up at and these 
times can be used to define day and night.  
The prognostic importance of the circadian blood pressure profile was recognised in 
1988 when the concept of dippers and non-dippers was introduced after non-
dipping hypertensive patients were found to have a higher risk of stroke compared 
to dippers. (31) Dipping is defined as a 10-20% fall in night-time blood pressure 
relative to daytime blood pressure while non-dipping is defined as less than 10% fall 
in night-time blood pressure. In addition extreme dippers are defined as those with 
a night-time drop of greater than 20% and reverse dippers as those with a night-
time blood pressure that rises relative to daytime blood pressure. (32)  
Nocturnal hypertension is defined as elevated night-time blood pressure ≥120/70 
mmHg. It has been found to be more reproducible than dipping status and 
therefore some have advocated its use to assess the effect of antihypertensive 
therapy at night. (33) One study found a higher prevalence of cardiovascular risk 
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factors and target organ damage in those with both non-dipping and nocturnal 
hypertension compared to those with either profile alone or a normal profile. (34)  
Isolated nocturnal hypertension was described in 2007 and is defined as elevated 
night-time blood pressure in the presence of normal daytime blood pressure i.e. 
night-time blood pressure of ≥120/70 mmHg with daytime blood pressure of 
<135/85 mmHg. (35) Those with isolated nocturnal hypertension have been found 
to have a higher risk of mortality and cardiovascular events compared to 
normotensive individuals. (36) Those with sustained day-night hypertension had the 
greatest risk but those with isolated daytime and nocturnal hypertension had 
overall similar rates of events.  
1.4. The prognostic importance of nocturnal blood pressure 
Following the initial description of dipping and non-dipping in 1988 further data on 
clinical events associated with dipping status followed. In 1997 Ohkubo et al found 
higher mortality in reverse dippers and non-dippers in a rural Japanese community 
sample. Findings persisted even after adjustment for absolute blood pressure 
levels. Kario et al found stroke rates to be higher in extreme dippers and reverse 
dippers in an older hypertensive sample in 2001. Total mortality and cardiovascular 
mortality was higher in reverse dippers. However this was attenuated after 
adjusting for the 24 hour blood pressure level. (37) Clement et al found 
contradictory findings in 2003 regarding dipping status, while absolute ambulatory 
blood pressures were independent risk factors for new cardiovascular events the 
night-day blood pressure ratio was not found to be an independent risk factor in 
1963 treated hypertensive patients followed up for 5 years. (18)  
Subsequent studies began to focus on the superiority of absolute ambulatory blood 
pressure levels over office blood pressure levels as well as dipping status. In 2004 
Nakano and colleagues found that ambulatory blood pressure levels rather than 
dipping status better predicted fatal and non-fatal vascular events in a longitudinal 
analysis of type 2 diabetic subjects, in particular night-time systolic blood pressure 
was found to be an independent predictor of nonfatal vascular events in an 
adjusted cox proportional hazards model. (38) In 2005 the Dublin Outcome Study 
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demonstrated ambulatory blood pressure to be superior to office blood pressure 
for the prediction of cardiovascular mortality and significantly night-time blood 
pressure was better than daytime blood pressure as a predictor of outcomes in 
5292 untreated hypertensive patients. (19) Hansen et al found similar results in a 
population study in Denmark in 2006 examining cardiovascular mortality, ischaemic 
heart disease and stroke. They also found a blunted fall in night-time blood 
pressure to be a risk factor in those with daytime ambulatory hypertension but not 
in those with daytime ambulatory normotension. (39) In 2007 Ben-Dov et al 
specifically focused on sleep blood pressure and all-cause mortality in an ABPM 
service database. (40) They found sleep blood pressure to have independent and 
greater predictive power than awake blood pressure. Dipping status also 
significantly predicted mortality in adjusted models with reverse dippers having the 
highest risk followed by non-dippers. In addition, compared to dipper 
normotensives, dipper awake hypertensives, non-dipper awake normotensives and 
nondipper awake hypertensives were found to have increasing risk in that order.  
Boggia et al carried out an analysis of the International Database of Ambulatory 
Blood Pressure in relation to Cardiovascular Outcomes (IDACO) database consisting 
of population studies from Denmark, Belgium, Sweden, Japan, China and Uruguay. 
They found systolic and diastolic night-time blood pressures to be a significant 
predictor of total, cardiovascular and non-cardiovascular fatal and non-fatal events 
although significance was lost for coronary events in fully adjusted models. On the 
other hand while night-to-day ratios were predictive of fatal events they were not 
consistent predictors of combined fatal and non-fatal events. (41) Brotman et al 
focused on dipping and non-dipping in 2008 and found higher mortality rate with 
blunted nocturnal blood pressure decline in patients referred for ABPM although 
this effect was attenuated when comorbid conditions were also considered. (42) 
Muxfelt et al found non-dipping to be an independent risk factor for cardiovascular 
mortality in patients with resistant hypertension attending an outpatient hospital 
clinic. (43) Fagard et al carried out a meta-analysis on 3468 patients from 4 
prospective studies in Europe in 2008 and found daytime ambulatory blood 
pressure did not add to the prognostic power of night-time ambulatory blood 
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pressure. (44) Hansen et al carried out a comprehensive meta-analysis in 2011 and 
confirmed the prognostic importance of night-time over daytime blood pressure. 
(45) They included studies of hypertensive patients and population studies with 
mortality or composite cardiovascular endpoints and examined absolute blood 
pressure and dipping status. The results of 2 further systematic reviews concluded 
the absolute night-time blood pressure to be better than dipping status in 
predicting cardiovascular and renal outcomes. (46, 47) Of note these reviews 
included studies of intermediate and clinical endpoints.  A very recent meta-
analysis including 10 cohorts with 17312 hypertensive patients examined the 
prognostic importance of dipping status analysed as a continuous and categorical 
variable. (48) The authors found the continuous systolic night-to-day ratio to be an 
independent predictor of clinical outcomes when adjusted for twenty four hour 
blood pressure. However the hazard ratios per 1 standard deviation rise were lower 
than those for the twenty four hour blood pressure level. 
Night-time blood pressure appears to be of particular prognostic importance in 
both hypertensive and population cohorts. (45) The mechanisms behind this are 
not clear, nor is it clear that normalising night-time blood pressure improves 
prognosis. However there have been some promising intervention studies involving 
chronotherapy, the administration of anti-hypertensive medications in the evening 
to reduce night-time blood pressure. In the MAPEC (Monitorización Ambulatoria 
para Predicción de Eventos Cardiovasculares, ie, Ambulatory Blood Pressure 
Monitoring for Prediction of Cardiovascular Events) study patients were 
randomised to take all of their anti-hypertensive medications on wakening in the 
morning or at least 1 of them at bedtime. After a median follow-up period of 5.6 
years the decrease in nocturnal blood pressure was associated with a reduced risk 
of total cardiovascular events even when it was included in the same model as the 
decrease in daytime blood pressure. Similarly patients with chronic kidney disease 
who ingested at least one anti-hypertensive medication at night had lower hazard 
ratio of total cardiovascular events than those taking all of their medications in the 
morning.  (49, 50)  
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The evidence is clear that night-time blood pressure is of greater prognostic 
importance than daytime blood pressure. However there is some conflicting data 
on which nocturnal blood pressure profile is most important. Also there have been 
relatively few interventional studies aimed at normalising abnormal nocturnal 
blood pressure profiles and while these have been promising reverse causality 
remains a possibility. Abnormal nocturnal blood pressure may be a marker rather 
than a cause of cardiovascular events.  
1.5. The cardiovascular disease continuum 
Despite improvements in outcomes in some higher and middle income countries 
cardiovascular disease remains a leading cause of death worldwide. (51) 
Cardiovascular disease develops as a continuum with risk factors leading to tissue 
damage which results in organ damage which eventually results in clinical events. 
(52-54) Asymptomatic organ damage is therefore an intermediate stage on this 
continuum. The mechanisms involved are numerous, overlap and may not occur in 
sequence. They include oxidative stress, endothelial dysfunction, inflammation and 
tissue remodelling. (53) Hypertension leads to damage throughout the 
cardiovascular system. Imaging and laboratory techniques have allowed us to 
document intermediate stages of damage in various organs. (4) This information on 
organ damage can be used to guide prevention strategies. (55) These intermediate 
stages of organ damage are considered surrogate markers. Surrogate markers are 
measurements that predict clinical events and ideally should be on the causal 
pathway. (56) Information on surrogate markers can be gathered in a shorter 
timeframe and at less expense than clinical outcomes making their use appealing 
but they are not without controversy. Measurement error or unmeasured 
confounding affecting the association between the outcome and the surrogate 
always need to be considered. (57)  
1.6. Target organ damage 
Target organ damage refers to damage of the vascular system or of organs supplied 
by the vascular system such as the heart, kidneys, brain or eyes. A number of 
different techniques that document organ damage will be considered in this thesis. 
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Some, such as the electrocardiogram and microalbuminuria, are considered routine 
in the evaluation of patients with hypertension. Others such as pulse wave velocity, 
echocardiography and carotid ultrasound are recommended based on history, 
physical examination and routine investigations. (4) All provide important 
prognostic information. 
1.6.1. Electrocardiography 
Sokolow and Lyon first proposed electrocardiogram (ECG) voltage criteria for left 
ventricular hypertrophy (LVH) in 1949. (58) In 1970 analysis from the Framingham 
Study highlighted the association of ECG LVH with coronary artery disease and 
death. (59) ECG LVH is now a recognised independent predictor of prognosis. (59, 
60) There are many criteria for ECG LVH. (61) Generally sensitivity is low with good 
specificity but this varies according to the criterion selected. Adding QRS duration 
to QRS voltage does improve sensitivity but this is still generally less than 50%. (62) 
New imaging modalities including echocardiography and magnetic resonance 
imaging allow for more accurate assessment of LVH. However an ECG can cheaply 
be carried out in most clinical settings and therefore has retained a role in the 
assessment of those with hypertension. (4) 
1.6.2. Microalbuminuria 
The detection of albumin in the urine is associated with increased cardiovascular 
risk. (63) It is accepted as a surrogate marker for renal endpoints. (64) Albuminuria 
reflects damage to the glomerular filtration barrier and may reflect generalised 
damage throughout the vascular tree. (65) Endothelial dysfunction may be the 
pathophysiology behind this. (66) Albumin excretion can be measured by 24 hour 
collection, urine dipstick or a spot urine sample for albumin:creatinine ratio. 
Albuminuria is a continuous risk factor and while thresholds of normality are used 
in clinical practice cardiovascular mortality increases at levels considered within 
these normal ranges. (63, 67)  
1.6.3. Arterial stiffness 
Arterial stiffness is the resistance of a vessel to deformation and is one of the 
earliest detectable abnormalities of the vasculature. (68) Pulse wave velocity is 
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considered the gold standard measurement of arterial stiffness. (69) It is 
determined by measuring the transit time of a pulse wave between 2 sites along 
the vascular tree. The stiffer the vessel the faster the pulse wave is transmitted. 
(68)  
Applanation tonometry is another technique which allows non-invasive derivation 
of the central blood pressure waveform. This is usually employed at the radial 
artery. The central waveform is made up of a forward propagating wave and a 
reflected wave from branching points more distally in the vascular tree. Analysis of 
the waveform derived from applanation tonometry allows quantification of the 
augmentation of the central blood pressure by reflected waves i.e. the amount of 
pressure added to the systolic pressure by reflected waves or the augmented 
pressure. The ratio of the augmentation pressure to central pulse pressure is known 
as the augmentation index. (70) Stiffer vessels reflect waves faster and result in a 
higher augmentation index. 
The ambulatory arterial stiffness index (AASI) is a surrogate measurement of 
arterial stiffness derived from ABPM. It is derived by subtracting the regression 
slope of diastolic and systolic blood pressure from 1 (1 minus the slope of diastolic 
on systolic pressure). (71)  
A meta-analysis of 17 longitudinal studies found increased arterial stiffness 
measured by pulse wave velocity to be associated with increased risk of 
cardiovascular and all-cause mortality. (72) Similarly a meta-analysis found the 
augmentation index to be associated with cardiovascular events and all-cause 
mortality. Central systolic blood pressure and central pulse pressure were 
associated with total cardiovascular events in the same study. (73) Dolan et al 
found the AASI to be associated with cardiovascular mortality and stroke mortality 
in hypertensive patients in the Dublin Outcome Study. (74) 
1.6.4. Echocardiography 
Hypertensive heart disease is characterized by cardiac hypertrophy in response to 
increased cardiac afterload. This results in systolic and diastolic dysfunction as well 
as other structural abnormalities. These structural abnormalities progress to 
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manifest clinically as arrhythmias and symptomatic heart failure. (75) Two-
dimensional (2D) echocardiography can demonstrate many of the effects of 
hypertension on cardiac function and structure.  
Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) is an increase in left ventricular (LV) mass. It is 
recognised as an independent predictor of morbidity and mortality. (76-78) In 
addition regression of LVH has been shown to be associated with a reduced 
incidence of cardiovascular disease. (79) The prevalence of LVH in hypertensive 
patients ranges from 36-41%. (77) Methods to measure LV mass using 
echocardiography include Devereux’s Formula (76) and the Area Length Method. 
(77) LV mass should be indexed to allow comparisons between people of different 
body size and most large population studies have done this to body surface area. 
(80) 
Diastolic dysfunction 
Hypertension may lead to diastolic dysfunction which can occur in the presence or 
absence of LVH. Diastolic dysfunction leads to elevated LV filling pressures. (81) 
There is no single measure of diastolic dysfunction. The different techniques need 
to be considered together to make an overall integrated assessment.  Diastolic 
dysfunction is classified into stages using the various echocardiographic 
parameters:  
Stage I - Impaired relaxation 
Stage II - Pseudo-normalisation 
Stage III - Restrictive which can be reversible or fixed 
Pulsed-wave doppler assessment of transmitral flow with the sample volume at the 
mitral valve tips forms the basis of assessment. From this, peak early diastolic filling 
velocity (E) and peak late diastolic filling velocity (A), can be obtained as well as E:A 
ratio. Other important information available from this technique is the E wave 
deceleration time. (82) E wave deceleration time reflects LV compliance. It 
increases in early diastolic dysfunction. However, as diastolic dysfunction 
progresses filling pressures rise and there is a decrease in the deceleration time.  
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Isovolumetric relaxation time (IVRT) is the time from closure of the aortic valve to 
opening of the mitral valve. It is measured from a modified apical 4 chamber view 
which includes the outflow tract and aortic valve. A pulsed-wave doppler signal that 
simultaneously demonstrates aortic outflow and mitral inflow should be obtained. 
IVRT is the time interval between the two signals. It is prolonged in early diastolic 
dysfunction but like the E wave deceleration time becomes shorter as disease 
progresses. 
The myocardium moves as the ventricle fills in diastole and this can be recorded by 
tissue doppler imaging (TDI). The myocardial diastolic motion pattern is similar to 
that of mitral inflow but lower in velocity and in the opposite direction. TDI is 
carried out with the sample volume at the ventricular basal wall at or within 1 cm of 
the mitral valve leaflet insertion point. Signals are recorded from lateral and septal 
walls. This allows assessment of peak early diastolic myocardial velocity (e’) and 
peak late diastolic myocardial velocity (a’). The E/e’ ratio can then also be 
calculated which allows an estimation of left atrial (LA) filling pressure to be made. 
(83) 
Pulsed-wave doppler interrogation of pulmonary venous flow allows assessment of 
LA filling. This should be looked at in conjunction with the other parameters of 
diastolic function. Peak systolic pulmonary vein flow velocity (S), peak diastolic 
pulmonary vein flow velocity (D), peak pulmonary vein atrial reversal (AR) velocity 
and AR duration (ARdur) can be obtained. 
The assessment of diastolic dysfunction involves an integrated approach taking into 
consideration each of the individual parameters. Figure 1.1. The volume status of 
the patient needs to be considered as it influences findings. Heart rate and rhythm 
also have an impact. It is normal to see some degree of diastolic dysfunction in 
older patients so age is also important. A valsalva manoeuvre should be used in 
order to distinguish the different stages. 
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Figure 1.1. Stages of diastolic dysfunction. Redfield MM, Jacobsen SJ, Burnett, Jr JC, 
Mahoney DW, Bailey KR, et al. JAMA 2003. Reproduced with permission. (84) 
Left atrial size 
As LV pressure rises so too will LA pressure to maintain diastolic filling of the LV. 
This increases LA wall tension and leads to chamber dilatation. LA size can therefore 
be considered a chronic reflection of filling pressures. LA size can be measured by 
diameter from the parasternal long axis view or alternatively by area or volume 
from apical views.  However, indexed LA volume has been demonstrated to be a 
more sensitive marker of future cardiovascular events than LA diameter or area. 
(85) LA volume has also been shown to be a marker for diastolic dysfunction 
severity. (86) LA enlargement was correlated to blood pressure in the Framingham 
Heart study. (87) LA volume has been shown to be increased even in those with 
mild hypertension. (88) LA size is also of clinical relevance with respect to atrial 
fibrillation and stroke risk. 
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Myocardial strain  
Strain is a measure of myocardial deformation, or contraction and relaxation, 
usually expressed as a percentage with negative values representing myocardial 
shortening. Myocardial contraction occurs in three dimensions longitudinal, radial 
and circumferential (Figure 1.2). (89) Longitudinal strain is measured from apical 
views while radial and circumferential strain is measured from short axis views of 
the LV.  
 
Figure 1.2. Myocardial strain dimensions. Blessberger H, Binder T. Non-invasive 
imaging: Two dimensional speckle tracking echocardiography: basic principles. 
Heart 2010. Reproduced with permission. (89) 
TDI was initially used to assess strain. (90) However TDI is angle dependent. Speckle 
tracking echocardiography is a means of assessing myocardial function which is 
largely angle independent and can be done offline after image acquisition. The 
myocardium scatters the sound waves which generate speckles specific for an area 
of myocardium. Blocks of speckles or kernels can be tracked from frame to frame 
using specialised software and provide information on myocardial displacement. 
Parameters of myocardial function such as strain and strain rate can be derived. 
(91) Global longitudinal strain (GLS) is a measure of the myocardial systolic 
deformation over the longitudinal axis. (90) GLS seems to be more reproducible 
than radial or circumferential strain. (92) 
Speckle tracking echocardiography allows the detection of subtle myocardial 
dysfunction and may be an appropriate tool to assess subclinical cardiac 
dysfunction. Abnormal GLS is associated with cardiovascular risk factors such as 
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type II diabetes mellitus (93) and hypertension. (94) Reduced GLS is associated with 
abnormal left ventricular geometry in hypertensive patients. (95) Anti-hypertensive 
therapy has been shown to be associated with improvements in strain. (96) 
Cumulative blood pressure exposure over 25 years in the CARDIA (Coronary Risk 
Development in Young Adults) study was associated with subclinical systolic and 
diastolic dysfunction assessed by speckle tracking echocardiography in middle age. 
(97)  
Few researchers have addressed the association of night-time blood pressure with 
left ventricular GLS. Seo et al demonstrated reduced strain measured by TDI in non-
dippers compared to dippers in 2006. (98) More recently Kalaycioglu et al used 
speckle tracking echocardiography to demonstrate a significant reduction in GLS in 
non-dippers compared to dippers in treated hypertensive diabetic patients. They 
also found night-time systolic blood pressure to be independently associated with 
GLS and global longitudinal strain rate (GLSR). (99) Tadic et al similarly 
demonstrated GLS to be significantly lower in non-dippers compared to dippers in 
untreated hypertensive patients. (100) 
Data is also emerging on the prognostic importance of strain. In 2009 Stanton et al 
found GLS to be a better predictor of mortality than ejection fraction or wall motion 
score in subjects undergoing clinically indicated echocardiography. (101) Russo et al 
found impaired GLS in a community sample with normal ejection fraction in 16.1% 
of a community based sample of middle aged adults. Abnormal GLS was a 
significant independent predictor of a combined endpoint of ischaemic stroke, 
myocardial infarction and vascular death. (102) GLS has been found to predict 
mortality in end stage renal disease in African-American patients on dialysis in a 
small study. (103)  
1.6.5. Carotid intima media thickness 
Arteries are composed of 3 layers. The outer layer or the adventitia is made up of 
connective tissue, the middle layer or media is composed of smooth muscle fibres 
and elastic tissue and the inner intima is made up of a thin layer of endothelium 
overlying an elastic membrane.  
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The arterial tree consists of elastic arteries, muscular arteries and arterioles. Elastic 
arteries are the conducting vessels and serve as a pressure reservoir. They contain a 
large amount of collagen and elastin in the media. Muscular arteries are distributing 
vessels. They contain a large amount of smooth muscle in the media and can dilate 
or constrict. Arterioles are the smallest arteries and are composed almost entirely 
of smooth muscle cells. (104)  
The carotid artery is an elastic artery. The thickness of the intima and media layer of 
the carotid artery wall or carotid intima media thickness (CIMT) can be measured by 
B mode ultrasound. This is usually visible as a double line which is traced over a 
length of 1 cm and average thickness can be calculated by automated software. 
Figure 1.3. 
 
Figure 1.3. Carotid intima-media thickness tracing at distal 1 cm of common carotid 
artery 
Carotid Intima- Media Thickness (CIMT) is recognised to be associated with 
cardiovascular risk factors and is associated with the incidence of myocardial 
infarction and stroke. (105, 106) There is evidence for the validity of CIMT as a 
suitable surrogate measure of atherosclerotic disease. (107, 108) In addition CIMT 
has been shown to have an additional role beyond traditional risk factors in risk-
stratifying patients. (109-111) However there is conflicting data with an earlier 
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meta-analysis corroborating CIMT as a strong predictor of cardiovascular events 
(112) and a more recent one concluding that while adding common carotid IMT to 
traditional tools does improve risk prediction the overall impact is small and is 
unlikely to be clinically important.  (113) The presence of plaques is important as 
they improve predictive performance (111, 114, 115), and a meta-analysis has 
confirmed that plaques perform better than CIMT in predicting future coronary 
events. (116) Anti-hypertensive therapy slows the rate of progression of CIMT. (117, 
118) Similarly statin therapy has been shown to reduce the progression of 
maximum CIMT. (119) 
There are difficulties when trying to interpret previous work on CIMT. Different 
studies have focused on different segments of the carotid system and used 
different reference points to differentiate these segments. (120) The distal segment 
of the common carotid segment is easier to image than the internal carotid artery. 
(121) Some studies have examined maximum CIMT (105) while others have taken 
mean measurements. (111) Some investigators have included the presence of 
plaques in their analysis while others have not. Plaques are more likely to form in 
the bifurcation segment where there is turbulent flow while CIMT is more likely to 
increase in areas of laminar flow such as the distal common carotid segment. CIMT 
increases as we age. This occurs even in the absence of atherosclerosis. Therefore 
increased CIMT does not necessarily mean atherosclerosis. (122) CIMT is most 
strongly associated with hypertension and plaque area is most strongly associated 
with smoking and cholesterol while plaque volume is most strongly associated with 
diabetes. CIMT may reflect hypertrophy of the vessel wall while plaques represent 
more advanced atherosclerosis. (123)  
1.7. Nocturnal blood pressure and target organ damage 
Many studies have evaluated the association of non-dipping with target organ 
damage and found positive associations. (124-129) Fewer studies have assessed the 
association of the absolute night-time blood pressure with subclinical target organ 
damage relative to dipping status. In 2007 Perez-Loret et al proposed the definition 
of nocturnal hypertension by a cut-off of 120/70 mmHg was better than dipping 
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status as a predictor of LVH documented by echocardiography in a cross-sectional 
study of consecutively referred out-patients. (130) In another cross-sectional study 
Leitao et al assessed the association of albumin excretion, LV mass and retinopathy 
with ambulatory blood pressure patterns in diabetic outpatients. They found 
systolic blood pressure means rather than dipping status to be better associated 
with albumin excretion and LV mass. Absolute night-time blood pressures were 
important as independent predictors of diabetic retinopathy in adjusted models as 
was diastolic non-dipping but not systolic non-dipping. (131) Cuspidi and colleagues 
have examined target organ damage in those with persistent nocturnal 
hypertension and persistent non-dipping  in further cross-sectional analyses. They 
concluded that both patterns can occur independently of each other and that 
target organ damage is more prevalent in those with nocturnal hypertension 
despite more than 50% being dippers (132) while they found no significant 
difference in target organ damage documented by echocardiography, carotid 
ultrasound and urinary albumin excretion between dippers and non-dippers. (133) 
In addition in a longitudinal analysis of the PAMELA (Pressioni Arteriose Monitorate 
E Loro Associazioni) population study absolute night-time blood pressure level 
rather than non-dipping was a better predictor of new LVH on echocardiography 
after 10 years of follow-up. (134) Wang et al found Chinese patients with nocturnal 
hypertension and chronic kidney disease had lower estimated glomerular filtration 
rate (eGFR), higher left ventricular mass index (LVMI) and higher CIMT compared to 
those with nocturnal normotension while dippers and non-dippers had similar 
levels of eGFR, LVMI and CIMT at comparable levels of night-time blood pressure in 
a further cross-sectional analysis. (135) Yi et al found nocturnal systolic blood 
pressure levels >127 mmHg rather than non-dipping predicted LVH in adjusted 
analyses although the effect size was small. (136) Koroboki et al found nocturnal 
hypertension rather than dipping status to be an independent risk factor for higher 
LVMI. (137) Recently Androulakis et al found increased arterial stiffness, CIMT and 
LV mass in those with nocturnal hypertension compared to normotension while 
non-dipping was found to be associated with differences in arterial stiffness and 
creatinine clearance. (138)  
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De La Sierra et al have examined differences in cardiovascular risk profile in those 
with nocturnal hypertension and non-dipping and found having both profiles was 
associated with the highest prevalence of risk factors and previous events. Those 
with neither were at lowest risk while those with either pattern were intermediate 
risk. They suggest that non-dipping may be a more advanced marker of vascular 
damage. (34) 
The literature suggests that ABPM provides more accurate measurement of blood 
pressure and that night-time blood pressure has greater prognostic importance 
than daytime blood pressure. Abnormal nocturnal blood pressure profiles also 
seem to be associated with greater subclinical target organ damage, but there is 
some conflicting data about which nocturnal profile is most important. This is 
important to elucidate so the most appropriate target of future therapeutic trials 
can be established. 
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1.8. Research aim and objectives 
The overall aim of this thesis is to investigate how using ABPM refines blood 
pressure measurement and to further explore the association of nocturnal blood 
pressure and target organ damage.  
 
In particular the objectives are: 
1. To examine how using ABPM refines office blood pressure measurement at an 
individual and population level (Chapter 2) 
2. To determine if absolute ambulatory blood pressure or dipping status is better 
associated with target organ damage (Chapter 3) 
3. To explore the association of isolated nocturnal hypertension and target organ 
damage (Chapter 4) 
4. To investigate the association of night-time blood pressure with ultrasound 
markers of cardiac and vascular damage (Chapter 5 and 6)
 
1.9. Theoretical framework   
Evidence supports the cardiovascular disease continuum with risk factors resulting 
in organ damage, which eventually leads to clinical events. (52-54) This thesis 
explores the association of blood pressure with target organ damage and so the 
cardiovascular disease continuum is the main theory behind this work. Figure 1.4.              
                                                                                                                 
                                                                                                                                                    
 
 
 
 
 
 
 
 
•  
 
Risk Factor Clinical Disease 
Subclinical target 
organ damage 
 
Figure 1.4. The cardiovascular disease continuum   
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1.10. Conceptual framework 
As already discussed ambulatory blood pressure, and nocturnal blood pressure in 
particular, have greater prognostic significance than office blood pressure. It is not 
well understood why nocturnal blood pressure should have greater prognostic 
significance. Exploring the association of nocturnal blood pressure with target organ 
damage may explain where nocturnal blood pressure sits on the cardiovascular 
disease continuum and why it has greater prognostic significance. This is the central 
concept behind this thesis. The questions that will be investigated are outlined in 
figures 1.5 and 1.6. 
 
 
 
 
 
 
 
 
 
Blood Pressure 
 
 
 
 
How does ambulatory blood 
pressure monitoring refine office 
blood pressure measurement?   
Chapter 2 
Target Organ Damage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is ambulatory blood pressure or 
dipping status better associated with 
subclinical target organ damage? 
Chapter 3 
What is the association of isolated 
nocturnal hypertension with 
subclinical target organ damage? 
Chapter 4 
What is the association of night-time 
systolic blood pressure with 
ultrasound markers of subclinical 
target organ damage? Chapter 5 and 
6 
Importance of nocturnal blood 
pressure 
Is night-time systolic blood pressure 
or daytime systolic blood pressure 
better associated with subclinical 
target organ damage? Chapter 3 
Figure 1.5. Conceptual Framework 
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2.1. Abstract 
Introduction 
Accurate measurement of blood pressure (BP) is essential for diagnosis and 
management of hypertension. The aim of this paper is to examine the prevalence, 
awareness, treatment and control rates of hypertension in a community based 
sample and to examine the impact of using 24 hour ambulatory blood pressure 
monitoring (ABPM) on these rates. We also aim to examine the sensitivity and 
specificity of office BP measurements and to describe the prevalence of white coat 
and masked hypertension. 
Methods  
The Mitchelstown Cohort Study was established to examine cardiovascular health 
in a middle-aged Irish community sample. The most recent BP recorded by the 
participant’s GP in the electronic health record was documented as office BP. All 
participants were invited to have their BP measured during the study visit and the 
average of the second and third BP readings was defined as the study BP. All 
participants were invited to undergo 24 hour ABPM. Hypertension was defined 
using accepted thresholds or by current anti-hypertensive medication use. 
Participants were defined as aware of their hypertension if they self-reported a 
doctor diagnosis of hypertension, and as treated if they self-reported anti-
hypertensive medication use. Control of hypertension was defined as a measured 
BP below the normal threshold and was calculated for prevalent and treated cases. 
Results 
Of 2047 participants, 1207 (response rate 59%), under-went 24 hour ABPM. Nine 
hundred and thirty one (45%) study participants underwent 24 hour ABPM, had a 
previous office and study BP available. The mean office BP was 134/79 mmHg and 
mean study BP was 134/83 mmHg. Based on the study BP, the prevalence of 
hypertension was 60% with an awareness rate of 59% and 60% were treated. Of the 
prevalent cases 27% were controlled while 46% of those on treatment were 
controlled. By ABPM the mean daytime BP was 131/77 mmHg and mean night-time 
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BP was 112/63 mmHg. Using the daytime ABPM threshold the prevalence of 
hypertension was 61%. The awareness rate was 59% and 59% were treated. Of the 
prevalent cases 32% were controlled while 54% of treated cases were controlled. In 
treated individuals 21% of those with elevated study blood pressure had normal 
blood pressure based on the daytime ABPM threshold while 14% of those with 
normal study blood pressure were found to have uncontrolled hypertension by 
ABPM. In untreated individuals the prevalence of white coat hypertension was 11% 
and masked hypertension was 13% based on the daytime ABPM threshold. 
Discussion 
Awareness, treatment and control rates of hypertension remain suboptimal. The 
routine use of ABPM in the diagnosis and management of hypertension in primary 
care will facilitate more appropriate treatment initiation and titration. 
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2.2. Introduction 
Hypertension is a leading risk factor for cardiovascular mortality. In 2009 the World 
Health Organisation estimated that raised blood pressure caused 51% of stroke 
deaths and 45% of coronary heart disease deaths worldwide. (1) However, many 
people with hypertension are undiagnosed and of those who are diagnosed many 
are poorly controlled. (2) 
Accurate measurement of blood pressure is essential for the diagnosis and 
management of hypertension. Traditionally measurements are carried out in a 
clinical setting and a diagnosis of hypertension is made based on this office reading. 
Ambulatory blood pressure monitoring (ABPM) provides information over a 24 or 
48 hour period and in particular gives important information on night-time blood 
pressure.  Ambulatory blood pressure has been shown to be superior for the 
prediction of clinical events. (3, 4) 
A systematic review and meta-analysis on the relative effectiveness of clinic blood 
pressure measurements and home blood pressure monitoring (HBPM) compared to 
ABPM concluded that using clinic or HBPM alone might result in over-diagnosis of 
hypertension. (5) A subsequent UK study on the cost-effectiveness of options for 
the diagnosis of hypertension in primary care reported that ABPM would reduce 
misdiagnosis and save costs. It was suggested that in the UK the increased costs 
related to ABPM would be counterbalanced by cost savings from better targeted 
therapy. (6) The National Institute for Health and Care Excellence (NICE) in 2011 
recommended that if the office blood pressure is 140/90 mmHg or higher, ABPM 
should be offered to confirm the diagnosis of hypertension. (7) The European 
Society of Hypertension (ESH) guidelines in 2013 state that office blood pressure 
remains the ‘gold standard’ for screening, diagnosis and management of 
hypertension. (8) They recommend HBPM or ABPM be carried out in certain 
clinically indicated situations including suspected white coat hypertension, drug 
resistance and hypotensive symptoms. Assessment of night-time blood pressure is 
also a specific indication for ABPM. 
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Generally studies examining hypertension prevalence have used office or home 
blood pressure readings measured using standardised techniques. (9) A recent 
study highlights the prevalence of masked uncontrolled hypertension among those 
on treatment for hypertension. (10) While many studies have investigated masked 
hypertension and white coat hypertension diagnosed by ABPM, (11-13) few 
population studies have compared the effect of different methods of measurement 
on prevalence rates of hypertension. (14)  
The aim of this paper is to examine the prevalence, awareness, treatment and 
control rates of hypertension in a community based sample and to examine the 
impact of using ABPM on these rates. We also aim to examine the sensitivity and 
specificity of office blood pressure measurements and the prevalence of white coat 
and masked hypertension in the sample. 
2.3. Methods 
Details of the Mitchelstown Cohort have previously been described. (15) In 
summary, patients were recruited from a single large primary care centre, the 
Livinghealth Clinic in Mitchelstown, a town located in the south of Ireland. The 
practice serves a population catchment area of approximately 20,000. Those 
registered with the clinic in the 50-69 year old age bracket were assigned a random 
number. Participants were invited based on this random number in batches of 150 
until the target sample size of 2000 was achieved.  
Participants self-reported a history of doctor diagnosed hypertension and anti-
hypertensive medication use by questionnaire.  
After the participant had been in a relaxed seated position for at least 5 minutes 
three blood pressure readings were taken on the right arm, 1 minute apart, using 
the OMRON Model M7 digital automatic blood pressure monitor. (16) The average 
of the second and third blood pressure reading was defined as the study blood 
pressure. 
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Participants were offered 24 hour ABPM at the time of their study visit. ABPM 
measurements were performed using the MEDITECH ABPM-05 and data was stored 
using the dabl ABPM system. (17) 
Consent was obtained to access the electronic patient record and if available the 
most recent blood pressure recorded by the participant’s general practitioner (GP) 
was documented as the office blood pressure.  
Participants whose electronic patient record included codes for elevated blood 
pressure, uncomplicated hypertension and complicated hypertension (International 
Classification of Primary Care, Second edition (ICPC 2) codes K85, K86, K87) were 
defined as having coded hypertension.   
Hypertension was defined using the blood pressure thresholds for the different 
measurement techniques or by current antihypertensive medication use. Study and 
office thresholds were systolic blood pressure ≥ 140 mmHg and/or a diastolic blood 
pressure ≥ 90 mmHg. For ABPM the daytime and night-time windows were defined 
by diary records. ABPM data was excluded if there were < 14 daytime readings 
and/or < 7 night-time readings. (18) The daytime thresholds were a systolic blood 
pressure ≥ 135 mmHg and/or a diastolic blood pressure ≥ 85 mmHg. Night-time 
thresholds were a systolic blood pressure ≥ 120 mmHg and/or a diastolic blood 
pressure ≥ 70 mmHg. Twenty four hour thresholds were a systolic blood pressure ≥ 
130 mmHg and/or a diastolic blood pressure ≥ 80 mmHg. Daytime and/or night-
time hypertension was defined by combining the daytime hypertension threshold 
with the night-time hypertension threshold. 
Participants were classified as being aware of their hypertension if they answered 
“yes” to the question “Have you ever been told by a doctor that you have, or have 
had, high blood pressure?” Participants were classified as treated if they answered 
“yes” to the question “Has your doctor given you a prescription for blood pressure 
tablets?”  
Control of hypertension was defined by a blood pressure value of < 140/90 mmHg 
for the study and office blood pressure measurements. For ABPM readings 
56 
 
controlled hypertension was defined by blood pressure values < 135/85 mmHg for 
daytime, < 120/70 mmHg for night-time and < 130/80 mmHg for twenty four hour 
blood pressure.  
Statistical Analysis: 
Statistical analysis was carried out using Stata 12. Baseline characteristics are 
presented as absolute numbers with corresponding percentages for categorical 
variables and as means with standard deviations for continuous variables. 
Prevalence, awareness, treatment and control rates of hypertension were 
calculated and compared using the different measurement techniques and 
thresholds. Control rates were calculated for both prevalent cases and treated 
cases. The sensitivity and specificity of the study and office blood pressure 
measurements were calculated using the ABPM daytime threshold as the gold 
standard. 
Ethical Approval: 
Ethical approval for the study was obtained from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. All participants provided written 
informed consent. The study was carried out in accordance with the Declaration of 
Helsinki. 
2.4. Results 
Of 3051 invitees, 2047 (67%) participants were recruited to the study. Of these 
2042 (99.8%) had their blood pressure measured for the study, 1723 (84.2%) had a 
previous blood pressure documented by their GP and 1207 (59.0%) underwent 24 
hour ABPM. We excluded 128 from the ABPM analysis because of incomplete data. 
Nine hundred and thirty one (45%) study participants had satisfactory data for 24 
hour ABPM, study and previous office blood pressures. The baseline characteristics 
of the full sample and those with all 3 measures are shown in Table 2.1. Those in 
the subsample were more likely to report a doctor diagnosis of hypertension and to 
report use of anti-hypertension medications, 36% versus 29% in the overall group 
for both. The groups were similar in other measured characteristics.  
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The mean office blood pressure was 134/79 mmHg and the mean study blood 
pressure was 134/83 mmHg. The mean daytime blood pressure was 131/77 mmHg 
and mean night-time blood pressure was 112/63 mmHg. The prevalence of 
hypertension ranged from 50-64% depending on the measurement method and 
threshold used, Table 2.2 and Figure 2.1. For ABPM the chosen threshold impacted 
on rates with the twenty four hour threshold resulting in lower prevalence rates 
and higher awareness, treatment and control rates compared to the other 
thresholds. Of those who were hypertensive by the office blood pressure, 31% 
(161/521) were coded as hypertensive in the electronic health record, and of these 
individuals 80% (120/150) were aware and 81% (128/159) were treated while 49% 
(63/128) were controlled based on the office blood pressure. (Data not shown, note 
some missing data for awareness and treatment questions).  
Table 2.3 compares ABPM to the study blood pressure. A quarter to a third of 
individuals included in the study had their blood pressure status changed based on 
the daytime ABPM threshold. In treated individuals 21% (70/329) with elevated 
study blood pressure had normal blood pressure based on the daytime ABPM 
threshold. On the other hand 14% (45/329) were found to have uncontrolled 
hypertension by ABPM despite normal study blood pressure. In untreated 
individuals the prevalence of white coat hypertension was 11% (61/577) and 
masked hypertension was 13% (74/577). Variations are seen depending on the 
chosen threshold and treatment status, for example, untreated individuals had a 
higher rate of white coat hypertension (21%, 124/577), and a lower rate of masked 
hypertension (5%, 28/577), when the twenty four hour threshold was chosen.  
Using daytime blood pressure measured by ambulatory blood pressure monitoring 
as the gold standard the sensitivity and specificity of the study blood pressure was 
70% (95% CI 66% – 75%) and 76% (95% CI 72% – 79%) respectively, versus 56% 
(95% CI 51% – 61%) and 74% (95% CI 70 – 77%) for office blood pressure.  
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Table 2.1. Baseline characteristics 
 Total sample 
 
n =2047 
Subsample with all 3 
measures 
n=931 
 n (%)/mean (+/-SD) n (%)/mean (+/-SD) 
 
Age 60 (+/-6) 60 (+/-5) 
Male 1008 (49) 435 (47) 
   
Smoking status   
Non-smoker 1002 (51) 470 (52) 
Former smoker 671 (34) 283 (32) 
Current smoker 292 (15) 146 (16) 
   
Medical History   
Hypertension 567 (29) 329 (36) 
Myocardial Infarction 49 (2) 24 (2.6) 
Stroke 22 (1) 11 (1.2) 
Heart failure 8 (0.4) 5 (0.6) 
Diabetes 174 (9) 82 (9) 
   
Anti-hypertensive 
medication 
584 (29) 329 (36) 
Cholesterol lowering 
medication 
711 (36) 352 (38) 
   
BMI 29 (+/-5) 29 (+/-5) 
Waist circumference 97 (+/-13) 97 (+/-13) 
LDL 3.2 (+/-0.9) 3.2 (+/-0.9) 
Creatinine 71 (+/-16) 71 (+/-15) 
ACR 0.7 (+/-2.1) 0.7 (+/-1.9) 
eGFR 90 (+/-13) 89 (+/-13) 
   
Office systolic 132 (+/-13) 134 (+/-15) 
Office diastolic 78 (+/-9) 79 (+/-9) 
Study systolic 130 (+/-17) 134 (+/-15) 
Study diastolic 80 (+/-10) 83 (+/-10) 
   
Daytime systolic  131 (+/-13) 
Daytime diastolic  77 (+/-9) 
Night-time systolic   112 (+/-14) 
Night-time diastolic  63 (+/-8) 
Twenty four systolic  124 (+/-13) 
Twenty four diastolic  72 (+/-8) 
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Table 2.2. Hypertension prevalence, awareness, treatment and control 
 Prevalence Awareness Treatment Control 
Prevalent Cases 
Control 
Treated Cases 
Total n=931 
 
 n/N (%) n/N (%) n/N (%) n/N(%) n/N (%) 
Study Hypertension  557/931 (60) 314/528 (59) 329/549 (60) 151/557 (27) 151/329 (46) 
 
Office Hypertension    521/931 (56) 313/492 (64) 329/512 (64) 161/521 (31) 161/329 (49) 
      
Daytime Hypertension 568/931 (61) 316/535 (59) 329/553 (59) 179/568 (32) 179/329 (54) 
Night-time Hypertension 479/931 (51) 311/450 (69) 329/469 (70) 205/479 (43) 205/329 (62) 
Twenty four hour Hypertension 462/931 (50) 309/435 (71) 329/452 (73) 225/462 (49) 225/329 (68) 
Daytime and/or night-time Hypertension 593/931 (64) 
 
317/559 (57) 329/577 (57) 
 
151/593 (25) 151/329 (46) 
 
Due to missing data N in columns 2 and 3 do not represent n in column 1 
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Figure 2.1. Prevalence, awareness, treatment and control rates of hypertension by different measurement thresholds 
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Table 2.3. Impact of ABPM on blood pressure classification 
Total n=931 
Treated n = 577 
Untreated n = 329 
Hypertensive 
by study BP 
and ABPM 
 
n/N(%) 
Normotensive 
by study BP and 
ABPM 
 
n/N(%) 
Study hypertension 
and ABPM 
normotension 
 
n/N(%) 
Study normotension 
and ABPM 
hypertension 
 
n/N(%) 
Daytime threshold     
All  273/931 (29) 400/931 (43) 133/931 (14.5) 125/931 (13.5) 
Treated 108/329 (33) 106/329 (32) 70/329 (21) 45/329 (14) 
Untreated 156/577 (27) 286/577 (49) 61/577 (11) 74/577 (13) 
     
Twenty four hour threshold     
All 181/931 (19) 469/931 (50) 225/931 (24) 56/931 (6) 
Treated 81/329 (25) 128/329 (39) 97/329 (29) 23/329 (7) 
Untreated 93/577 (16) 332/577 (58) 124/577 (21) 28/577 (5) 
     
Night-time threshold 
All 
Treated 
Untreated  
 
 
194/931 (21) 
91/329 (28) 
97/577 (17) 
 
444/931 (48) 
118/329 (36) 
316/577 (55) 
 
212/931 (23) 
87/329 (26) 
120/577 (21) 
 
81/931 (9) 
33/329 (10) 
44/577 (8) 
Combined day and night thresholds     
All 300/931 (32) 383/931 (41) 106/931 (11) 142/931 (15) 
Treated 126/329 (38) 99/329 (30) 52/329 (16) 52/329 (16) 
Untreated 164/577 (28) 279/577 (48) 53/577 (9) 81/577 (14) 
     
Information on antihypertensive medication was missing for 25 subjects 
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2.5. Discussion 
Our study demonstrates a high prevalence of hypertension ranging from 50-64% 
depending on the measurement method and blood pressure threshold chosen. The 
awareness rate varied from 57-71%, while 57-73% were treated. Control rates 
ranged from 25-49% in prevalent cases and 46-68% in those on treatment. These 
figures are similar to recent data from a nationally representative sample of 
community dwelling older Irish adults. Prevalence rate was 63.7%, awareness was 
54.5%, 58.9% were on anti-hypertensive medication and 51.6% of those on 
treatment were controlled. (19) While these figures are suboptimal they do 
compare favourably internationally. A cross-sectional analysis from the PURE study 
demonstrated an awareness rate of 46.5% with 40.6% receiving treatment and 
32.5% of those on treatment controlled across high, middle and low income 
countries. The rates for high income countries alone were 49%, 46.7% and 40.7%. 
(20) A study carried out in Spain demonstrated achieved blood pressure targets in 
46.3% of those in the PRESCAP 2010 cross-sectional study. (21) Other work from 
the same study highlights therapeutic inertia where health care providers often do 
not initiate or intensify therapy appropriately during visits. This has improved from 
2002 to 2010 but remains an issue. Treatment was modified in just 41.4% of those 
with uncontrolled blood pressure in 2010 improved from 18.3% in 2002. (22) 
The prognostic importance of 24 hour ambulatory blood pressure is well known. (3, 
4) It is important to examine the day and night blood pressure windows as the 
night-time blood pressure is recognised to be of greater prognostic significance. 
(23) Our findings confirm the clinical utility of ABPM in the management of those 
with hypertension. A large proportion of apparently normotensive participants 
were hypertensive by ABPM and vice versa. Gijon-Conde et al. recently 
demonstrated that a half of older apparently uncontrolled hypertensives were 
normotensive by ABPM. (24) Similarly in our study 21% of those on treatment with 
apparently uncontrolled hypertension by the study blood pressure were 
normotensive based on the daytime ABPM threshold.  Banegas et al found a high 
rate of masked suboptimal blood pressure control in individuals with apparently 
well-controlled office blood pressure. (25) Masked uncontrolled hypertension was 
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also prevalent in our study at 14%. Therefore ABPM allows appropriate 
management of treatment. In untreated individuals white coat hypertension 
prevalence was 11% and masked hypertension prevalence was 13% using the 
daytime threshold. These are similar to rates in the IDACO database  (26) Lovibond 
et al. have highlighted the potential cost savings with the use of ABPM due to more 
appropriately targeted therapy. (6) Also the use of 24 hour ABPM may help to 
overcome therapeutic inertia. The Rambler Study demonstrated that the use of 24 
hour ABPM impacted on GP prescribing of anti-hypertensive medication in Ireland. 
(27) 
The method of blood pressure measurement and threshold level chosen had an 
impact on prevalence rates in this study. The higher sensitivity of the study blood 
pressure over the office blood pressure likely reflects the use of standardised 
methods and highlights the importance of measuring office blood pressure 
according to guidelines to maximise accuracy. (8) Using the recommended 24 hour 
threshold resulted in more people being categorised as normotensive than using 
the daytime threshold level or a combination of both the daytime and night-time 
thresholds. There has been considerable debate over diagnostic thresholds for 
ABPM. (28) Blood pressure, and its relationship with cardiovascular disease, is 
continuous and the use of diagnostic thresholds therefore has limitations, which is 
highlighted by our study. (29) However clinicians do require diagnostic thresholds 
of normality for 24 hour ABPM when treating patients but they also need to be 
aware of the limitations of these thresholds. 
This study offers an opportunity to reflect on the use of health information 
technology, and electronic health records in particular, in the management of 
hypertension. Accurate information is essential to facilitate optimal patient care, 
clinical governance and healthcare planning. This is important given recently 
highlighted barriers to medical coding (30) and present financial constraints within 
healthcare systems. While the impact of health information technology on time 
utilisation is mixed it has been shown to improve the delivery of preventative care, 
improve clinical monitoring and reduce medication errors. (31) GPs generally carry 
out more coding than their hospital colleagues. (32) In the Irish healthcare setting 
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individual GPs carry out their own coding with no healthcare policy incentives or 
supports to do so. In our study those who were coded as hypertensive in the 
electronic health record were more likely to be aware of and to be on treatment for 
their hypertension while control rates were similar to the overall office 
hypertension group. These increased awareness and treatment rates needs to be 
translated into better control rates.  In the United Kingdom the introduction of 
incentivised care did result in improved recording and documentation of health 
indicators. (33-35) Policy makers need to realise the importance of investment in 
information technology and supports to facilitate coding in primary and secondary 
care which should in turn impact on hypertension awareness, treatment and 
control rates. 
Our study is limited by selection bias, those with a previous diagnosis of 
hypertension or on anti-hypertensive medication were more likely to agree to 
undergo 24 hour ABPM. Of the total sample 29% self-reported a previous doctor 
diagnosis of hypertension versus 36% of those included in this sub-sample. 
Therefore our findings may not be generalisable to the general population and the 
ABPM results may be an over-estimate of actual prevalence.  However table 2.3 
highlights the potential impact of ABPM on the management of both treated and 
untreated individuals. Our results are based on 1 ABPM recording and it is 
recognised that night-time blood pressure profiles in particular are not fully 
reproducible which may again have an impact on prevalence when blood pressure 
is measured by ABPM. (36) The fact that blood pressure was measured using 
standardised methods in a large community based sample with the availability of 
previously documented office blood pressure and 24 hour ABPM are major 
strengths of this study. The availability of hypertension coding data is a further 
strength as it gives deeper insight into the challenges faced in the management of 
hypertension in daily clinical practice.   
Conclusion: 
This study highlights a number of important points. Firstly, hypertension remains a 
public health priority. It is highly prevalent, and treatment and control rates are 
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suboptimal. Secondly, the use of 24 hour ABPM may not hugely impact overall 
population prevalence rates but at an individual level it provides a more accurate 
assessment of blood pressure status and therefore refines diagnosis and 
management of hypertension and should be considered a vital tool in the provision 
of care. Finally, healthcare information technology should be fully utilised so 
patients can receive best practice care and the burden of hypertension and its 
public health consequences can be reduced.  
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3.1. Abstract 
Introduction 
The prognostic significance of abnormal circadian blood pressure (BP) patterns is 
well established. Research to date has focused on both nocturnal dipping and 
absolute night-time BP levels, however, which of these variables should be the 
primary target for therapy remains unclear.  The aim of this study is to determine 
whether dipping status or absolute night-time BP levels have a stronger association 
with subclinical target organ damage (TOD). 
Methods 
The Mitchelstown Cohort was established to examine cardiovascular health in an 
adult population sample recruited from primary care. Night-time BP was 
categorised by dipping status. Subclinical TOD was defined as Cornell Product left 
ventricular hypertrophy (LVH) voltage criteria on ECG and urine albumin:creatinine 
ratio (ACR) ≥ 1.1 mg/mmol. Multi-variable logistic regression analysis was used to 
assess the association between night-time BP and TOD. 
Results 
Of 2047 participants, 1207 (response rate 59%), under-went 24 hour ambulatory BP 
monitoring. We excluded 161 studies due to incomplete data. Of 1046 participants, 
178 (17%) had evidence of TOD. Each 10 mmHg rise in night-time systolic BP 
increased the odds of TOD. Odds ratio (OR) ACR ≥ 1.1 mg/mmol 1.5 (95% CI 1.2 – 
1.8) and OR LVH 1.4 (95% CI 1.1 -1.8). In multi-variable analysis neither daytime 
systolic blood pressure or dipping status was associated with increased risk of 
target organ damage. 
Conclusion 
Absolute BP level rather than dipping status may be a superior early marker of risk 
associated with night-time BP. Interventional studies are required to determine 
whether there is a benefit in specifically targeting absolute night-time BP levels to 
prevent clinically important outcomes.  
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3.2. Introduction 
Since the introduction of 24 hour ambulatory blood pressure monitoring (ABPM) in 
the 1960s (1-3), much has been learned regarding the diurnal blood pressure 
profile. The circadian variability of blood pressure has been recognised for a 
number of decades. (4) The blood pressure dipping phenomenon was first 
described in 1988. (5) A fall of 10% or more in night-time blood pressure relative to 
daytime is considered optimal or normal dipping. A fall of less than 10% constitutes 
non-dipping while a rise in night-time blood pressure is reverse dipping or riser 
pattern. Non-dipping and reverse dipping patterns are associated with higher 
prevalence of cardiovascular risk factors. (6) 
There have been numerous observational studies on the prognostic importance of 
night-time blood pressure and a meta-analysis confirms that night-time systolic 
blood pressure is a stronger predictor of clinical endpoints than daytime systolic 
blood pressure. (7) The definition of nocturnal hypertension using ABPM is a mean 
night-time blood pressure value of ≥ 120/70 mmHg. (8) 
Subclinical target organ damage is a prognostic marker for future cardiovascular 
events. It can be detected in the heart, kidneys, brain, vasculature and retina by 
various methods. (9) Many studies have addressed dipping status and subclinical 
target organ damage (10-15) while fewer have examined nocturnal hypertension 
and its association with cardiovascular risk factors and subclinical target organ 
damage. (16, 17) Few studies have compared the relative value of dipping status 
versus the absolute blood pressure with respect to the association with subclinical 
target organ damage. (17-19) 
Microalbuminuria has been shown to be a marker of future cardiovascular events. 
One study demonstrated increased risk at albumin:creatinine ratio (ACR) of ≥ 0.58 
mg/mmol (20) while a meta-analysis in 2010 demonstrated increased risk of 
mortality with ACR of ≥ 1.1 mg/mmol in population based cohorts. (21) An 
association with adverse cardiac mechanics has also been shown with 
microalbuminuria within the accepted normal range. (22) Electrocardiogram (ECG) 
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left ventricular hypertrophy (LVH) voltage criteria is a recognised independent 
predictor of prognosis. (23, 24) 
The Mitchelstown Cohort examines cardiovascular health in an Irish adult primary 
care based population sample. The objective of this study is to examine the 
prevalence of risk factors in subjects with subclinical target organ damage and to 
determine if dipping status or absolute night-time blood pressure levels have a 
stronger association with subclinical target organ damage.  
3.3. Methods 
Study Population: 
Details of the Mitchelstown Cohort have previously been described. (25) In 
summary, patients were recruited from a single large primary care centre, the 
Livinghealth Clinic in Mitchelstown, a town in the south of Ireland. The practice 
serves a population catchment area of approximately 20,000. Those registered with 
the clinic in the 50-69 year old age bracket were assigned a random number. 
Participants were invited based on this random number in batches of 150 until the 
target sample size of 2000 was achieved. Those who accepted the invitation were 
offered 24 hour ABPM at the time of their study visit.  
 
Baseline Assessment: 
Participants self-reported a previous doctor diagnosis of hypertension, myocardial 
infarction, stroke, heart failure and diabetes by questionnaire. They also self-
reported anti-hypertensive and cholesterol lowering medication use as well as 
smoking status. The International Physical Activity Questionnaire (IPAQ) was used 
to measure physical activity levels. (26) 
A blood sample was taken after an 8 hour fast. This was analysed for glucose, 
lipoprotein profile, glycosylated haemoglobin (HbA1C), full blood count and 
biochemical profile. Subjects brought a sample of the first urine they voided on the 
morning of their appointment. This was analysed for ACR, sodium and potassium. 
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Diabetes mellitus was defined as HbA1c level greater than or equal to 6.5% (27) or 
self-reported doctor diagnosis of diabetes. The CKD-EPI equation was used to 
estimate glomerular filtration rate (eGFR) from serum creatinine. (28, 29) 
A trained researcher or nurse carried out the physical measures. Height was 
measured without foot-ware using a Seca Leicester portable height measure. 
Weight was measured using a portable electronic TANITA WB100MA weighing 
scale. Body mass index (BMI) was then calculated.  
A 12 lead ECG was obtained in the standard manner using a Siemens – Eclipse 850i 
machine. All ECGs were recorded at a standard 10 mm/mv.  ECGs were reviewed 
and coded for LVH using Cornell Product voltage criteria by Dr Anne Marie O’Flynn. 
 
Blood Pressure Measurements: 
After the participant had been in a relaxed seated position for at least 5 minutes 
three blood pressure readings were taken on the right arm, 1 minute apart, using 
the OMRON Model M7 digital automatic blood pressure monitor.  The average of 
the second and third blood pressure reading was taken as the study blood pressure. 
ABPM measurements were performed using the MEDITECH ABPM-05 and data was 
stored using the dabl ABPM system. The monitors were programmed to record the 
blood pressure every 30 minutes throughout the 24 hour period. Participants kept a 
diary of the times they went to bed and got up. Diary times were used to calculate 
mean daytime and night-time blood pressures. Mean 24 hour blood pressure was 
calculated as the mean of all the readings throughout the 24 four hour period. Also 
the daytime fixed interval was defined from 9am to 9pm and the night-time fixed 
interval from 1am to 6am. Both diary and fixed intervals were initially used to 
categorise dipping patterns.  
Dipping status was defined as follows (6): 
(1) Dipping pattern: 10 to 20% fall in night-time systolic blood pressure  
(2) Non-dipping pattern: < 10% fall in night-time systolic blood pressure  
(3)  Extreme dipping pattern: > 20% fall in night-time systolic blood pressure  
(4)  Reverse dipping pattern: Rise in night-time systolic blood pressure  
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Subclinical Target Organ Damage:                                                                                               
Subclinical microvascular disease was defined by urine ACR ≥ 1.1 mg/mmol. (21) 
Subclinical cardiac disease was defined by Cornell Product ECG voltage criteria for 
LVH i.e. SV3 + RaVL (+6 in women) X QRS duration ≥ 2440 mm x ms. (30) 
Statistical Analysis: 
Statistical analysis was carried out using Stata 12. Exploratory analysis was carried 
out for fixed and diary intervals. Mean blood pressures for each interval were 
calculated. Correlations between mean diary and fixed interval blood pressures 
were assessed using Pearson’s Correlation Coefficient. Normally distributed 
continuous variables were compared between groups using ANOVA and linear 
regression. The Kruskall-Wallis test was used for non-normally distributed variables. 
Proportions of categorical variables were compared using the chi-square test. 
The association of dipping status and absolute night-time blood pressure levels with 
subclinical target organ damage was assessed using multi-variable logistic 
regression. In the partially adjusted models adjustments were made for sex, age, 
diabetes, anti-hypertensive medication, smoking and BMI. Further adjustments for 
absolute blood pressure levels were made in the fully adjusted models ie. absolute 
daytime blood pressure was further adjusted for absolute night-time blood 
pressure and vice versa,  and, dipping status was further adjusted for absolute 
night-time blood pressure. Model performance was evaluated using the likelihood 
ratio test.  
Ethical Approval: 
Ethical approval for the study was obtained from the Clinical Research Ethics 
Committee of the Cork teaching hospitals. The study was carried out in accordance 
with the Declaration of Helsinki. Written informed consent was obtained from all 
study participants. 
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3.4. Results 
Of the 3051 individuals invited to participate, 2047 completed the questionnaire 
and physical examination components of the baseline assessment (response rate: 
67%). These 2047 participants were also invited to undergo ABPM and 1207 
accepted (response rate: 59%). Of these, 128 were excluded due to incomplete 
recordings (<14 daytime and/or <7 night-time readings (31)), 26 were excluded 
because they had missing data on microalbuminuria or LVH and a further 7 were 
excluded from the diary interval analysis due to lack of diary documentation. The 
analysis therefore includes 1046 participants. 
Exploratory analysis using fixed intervals was initially carried out. The correlations 
between mean day and night blood pressures using fixed intervals and diary 
intervals were very high with an R > 0.99.  Concordance for dipping status between 
diary and fixed intervals was 89.6%. Diary intervals were used for all further 
analysis. 
The baseline characteristics of the participants by presence of subclinical target 
organ damage are presented in Table 3.1. A greater proportion of those with target 
organ damage were on anti-hypertensive treatment, approximately one half versus 
one third of those without evidence of target organ damage. Blood pressure levels 
adjusted by age and sex are presented in Table 3.2. The night-time systolic blood 
pressure and night-time pulse pressure of those in the 3 categories of target organ 
damage was significantly different from those without target organ damage.  
Night-time systolic blood pressure was significantly associated with markers of 
target organ damage in all models. In the unadjusted model there was an 
approximate 50% increase in odds of target organ damage, OR of ACR ≥ 1.1 
mg/mmol was 1.6 (95% CI 1.4 -1.8) and OR of  LVH was 1.4 (95% CI 1.2 – 1.6) for 
each 10 mmHg rise in night-time systolic blood pressure. This association was 
somewhat attenuated in the fully adjusted model which included daytime systolic 
blood pressure, OR of ACR ≥ 1.1 mg/mmol was 1.5 (95% CI 1.2 – 1.8) and OR LVH 
1.4 (95% CI 1.1 -1.8) (Table 3.3). The diastolic blood pressure was not associated 
with increased risk of LVH in any model. Adding daytime blood pressure to the 
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model did not significantly improve the fit. Daytime systolic blood pressure levels 
were also associated with target organ damage in unadjusted models. However the 
odds ratios were smaller than those for night-time blood pressure, OR of ACR ≥ 1.1 
mg/mmol was 1.4 (95% CI 1.3 – 1.6) and OR of LVH was 1.2 (95% CI 1.0 -1.4) for 
each 10 mmHg rise in daytime systolic blood pressure.  Findings were attenuated in 
adjusted models, and when night-time systolic blood pressure was also included in 
the models, were no longer statistically significant.  (Table 3.3) 
Of 576 categorised as dippers, 28% had persistent elevation in their night-time 
blood pressure. Of 229 non-dippers, 51% had normal night-time blood pressure 
(Figure 3.1). Mean blood pressures by dipping status and target organ damage are 
shown in Figure 3.2. In the unadjusted and partially adjusted regression models 
extreme dippers had reduced odds of ACR ≥ 1.1 mg/mmol, while reverse dippers 
had increased odds of LVH. However in the fully adjusted model which included 
absolute night-time systolic blood pressure the findings for reverse dippers and LVH 
were attenuated and no longer statistically significant (Table 3.4). When the 
absolute night-time blood pressure was added the model fit significantly improved. 
The analysis was also carried out using dipping as a continuous variable with similar 
findings. (Supplemental tables 3.5 and 3.6, Appendix 3). 
Stratified Analysis: 
The analysis was repeated after stratifying participants based on their treatment 
status. There were 350 (33.5%) treated participants and 670 (64%) untreated 
participants. Information on treatment status was missing for 26 (2.5%) 
participants.  Night-time systolic blood pressure had a greater association with ACR 
≥ 1.1 mg/mmol than daytime systolic blood pressure in both treated and untreated 
individuals. However in untreated individuals both night-time and daytime systolic 
blood pressures had similar associations with LVH and the statistical significance of 
the association for LVH was attenuated in fully adjusted models. (Supplemental 
tables 3.7 and 3.8, Appendix 3) 
With respect to dipping status treated reverse dippers had increased risk of LVH in 
unadjusted and adjusted models (OR 4.9 (95% CI 1.0 – 23.3, p = 0.046 in fully 
78 
 
adjusted models including night-time systolic blood pressure). Untreated extreme 
dippers had reduced odds of ACR ≥ 1.1 mg/mmol in unadjusted and partially 
adjusted analysis. This was not statistically significant in fully adjusted models 
including night-time systolic blood pressure. (Supplemental tables 3.9 and 3.10, 
Appendix 3)
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Table 3.1. Baseline characteristics by target organ damage 
 
 
Total n = 1046 
No LVH and ACR       
< 1.1 mg/mmol 
n =870 
ACR ≥ 1.1 mg/mmol 
only 
n = 106 
LVH only 
 
n = 56 
LVH and  
ACR ≥ 1.1 mg/mmol 
n = 14 
P-value 
 n (%)/Mean (+/-SD) n (%)/Mean (+/-SD) n (%)/Mean (+/-SD) n (%)/Mean (+/-SD)  
      
Age 59 (+/-5) 60 (+/-6) 62 (+/-5) 61 (+/-5)  <0.001* 
Male 392 (45) 55 (52) 31 (55) 7 (50) 0.3 
Education category  
Primary 
Secondary 
Tertiary 
 
210 (26) 
414 (50) 
196 (24) 
 
41 (40) 
38 (37) 
23 (23) 
 
19 (36) 
30 (57) 
4 (7) 
 
7 (50) 
4 (29) 
3 (21) 
 
 
 
0.001* 
IPAQ category  
Low 
Moderate 
High 
 
408 (49) 
245 (30) 
175 (21) 
 
56 (57) 
28 (28) 
15 (15) 
 
29 (56) 
11 (22) 
11 (22) 
 
10 (77) 
3 (23) 
0 (0) 
 
 
 
0.2 
Smoking Status  
Non-smoker 
Former smoker 
Current smoker 
 
448 (53) 
257 (31) 
136 (16) 
 
55 (53) 
35 (33) 
15 (14) 
 
24 (45) 
23 (43) 
6 (11) 
 
8 (57) 
5 (36) 
1 (7) 
 
 
 
0.5 
 
Continued… 
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Table 3.1. Continued 
Medical History      
Hypertension 268 (32) 43 (43) 28 (53) 8 (57) 0.004* 
Myocardial Infarction 16 (2) 5 (5) 4 (7) 1 (7) 0.07 
Stroke 8 (1) 1 (1) 2 (4) 0 (0) 0.5 
Heart failure 3 (0.4) 1 (1) 1 (2) 1 (8) 0.01* 
Diabetes mellitus 72 (8) 14 (13) 5 (9) 4 (29) 0.03* 
Medication      
Anti-hypertensive 269 (32) 43 (42) 31 (55) 7 (50) 0.001* 
Cholesterol lowering  316 (37) 46 (44) 20 (36) 6 (43) 0.7 
BMI (kg/ m2) 29 (+/-5) 30 (+/-5) 29 (+/-5) 31 (+/-6) 0.004* 
Waist circumference (cm) 96 (+/-13) 101 (+/-15) 98 (+/-13) 103 (+/-16) 0.004* 
LDL (mmol/l) 3.2 (+/-0.9) 3.1 (+/-0.9) 3.4 (+/-0.7) 2.8 (+/-0.9) 0.1 
Creatinine (µmol/l) 71 (+/-15) 71 (+/-17) 72 (+/-15) 77 (+/-29) 0.6 
ACR (mg/mmol) 0.4 (+/-0.2) 3.0 (+/-3.8) 0.4 (+/-0.2) 7.0 (+/-11) <0.001* 
eGFR (mls/min) 89 (+/-12) 90 (+/-14) 88 (+/-12) 85 (+/-21) 0.5 
Cornell Product (mm x ms) 1374 (+/-444) 1523 (+/-462) 3046 (+/-646) 3210 (+/-914) <0.001* 
      
LVH = Left ventricular hypertrophy; ACR = Albumin:creatinine ratio; SD = Standard deviation; IPAQ = International Physical Activity 
Questionnaire; BMI = Body mass index; LDL = Low density lipoprotein; eGFR = estimated glomerular filtration rate 
* Statistically significant 
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Table 3.2. Blood Pressure levels by Target Organ Damage 
 
 
 
Total n = 1046 
No LVH and         
ACR < 1.1 mg/mmol 
 
n =870 
ACR ≥ 1.1 mg/mmol 
only 
 
n = 106 
LVH only 
 
 
n = 56 
LVH and  
ACR ≥ 1.1 mg/mmol 
 
n = 14 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
     
Study systolic 133 (3) 140 (4) ** 139 (3) 147 (4)* 
Study diastolic 82 (0.5) 85 (0.5)* 84 (0.4) 88 (0.4)* 
Day systolic 130 (3) 137 (3) *** 133 (3) 144 (3) ** 
Day diastolic 77 (3) 80 (3) *** 76 (3) 79 (2) 
Night systolic 111 (3) 120 (3) *** 116 (3)* 130 (3) *** 
Night diastolic 62 (2) 69 (2) *** 63 (2) 66 (2) 
24hour systolic 123 (3) 131 (3) *** 127 (3) 139 (3) *** 
24hour diastolic 72 (3) 75 (3) *** 71 (3) 74 (2) 
Day pulse pressure 53 (3) 57 (3) ** 57 (3) 65 (3) *** 
Night pulse  pressure 48 (3) 53 (3) *** 53 (3)* 64 (3) *** 
LVH = Left ventricular hypertrophy; ACR = Albumin:creatinine ratio; SD = Standard deviation 
Linear regression models adjusted by sex and age with p values compared to those with no target organ 
damage 
*** p <0.001 
** p <0.005 
* p < 0.05 
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Table 3.3.  Logistic regression results for absolute blood pressure and target organ damage 
 ACR ≥ 1.1 mg/mmol 
 
Odds Ratio (95%CI) 
 
 
P-value 
ECG LVH 
 
Odds Ratio (95%CI) 
 
 
P-value 
     
Night-time SBP (+10 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.6 (1.4 – 1.8) 
1.5 (1.3 – 1.7) 
1.5 (1.2 – 1.8) 
<0.001* 
<0.001* 
<0.001* 
1.4 (1.2 – 1.6) 
1.3 (1.1 – 1.5) 
1.4 (1.1 – 1.8)  
 
<0.001* 
0.002* 
0.009* 
Night-time DBP (+5 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.3 (1.2 – 1.5) 
1.3 (1.2 – 1.5) 
1.3 (1.1 – 1.6) 
 
<0.001* 
<0.001* 
0.001* 
1.1 (0.9 – 1.2) 
1.0 (0.9 – 1.2) 
1.1 (0.9 – 1.4) 
 
0.5 
0.6 
0.4 
Daytime SBP (+10 mmHg) 
Adjusted 
Fully adjusted 
 
1.4 (1.3 – 1.6) 
1.3 (1.2 – 1.6) 
1.0 (0.8 – 1.2) 
 
<0.001* 
<0.001* 
0.9 
1.2 (1.0 – 1.4) 
1.2 (1.0 – 1.4) 
0.9 (0.7 – 1.2) 
0.018* 
0.09 
0.5 
Daytime DBP (+5 mmHg) 
Adjusted 
Fully adjusted 
 
Twentyfour hour SBP (+10 mmHg) 
Adjusted 
 
Twentyfour hour DBP (+5 mmHg) 
Adjusted 
 
1.2 (1.1 – 1.3) 
1.2 (1.1 – 1.4) 
1.0 (0.9 – 1.2) 
 
1.5 (1.3 – 1.8) 
1.5 (1.3 – 1.7) 
 
1.3 (1.1 – 1.4) 
1.3 (1.1 – 1.5) 
<0.001* 
0.001* 
0.8 
 
<0.001* 
<0.001* 
 
<0.001* 
<0.001* 
1.0 (0.8 -1.1) 
1.0 (0.9 – 1.2) 
0.9 (0.8 – 1.1) 
 
1.3 (1.1 – 1.5) 
1.3 (1.0 – 1.5)  
 
1.0 (0.9 – 1.1) 
1.0 (0.9 – 1.2) 
0.6 
0.9 
0.5 
 
0.001* 
0.017* 
 
0.9 
0.8 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; CI = Confidence interval;                                               
SBP = systolic blood pressure; DBP = diastolic blood pressure 
Adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
Fully adjusted =  sex, age, diabetes, anti-hypertensives, smoking, BMI  plus daytime blood pressure further adjusted for 
night-time blood pressure and vice versa 
* Statistically significant 
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Figure 3.1. Night-time Blood Pressure Status by Dipping Status 
 
 
Total n = 1046 
576 (55%) 
Dippers 
417 (72%) 
Nocturnal 
Normotension 
159 (28%) 
Nocturnal 
Hypertension 
229 (22%)      
Non-dippers 
116 (51%) 
Nocturnal 
Normotension 
113 (49%) 
Nocturnal 
Hypertension 
217 (21%) 
Extreme Dippers  
199 (92%) 
Nocturnal 
Normotension 
18 (8%)  
Nocturnal 
Hypertension 
24 (2%)     
Reverse Dippers 
4 (17%)  
Nocturnal 
Normotension 
20 (83%) 
Nocturnal 
Hypertension 
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Figure 3.2. Mean blood pressures by dipping status and target organ damage 
LVH = Left ventricular hypertrophy; SBP = systolic blood pressure; DBP = diastolic blood 
pressure 
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Table 3.4. Logistic regression results for dipping status and target organ damage 
 ACR ≥ 1.1 mg/mmol 
 
n = 120 
ECG LVH 
 
n = 70 
ACR ≥ 1.1 mg/mmol 
 
OR (95%CI) 
 
 
P-value 
ECG LVH 
 
OR (95%CI) 
 
 
P-value 
 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
n  
67 
34 
14 
5 
n 
34 
18 
12 
6 
 
1 
1.3 (0.8 – 2.1) 
0.5 (0.3 – 0.9) 
2.0 (0.7 – 5.5) 
 
 
0.2 
0.03* 
0.2 
 
1 
1.4 (0.8 – 2.5) 
0.9 (0.5 – 1.8) 
5.3 (2.0 – 14.3) 
 
 
 
0.3 
0.8 
0.001* 
 
Partially 
adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
1.2 (0.8 – 2.0) 
0.5 (0.3 – 1.0) 
1.8 (0.6 -5.0) 
 
 
0.4 
0.04* 
0.3 
 
 
1 
1.1 (0.6 – 2.0) 
0.9 (0.4 – 1.8) 
3.8 (1.4 – 11.1) 
 
 
 
0.9 
0.7 
0.01* 
 
Fully adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
0.9 (0.6 – 1.5) 
0.7 (0.4 – 1.4) 
0.6 (0.2 – 2.0) 
 
 
 
0.7 
0.3 
0.4 
 
 
 
1 
0.9 ( 0.4 – 1.7) 
1.1 (0.5 – 2.2)  
2.1 (0.7 – 7.0) 
 
 
0.7 
0.9 
0.2 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; OR = Odds ratio; CI = Confidence interval 
Partially adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
Fully adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI  plus further adjusted for night-time systolic blood 
pressure 
* Statistically significant 
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3.5. Discussion 
This large primary care based population study describes the association between 
nocturnal blood pressure and subclinical target organ damage. Our findings 
demonstrate a significant association between the absolute night-time systolic 
blood pressure and LVH and ACR. The absolute daytime systolic blood pressure was 
associated with target organ damage in unadjusted and adjusted analysis but the 
odds ratios were less than those for night-time systolic blood pressure. When both 
daytime and night-time systolic blood pressures were included in the same models 
only the findings for night-time systolic blood pressure remained statistically 
significant. There was no association between dipping status and target organ 
damage in fully adjusted models. Cuspidi et al found target organ damage to be 
prevalent in those with nocturnal hypertension independent of dipping status. (16) 
Also, in dippers and non-dippers with nocturnal hypertension the prevalence of 
subclinical target organ damage was similar. (18) Tsioufis et al found the absolute 
night-time blood pressure to be better than dipping status for predicting both 
cardiovascular and renal outcomes in 2 systematic reviews. (32, 33) De La Sierra 
and colleagues reported on the prevalence of cardiovascular risk factors in patients 
classified by dipping and nocturnal hypertension status. (34) Those with both 
abnormalities had higher prevalence of additional cardiovascular risk factors. Non-
dipping was better associated with reduced renal function and history of previous 
cardiovascular events while the absolute blood pressure was better associated with 
microalbuminuria. They suggest that non-dipping may be a marker of more 
advanced disease. 
An ECG and spot urine sample are recommended as first line in the evaluation of 
those with hypertension. (9, 35) Both are readily available and can be measured at 
low cost. Therefore these were chosen as the tools to assess target organ damage 
in our study. The greater association of absolute night-time systolic blood pressure 
over daytime systolic blood pressure and dipping status with these markers of 
target organ damage suggest the absolute night-time systolic blood pressure is the 
most important parameter of the ABPM report. In addition the finding in the 
stratified analysis of a greater association of reverse dipping with LVH in treated 
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individuals adds support to the suggestion made by De La Sierra and colleagues that 
non-dipping may be a marker of more advanced disease.  
Therefore, categorising night-time blood pressure by dipping status alone may be 
an inadequate approach. In our analysis there was no significant association 
between dipping status and subclinical target organ damage in fully adjusted 
models while there was for absolute blood pressure level. While a dipping pattern is 
considered optimal (6) we have demonstrated that dippers are a heterogeneous 
group. The majority of dippers had normal night-time blood pressure but over a 
quarter had nocturnal hypertension and therefore are likely to be at increased 
cardiovascular risk long-term.  
A recent review discusses the complexities of dipping status versus the apparently 
more straightforward approach of categorising by absolute blood pressure values, 
with particular focus on isolated nocturnal hypertension. (36) Also, defining 
nocturnal blood pressure by absolute cut-offs rather than dipping status has been 
found to be more reproducible on follow-up ABPM. (37) Our work and evidence 
from the literature (18, 32, 33, 36, 37) supports the use of categories based on 
absolute blood pressures. It is more straightforward and it may be easier to apply in 
daily clinical practice. There is particularly relevant given the increasing emphasis 
on 24 hour ABPM in the diagnosis of hypertension. (38) 
We didn’t find any association between diastolic blood pressure and LVH. However, 
day and night pulse pressures were significantly associated with LVH in unadjusted 
and adjusted models which may explain this finding (Supplemental table 3.11, 
Appendix 3). Our sample had a large proportion of extreme dippers (21%) and over 
50% of the sample had a daytime pulse pressure of 50 mmHg or more with over 
40% having a night-time pulse pressure of  50 mmHg or more (data not shown).  A 
high pulse pressure has been shown to predict cardiovascular outcomes in older 
adults. (39, 40) Also, a wide pulse pressure can be considered a marker for central 
arterial stiffness (41) and therefore subclinical target organ damage.  
The use of fixed intervals or diary intervals doesn’t affect the prognostic value of 
ABPM. (42-45) We used diary rather than fixed intervals and though this reduced 
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the numbers in the final analysis, carrying out the analysis using fixed intervals did 
not change the results (data not shown). 
There are a number of limitations to our study. The cross-sectional design means 
we do not know the direction of the association between night-time blood pressure 
and target organ damage and reverse causality is a possibility. Much of the data 
was collected by questionnaire and as a result is subject to recall bias. However, 
studies have shown that self-reported history of doctor diagnosis is a valid tool for 
epidemiological research, in particular for hypertension, diabetes, stroke and 
myocardial infarction. (46)  
The overall sample was similar to the background population on demographic 
characteristics based on census data. (25) However, it is a GP based sample which 
could result in bias as those who are registered with a GP may be sicker than those 
from a true population sample. On the other hand they could be more health 
conscious than those who fail to register.  This selection bias could in turn impact 
on participant recall, for example those who had a previous ABPM with their GP 
may be more inclined to self-report a diagnosis of hypertension, or similarly, those 
with a previous history of cardiovascular disease will have had increased contact 
with health services and be more aware of risk factors. This may in turn have led to 
them being more inclined to agree to undergo ABPM for the study. Indeed those 
who agreed to undergo 24 hour ABPM were a higher risk group. Compared to those 
who didn’t undergo ABPM they were a year older (60 v 59 years, p < 0.001), more 
likely to have a doctor diagnosis of hypertension (35% v 21%, p < 0.001), more likely 
to report being on anti-hypertensive medication (35% v 22%, p < 0.001), had a 
higher BMI (29 kg/m2 v 28 kg/m2, p < 0.001), a lower eGFR (89 mls/min v 91 
mls/min, p = 0.001) and a higher Cornell Product (1511 mm x ms v 1406 mm x ms,  
p < 0.001). Also, a higher proportion of women underwent ABPM (53 % v 47%,        
p = 0.007).  
Our results are based on 1 ABPM recording and it is recognised that night-time 
blood pressure profiles are not fully reproducible. (47) The major strengths of our 
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study lie in the population based sample and the relatively large number 
undergoing 24 hour ABPM.  
Conclusion: 
Based on our findings the absolute night-time systolic blood pressure is the most 
important parameter to consider when assessing 24 hour ABPM and may be a 
superior early marker of cardiovascular risk. Further research should focus on the 
use of absolute blood pressure categories and their application in clinical practice. 
Chronotherapy (the administration of antihypertensive medications in the evening 
to reduce night-time blood pressure) may have a benefit in reducing cardiovascular 
events (48, 49), however randomised controlled trials are necessary to clearly 
demonstrate if specifically targeting mean night-time blood pressure or restoring 
the normal dipping profile reduces clinically important outcomes. Our results 
suggest the absolute night-time systolic blood pressure rather than non-dipping 
status should be the primary therapeutic target for these studies. 
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4.1.1. Abstract 
Introduction  
Isolated nocturnal hypertension (INH) is associated with greater mortality and 
cardiovascular events compared to those who are normotensive. Subclinical target 
organ damage (TOD) is a prognostic marker for cardiovascular events. Our objective 
is to systematically summarise evidence on the association between INH and 
subclinical TOD.  
Methods 
Observational population studies were considered. INH was defined as night-time 
blood pressure (BP) ≥ 120/70 mmHg with daytime BP < 135/85 mmHg. We 
systematically searched Pubmed, EMBASE and the Cochrane Library. Abstracts 
were reviewed by 2 assessors. Potentially eligible articles were compared with 
inclusion criteria.  
Results 
The search yielded 954 titles, 13 abstracts were selected for review and 4 articles 
fulfilled inclusion criteria. INH was associated with higher ambulatory arterial 
stiffness index (0.4 unit v 0.35 unit, p <0.05), pulse wave velocity (16.2 m/s v        
14.7 m/s, p<0.05), central (140.4% v 134.0%, p < 0.05) and peripheral (82.6% v 
76.5%, p <0.01) augmentation index in a Chinese study. In the same population 
there was no association with left ventricular hypertrophy (LVH) documented by 
electrocardiogram. Central aortic diastolic BP (75.9 mmHg v 69.4 mmHg, p =0.02) 
was higher in those with INH in a Swedish study. An American study demonstrated 
higher left ventricular mass (153.46 g v 136.16 g, p = 0.01) and greater odds of LVH 
(OR 3.03, 95% CI 1.02 – 9.05) in unadjusted analysis. There was no association with 
proteinuria.  
Discussion 
Evidence is inconclusive regarding the association between INH and subclinical 
TOD. Future research should focus on trying to elucidate the mechanisms that 
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generate INH and contribute to the higher mortality associated with this BP 
pattern. 
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4.1.2. Introduction 
Twenty four hour ambulatory blood pressure monitoring (ABPM) enables blood 
pressure to be recorded throughout the day and night away from the medical 
setting as a person carries out their usual activity. This provides more reliable 
assessment of blood pressure. (1) The National Institute of Health and Care 
Excellence in the United Kingdom now recommend 24 hour ABPM for the diagnosis 
of hypertension (2), while the JNC 7 and the European guidelines recommend 24 
hour ABPM in certain clinical situations such as suspected white coat hypertension, 
drug resistance, hypotensive symptoms and others. (1, 3) The European guidelines 
also give assessment of night-time blood pressure a specific indication for ABPM. 
Since the introduction of 24 hour ABPM much has been learned regarding the 
diurnal blood pressure profile. The prognostic importance of night-time blood 
pressure is recognised. (4) The dipping phenomenon and nocturnal hypertension 
have been the focus of much research. (5-8) Isolated nocturnal hypertension was 
first described in 2007 and describes elevated night-time blood pressure in the 
presence of normal daytime blood pressure i.e. night-time systolic blood pressure  
≥ 120 mmHg and/or night-time diastolic blood pressure ≥ 70 mmHg with daytime 
blood pressure of < 135/85 mmHg on ABPM. (9) Fan et al have demonstrated a 
higher risk of mortality and cardiovascular events in those with isolated nocturnal 
hypertension. (10) 
Subclinical target organ damage is a prognostic marker for future cardiovascular 
events. (11-14) It is recognised that the presence of organ damage refines 
cardiovascular risk assessment. (15, 16) It is recommended that all patients with 
hypertension undergo a physical examination to assess for organ damage. It can be 
considered an intermediate in the development of cardiovascular disease and can 
be detected in the heart, kidneys, brain, vasculature and retina by various methods. 
(1) 
Given the greater prognostic significance of night-time blood pressure we postulate 
that those with isolated nocturnal hypertension have more target organ damage. 
The objective of this paper is to systematically review available evidence on the 
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association between isolated nocturnal hypertension and subclinical target organ 
damage.   
4.1.3. Methods 
Inclusion Criteria: 
Study type 
Original observational population based research studies.  
Study Population 
Those recruited to population based observational studies undergoing 24 hour 
ABPM and an assessment of any target organ. 
Definition of isolated nocturnal hypertension 
Elevated night-time systolic blood pressure ≥ 120 mmHg and/or night-time diastolic 
blood pressure ≥ 70 mmHg and normal daytime blood pressure (< 135/85 mmHg) 
measured by ABPM. 
Comparison group 
Those with isolated nocturnal hypertension compared to a group who were 
normotensive by day and night. 
Subclinical target organ damage 
Recognised markers of subclinical damage in any target organ. 
Search Methods: 
We developed the search strategy for PubMed and adapted it for use in the other 
databases. We systematically searched Pubmed, EMBASE and the Cochrane Library. 
The following search terms were used as keywords and/or MESH 
terms:  (((((isolated OR masked) AND (nocturnal OR night-time OR nighttime OR 
night time) AND hypertension)) OR (((Hypertension) AND "Blood Pressure 
Monitoring, Ambulatory") AND "Circadian Rhythm"))) AND 
(((((((((((((((((((((microalbuminuria) OR (Left AND ventricular AND hypertrophy)) OR 
(Left AND ventricular AND mass)) OR electrocardio*) OR echocardio*) OR (arterial 
AND stiffness)) OR (augmentation AND index)) OR (Pulse AND wave AND velocity)) 
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OR (carotid AND ultrasound)) OR (carotid AND intima AND media AND thickness)) 
OR CIMT) OR (asymptomatic AND carotid AND stenosis)) OR (ankle AND brachial 
AND index)) OR (flow AND mediated AND dila*)) OR (endothelial AND dysfunction)) 
OR (((((((magnetic AND resonance AND imaging)) OR (computed AND tomography)) 
OR MRI) OR CT)) AND (((white AND matter AND hyperintensities)) OR (white AND 
matter AND lesions)))) OR retinopathy) OR (retinal AND photography)) OR 
(Coronary AND calcium AND score))) OR ((end OR target) AND organ AND (damage 
OR disease))) 
Potentially relevant articles were identified. Duplicates were removed. Two 
independent reviewers reviewed selected abstracts and the full text of relevant 
papers was obtained. These were compared against the inclusion criteria and 
assessed for quality using guidelines recommended by Hayden et al for quality 
appraisal in systematic reviews of prognostic studies, (17) (Table 4.1.1). The 
references of relevant articles were searched for further potential studies. 
There was one non-English article included. The authors were contacted for an 
English translation which wasn’t available. The article was translated with an online 
translation programme and this was checked with a native speaker.  
Because of heterogeneity in the outcomes assessed, pooling of results or meta-
analysis was not carried out. 
(Appendix 3. MOOSE Checklist for Search Strategy)(18) 
4.1.4. Results 
Figure 4.1.1 demonstrates the results of the literature search. The electronic search 
yielded 954 titles. On screening the titles 18 were considered potentially relevant.  
Duplicates were removed and 13 abstracts were selected for review. Of these 5 
were excluded and the full text of 8 articles was obtained. A further 4 were 
excluded at this point. One was a duplicate study, 1 was a review article and 2 
didn’t assess isolated nocturnal hypertension. 
Four studies are included in this narrative review. The design of these are 
summarised in Table 4.1.2. No single measure of subclinical target organ damage 
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was assessed by all 4 studies. The number of patients with isolated nocturnal 
hypertension in each study varied from 15 to 81 (Table 4.1.3). 
Li et al first described isolated nocturnal hypertension in 2007. (9) They studied a 
population based sample from rural China. Of 677 participants, 74 (10.9%) had 
isolated nocturnal hypertension. They excluded patients who had either a normal 
daytime or night-time blood pressure and were also on anti-hypertensive 
medications, as they couldn’t ascertain what category they would have fitted into in 
the untreated condition.  
They assessed arterial properties using radial and central augmentation indexes, 
ambulatory arterial stiffness index and brachial-ankle pulse wave velocity. They 
found all markers of arterial stiffness were significantly higher in those with isolated 
nocturnal hypertension compared to those who were normotensive with 
adjustments applied for sex, age, height and pulse rate (Table 4.1.3). 
Lu et al examined the relationship between isolated nocturnal hypertension and 
left ventricular hypertrophy documented by electrocardiography (ECG) in the same 
Chinese population. (19) They used Sokolow-Lyon voltage and Cornell Product 
criteria to define left ventricular hypertrophy.  
They found that those with isolated nocturnal hypertension had higher Sokolow-
Lyon voltage and Cornell Product compared to normotensive participants. However 
following adjustment for sex, age, BMI, alcohol, smoking status, cholesterol, fasting 
glucose and anti-hypertensive medications these findings were no longer 
statistically significant. The prevalence of left ventricular hypertrophy by cut-offs 
was not statistically different between those with isolated nocturnal hypertension 
and normotension (23.6% v 17.4%, p = 0.24) (Table 4.1.3). 
Wijkman et al examined isolated nocturnal hypertension in middle aged people 
with type 2 diabetes from 15 different primary healthcare centres in Sweden. (20) 
They defined isolated nocturnal hypertension as clinic blood pressure < 130/80 
mmHg, daytime ABPM blood pressure < 135/85 mmHg and night-time ABPM blood 
pressure ≥ 120/70 mmHg. Of a total sample of 414, 15 (3.6%) patients fulfilled this 
definition. They assessed arterial properties by measuring the central augmentation 
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index and carotid femoral pulse wave velocity. Left ventricular mass index was 
determined by echocardiography.  
They found no statistical difference in central pulse pressure, central augmentation 
index or aortic pulse wave velocity. Similarly there was no statistically significant 
difference in left ventricular mass between the isolated nocturnal hypertensive 
group and the normotensive group (Table 4.1.3). 
Ogedegbe et al examined isolated nocturnal hypertension in an African American 
sample of the Jackson Study. (21) The sample size was 425 and 81 (19.1%) had 
isolated nocturnal hypertension. The authors excluded those on anti-hypertensive 
therapy. Two-D and m-mode echocardiography was carried out and left ventricular 
mass and mass index calculated. Spot urinary albumin:creatinine ratio (ACR) was 
used to document proteinuria. 
They found higher left ventricular mass in those with isolated nocturnal 
hypertension in unadjusted models and in models adjusted for age and gender. This 
was not seen in fully adjusted models which included diabetes, cholesterol, 
metabolic syndrome, urinary sodium:creatinine ratio, daytime pulse pressure and 
alcohol. The odds ratio (OR) for left ventricular mass index ≥ 51 g/m2 was greater in 
unadjusted models for the isolated nocturnal hypertension group (OR 3.03, 95% CI 
1.02 – 9.05). However, the adjusted models were not statistically significant (OR 
2.58, 95% CI 0.75 – 8.94). This was the only study to examine proteinuria. There was 
no increased risk of proteinuria in those with isolated nocturnal hypertension in 
either unadjusted or adjusted analysis (Table 4.1.3). 
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Table 4.1.1. Quality assessment of included studies 
Author Li et al Lu et al Wijkman et al Ogedegbe et al 
Study Participation 
The study sample represents the population of 
interest on key characteristics, sufficient to limit 
potential bias to the results. 
 
 
Yes 
 
Yes 
 
Partly 
Isolated nocturnal 
hypertension 
study sample 
characteristics not 
adequately 
described 
 
 
Yes 
Study Attrition 
Loss to follow-up (from sample to study population) is 
not associated with key characteristics (i.e. the study 
data adequately represent the sample), sufficient to 
limit potential bias 
 
Partly 
No description of 
characteristics of 
non-responders 
 
 
Partly 
No information on 
response rate and 
non-responders 
 
Partly 
No information on 
response rate and 
non-responders 
 
Yes 
Prognostic Factor Measurement /Outcome 
Measurement 
The prognostic factor of interest is adequately 
measured in study participants to sufficiently limit 
potential bias 
 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
Confounding Measurement and Account 
Important potential confounders are appropriately 
accounted for, limiting potential bias with respect to 
the prognostic factor of interest 
 
 
Partly 
 
 
Partly  
 
 
No 
 
Yes 
 
 
Analysis 
The statistical analysis is appropriate for the design of 
the study, limiting potential for presentation of 
invalid results 
 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
1
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Electronic database search: n = 954  
 
Potentially relevant: n = 18 
 
936 not relevant on initial screen 
5 duplicates removed 
Abstracts selected for review: n = 13 
 5 excluded: 
1 didn’t assess isolated nocturnal 
hypertension  
 
1 assessed hard clinical endpoints 
 
3 conference abstracts 
- 1 duplicate analysis 
- 1 no normotensive 
comparison group 
- 1 didn’t assess isolated 
nocturnal hypertension 
Full text articles assessed for eligibility:  n = 8 
 4 excluded: 
1 review 
1 duplicate study 
2 didn’t assess isolated nocturnal 
hypertension 
Articles included in narrative synthesis: n = 4 
Figure 4.1.1 Flow chart of the systematic review search  
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Table 4.1.2. Design of included studies  
Author, 
publication date 
Setting Participants Study 
Design 
Sampling Cases Excluded Subclinical 
cardiovascular 
disease measure 
Confounders 
Li et al,  
2007 
14 villages in the 
JingNing county, 
a rural area 
approx. 500 km 
south of 
Shanghai, China 
Population 
based 
participants 
aged > 12 years  
Cross-
sectional 
2059 villagers 
invited to 
participate 
1490 (72.4%) gave 
informed consent 
733 (49%) 
underwent ABPM 
 
17 excluded due to lack 
of valid ABPM readings 
14 excluded due to lack 
of measurement of 
arterial properties 
25 excluded with either 
a normal day-time or 
night-time blood 
pressure on 
antihypertensive 
treatment  
Central and 
peripheral 
augmentation index 
 
Ambulatory arterial 
stiffness index 
 
Pulse wave velocity 
 
Sex, age, body 
height and pulse 
rate 
Lu et al,  
2008 
14 villages in the 
JingNing county, 
a rural area 
approx. 500 km 
south of 
Shanghai, China 
Population 
based 
participants 
aged > 12 years 
 
Cross-
sectional 
Total numbers 
screened not stated 
697 underwent 
ABPM 
 
8 under 18 years 
excluded 
 
17 excluded due to lack 
of valid ABPM readings 
 
25 excluded with either 
a normal day-time or 
night-time blood 
pressure on 
antihypertensive 
treatment 
Sokolow Lyon and 
Cornell Product LVH 
criteria on 12 lead 
ECG  
Sex, age, BMI, 
alcohol, smoking 
status, 
cholesterol, 
fasting glucose 
and anti-
hypertensive 
medications 
       Continued… 
 
 
 
 
1
06
 
 
107 
 
 
 
 
 
 
Table 4.1.2. Continued 
Wijkman et al, 
2009 
15 different 
primary 
healthcare 
centres in the 
counties of 
Östergötland 
and Jönköping, 
Sweden 
Patients with 
type 2 diabetes 
aged 55-65 
years  
Cross-
sectional 
Participants in the 
Cardiovascular Risk 
factors in Patients 
with Diabetes – a 
Prospective study 
in Primary care 
(CARDIPP) 
 
Total numbers 
screened not stated 
414 underwent 
ABPM 
314  excluded  with 
clinic blood pressure      
≥ 130/80 mmHg 
 
25 excluded due to 
elevated daytime 
ambulatory blood 
pressure  
Central aortic BP  
 
Central pulse 
pressure 
 
Central 
augmentation index 
 
Pulse wave velocity 
 
LVMI by 
echocardiography 
No adjustment 
for confounders 
Ogedegbe et al, 
2013 
Jackson, 
Mississippi, USA 
Non-
institutionalised 
African 
American 
adults aged 21 
– 94 years 
Cross-
sectional 
Participants of the 
Jackson Heart Study 
were invited to 
undergo 24 hour 
ABPM 
5301 invited to 
participate 
1150 (21.6%) 
agreed 
327 due to lack of valid 
ABPM readings 
 
398 excluded due to 
antihypertensive use 
LV mass and LVMI by 
echocardiography 
 
Urinary 
albumin:creatinine 
ratio > 30 mg/g 
 
Age, gender, 
diabetes, 
cholesterol, 
metabolic 
syndrome, 
urinary 
sodium:creatinine 
ratio, daytime 
pulse pressure 
and alcohol 
ABPM = Ambulatory Blood Pressure Monitoring; INH = Isolated nocturnal hypertension; BP = blood pressure ; LV = left ventricular;  LVH = left ventricular 
hypertrophy; LVMI = left ventricular mass index 
1
07
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Table 4.1.3. Results of included studies 
Author, 
publication date 
Number of 
participants 
INH/Total(%) 
Results  Summary of Findings 
Li et al,  
2007 
74/677 (10.9%) Central augmentation index, %                            
Peripheral augmentation index, %                        
Ambulatory arterial stiffness index, units           
Brachial-ankle pulse wave velocity, m/s              
140.4 v 134.0, p < 0.05 
82.6 v 76.5, p < 0.01 
0.4 v 0.35, p < 0.05 
16.2 v 14.7, p < 0.05 
INH group showed significant increases in all 4 
measured indexes of arterial stiffness 
compared to normotensive group 
Lu et al,  
2008 
72/647 (11.1%) Sokolow Lyon and Cornell Product LVH criteria 23.6% v 17.4%, p = 0.24 No difference in prevalence of LVH in those 
with INH from normotensives 
 
Wijkman et al, 
2009 
15/414 (3.6%) Central aortic diastolic BP, mmHg                                 
 
Central aortic systolic BP, mmHg 
Central pulse pressure 
Central augmentation index 
Aortic pulse wave velocity, m/s              
LVMI 
75.9 v 69.4, p = 0.02 
 
116.6 v 109.8, p = 0.15 
Figures not provided 
Figures not provided 
10.3 v 9.3, p = 0.06 
Figures not provided 
Central aortic diastolic BP higher in those with 
INH compared to normotensives 
 
No difference in central aortic systolic BP, 
central pulse pressure, central augmentation 
index, aortic pulse wave velocity or LVMI 
Ogedegbe et al, 
2013 
81/425 (19.1%) Unadjusted LV mass (g) 
Age and gender adjusted LV mass (g) 
Multivariable adjusted LV mass (g) 
 
Unadjusted LVH (OR LVMI ≥ 51g/m
2
)
  
Age and gender adjusted LVH (OR LVMI ≥ 51g/m
2
) 
Multivariable adjusted LVH (OR LVMI ≥ 51g/m
2
) 
 
Unadjusted proteinuria (OR UACR > 30mg/g) 
Age and gender adjusted proteinuria (OR UACR > 30mg/g) 
Multivariable adjusted proteinuria (OR UACR > 30mg/g) 
153.46 v 136.16, p = 0.01 
152.32 v 137.42, p = 0.02 
147.54 v 136.32, p = 0.12 
 
3.03 (95% CI 1.02 – 9.05, p = 0.05) 
2.89 (95% CI 0.96 – 8.69, p = 0.06) 
2.58 (95% CI 0.75 – 8.94, p = 0.13) 
 
3.34 (95% CI 0.91 – 12.28, p = 0.07) 
3.29 (95% CI 0.89 – 8.22, p = 0.08) 
1.95 (95% CI 0.46 – 8.22, p = 0.37) 
Higher LV mass in the INH group compared to 
normotensive group in unadjusted and age 
and gender adjusted model. Not seen in fully 
adjusted models. 
 
INH group greater odds of LVH in unadjusted 
model only 
 
No increased risk of proteinuria 
 
INH = isolated nocturnal hypertension; BP = blood pressure; LV = left ventricular;  LVH = left ventricular hypertrophy; LVMI = left ventricular mass index; OR = Odds Ratio; UACR = Urinary Albumin 
Creatinine Ratio 
 
1
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4.1.5. Discussion 
There is relatively little literature regarding the association of isolated nocturnal 
hypertension with subclinical target organ damage. Available evidence is 
inconclusive on this subject. Just 4 papers satisfied the inclusion criteria. No single 
measure of target organ damage was assessed by all of these. The studies included 
were cross-sectional in design and each had some weaknesses which further limits 
the capacity to draw inference. 
The Li et al study from China suggests an association with increased arterial 
stiffness but the issue of residual confounding remains in this study. They did not 
adjust for potential important confounders such as diabetes and renal disease. This 
isn’t addressed and is a potential source of bias. They do discuss other potential 
limitations such as the reproducibility of isolated nocturnal hypertension and the 
use of short fixed time intervals rather than diary intervals to analyse the ABPM 
results. 
On the other hand, Lu et al didn’t find any increased risk of left ventricular 
hypertrophy documented by ECG in the same population. They do adjust for 
confounders, but diabetes and renal disease are omitted. They discuss the limited 
reproducibility of night-time blood pressure and also acknowledge the limited 
sensitivity and specificity of the ECG. However, despite the recognised weaknesses 
of the ECG (22), it is a cheap investigation which is readily available to most 
practitioners and is a recognised independent predictor of prognosis, (12, 23) which 
makes it important to consider in research questions.  
The Wikjman et al study found the markers of arterial stiffness to be no different 
from those in the normotensive group.  The small numbers included in this analysis 
limits interpretation. Also, limited information is provided on the study sample. We 
contacted the study authors for this information but this was unavailable.   
The primary focus of this paper was to evaluate the impact of masked nocturnal 
hypertension, defined as a clinic blood pressure < 130/80 mmHg and night-time 
blood pressure ≥ 120/70 mmHg, on arterial stiffness and central blood pressure. 
The numbers included in the analysis for isolated nocturnal hypertension were 
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small as they extended the definition for masked nocturnal hypertension to include 
those who had normal daytime blood pressure on ABPM. The clinic blood pressure 
is not usually included in the definition for isolated nocturnal hypertension. They 
may have had higher numbers in their analysis had they used the usual definition. 
As a result of the small numbers adjustment for confounding was not possible in 
the isolated nocturnal hypertension analysis. 
Also, those on anti-hypertensive medication were not excluded which could also 
have had an impact on blood pressure categorisation. This is addressed in the 
discussion by the authors. A number of other limitations are also considered 
including the use of a single ABPM recording, the potential impact of obstructive 
sleep apnoea on night-time blood pressure and the influence of sleep depth which 
they couldn’t address.  
In the Ogedegbe et al study, just 21.7% of invited Jackson Study participants agreed 
to undergo ABPM. The authors do address this potential source of bias and report 
the differences between those who did and did not undergo 24 hour ABPM. They 
were younger (53.2 v 57.1 years, p < 0.01) and more likely to be male (67.9% v 
61.6%, p < 0.01). They also raise the issue of the sample size which may not have 
had sufficient power to detect differences between isolated nocturnal hypertension 
and normotension. The limited reproducibility of night-time blood pressure 
patterns and the fact that their results are based on one ABPM recording are 
discussed. Sleep quality and the impact of this on night-time blood pressure are 
also considered. 
Generalisability of the findings of all the studies is a potential issue when the 
numbers in each study who actually underwent 24 hour ABPM is considered. The 
only study to address this is that by Ogedegbe et al as outlined above. Li et al do 
provide the numbers screened and those undergoing ABPM but fail to discuss the 
potential impact of this on the generalisability of their findings. Lu et al and 
Wijkman et al fail to provide the total numbers screened for inclusion in their 
studies and there is no discussion on the generalisability of the findings. All authors 
acknowledge the potential limited reproducibility of the isolated nocturnal 
hypertension pattern. Analysis in all 4 of the studies was based on 1 ABPM 
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recording. Night-time blood pressure patterns are not always reproducible although 
using absolute values rather than dipping status was found to result in more 
reproducible results. (24) Li et al carried out a follow-up study on 30 participants 
with isolated nocturnal hypertension with a mean follow-up time of 3.5 years. They 
found that 33% still had isolated nocturnal hypertension, 33% developed day-night 
hypertension, while 27% were normotensive and 7% had isolated daytime 
hypertension. (9) 
Categorising a normally distributed continuous variable such as blood pressure 
impacts power to detect real associations. (25, 26) However, clinicians need a 
diagnostic reference with thresholds that define normal and abnormal when 
managing patients. Therefore, from a practical perspective, there are advantages to 
using categories. The numbers of patients with isolated nocturnal hypertension in 
the 4 studies were not large which further reduces power to detect a true 
association. 
Studies that included participants taking anti-hypertensive medications were not 
excluded from the review.  Anti-hypertensive medications potentially influence 
blood pressure categorisation. Those on treatment may demonstrate isolated 
nocturnal hypertension but in the untreated state they may have demonstrated a 
sustained hypertension pattern. This is only really relevant for the Wikjman et al 
study as the Chinese studies excluded those on medications with either a normal 
daytime or night-time blood pressure and the Ogedegbe et al study excluded those 
on medications altogether. Given the small numbers in the Wikjman et al study this 
is unlikely to have had an impact on the overall findings.  
The prevalence of isolated nocturnal hypertension is 6% in Western Europe and 
7.9% in Eastern Europe which is significantly lower than that in Asia (10.9% in China 
and 10.2% in Japan), South Africa (10.2%) (27) or in African Americans (19.1%). (21) 
The mechanisms underlying the differences in prevalence rates and the increased 
risk associated with isolated nocturnal hypertension are not clear. Documenting 
changes in the cardiovascular system prior to the development of clinical disease 
may help us to further understand these potential mechanisms. Blunted sodium 
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metabolism, obstructive sleep apnoea and reverse causality have been proposed. 
(27) The outcomes assessed in this review can be considered surrogate markers. 
The use of surrogate markers is not without controversy. (28, 29) They need to 
accurately measure disease and predict future events while measurement needs to 
be meticulous.(30) However, the measures used in the 4 studies in this review all 
have a weight of literature behind them and are recognised as valid tools. (30, 31)  
The strengths of this review include a focused question with relative paucity of 
information and it identifies an evidence gap as the question isn’t answered by the 
available literature. The inclusion of non-English articles makes it likely that all 
relevant studies were identified. However, as with any systematic review there is 
always the possibility of missed studies.  
Conclusion: 
The evidence is inconclusive with respect to the association between isolated 
nocturnal hypertension and subclinical target organ damage. Future research 
should focus on elucidating the mechanisms that generate isolated nocturnal 
hypertension and the higher mortality risk associated with it demonstrated by Fan 
et al. (10) The reproducibility of this particular blood pressure pattern also needs to 
be elucidated. Specifically, research should focus on whether normalising isolated 
nocturnal hypertension in prospective studies reduces cardiovascular events.  
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4.2.1. Introduction 
Isolated nocturnal hypertension was first described in 2007 and describes elevated 
night-time blood pressure with normal daytime blood pressure. (1) In a systematic 
review of the literature we found the association between isolated nocturnal 
hypertension and subclinical target organ damage to be inconclusive. (2) However 
those with this blood pressure phenotype have higher mortality risk compared to 
those who are normotensive as demonstrated by the IDACO investigators. (3) Given 
the knowledge deficit identified in our systematic review the aim of this study is to 
examine the association between isolated nocturnal hypertension and target organ 
damage in the Mitchelstown Cohort Study.  
4.2.2. Methods  
Details of the Mitchelstown Cohort have previously been described.  (4)  
Blood Pressure Assessment: 
After the participant had been in a relaxed seated position for at least 5 minutes 
three blood pressure readings were taken on the right arm, 1 minute apart, using 
the OMRON Model M7 digital automatic blood pressure monitor.  The average of 
the second and third blood pressure reading was taken as the study blood pressure. 
Those recruited were also offered 24 hour ambulatory monitoring and 1207 (59%) 
agreed. ABPM measurements were performed using the MEDITECH ABPM-05 and 
data was stored using the dabl ABPM system. The monitors were programmed to 
record the blood pressure every 30 minutes throughout the 24 hour period. 
Participants kept a diary of the times they went to bed and got up. Diary times were 
used to calculate mean daytime and night-time blood pressures. Based on the 
ABPM results the sample was divided into 4 groups: normotension, isolated 
nocturnal hypertension, isolated daytime hypertension and day-night hypertension. 
We excluded those on treatment.  
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Target Organ Damage: 
Subjects brought a sample of the first urine they voided on the morning of their 
baseline appointment. This was analysed for albumin:creatinine ratio (ACR) which 
was used to document subclinical microvascular disease. A 12 lead ECG was 
obtained in the standard manner using a Siemens – Eclipse 850i machine. All ECGs 
were recorded at a standard 10 mm/mv.  ECGs were reviewed and coded for 
Cornell Product voltage criteria by Dr Anne Marie O’Flynn (i.e. SV3 + RaVL (+6 in 
women) X QRS duration ≥ 2440 mm x ms). This was used to document subclinical 
cardiac disease. 
Statistical Analysis: 
Statistical analysis was carried out using Stata 12. Baseline characteristics are 
presented as absolute numbers with corresponding percentages for categorical 
variables and as means with standard deviations for continuous variables. Normally 
distributed continuous variables were compared between groups using ANOVA. 
The Kruskall-Wallis test was used for non-normally distributed variables. 
Proportions of categorical variables were compared using the chi-square test. The 
association between blood pressure patterns and target organ damage was 
assessed by ANOVA and linear regression. Multivariable models were adjusted for 
sex, age, diabetes mellitus, smoking and BMI. 
4.2.3. Results 
Of 1207 who underwent ABPM, 128 were excluded due to incomplete recordings 
(<14 daytime and/or <7 night-time readings), 26 were excluded because they had 
missing data on microalbuminuria or LVH and a further 7 were excluded from the 
diary interval analysis due to lack of diary documentation. In addition we excluded 
those on treatment or those whose treatment status was unclear from the 
questionnaire. The analysis therefore includes 685 participants.  
Of 685 participants included, 29 (4%) had isolated nocturnal hypertension and 399 
(58%) were normotensive by day and night. There were 121 (18%) participants with 
isolated daytime hypertension and 136 (20%) with sustained day-night 
hypertension. The baseline characteristics by these blood pressure phenotypes are 
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presented in table 4.2.1. Blood pressure levels of the different groups are presented 
in table 4.2.2.  
In unadjusted analysis only those with sustained day-night hypertension had a 
statistically significant higher ACR compared to those who were normotensive (1.21 
mg/mmol v 0.52 mg/mmol, p < 0.001). Findings were similar in sex and age 
adjusted and multivariable adjusted models. The difference between those with 
isolated nocturnal hypertension and normotension was not statistically significant 
(1.01 mg/mmol v 0.52 mg/mmol, p = 0.1). Both those with sustained day-night 
hypertension and those with isolated daytime hypertension had statistically higher 
Cornell Product voltage than those who were normotensive. The findings for 
isolated nocturnal hypertension were not statistically significant (1525 mm x ms v 
1332 mm x ms, p = 0.08). Findings were similar in sex and age adjusted and 
multivariable adjusted models (Table 4.2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
120 
Table 4.2.1. Baseline characteristics by blood pressure status in untreated participants 
n=685 
 
 
 
Normotensive 
 
n = 399 (58%) 
 
mean(+/-SD)/n(%) 
Isolated Daytime 
Hypertension 
n = 121 (18%) 
 
mean(+/-SD)/n(%) 
Isolated Nocturnal 
Hypertension 
n = 29 (4%) 
 
mean(+/-SD)/n(%) 
Day-night 
Hypertension 
n = 136 (20%) 
 
mean(+/-SD)/n(%) 
P-value 
      
Age  59 (+/-5) 58 (+/-6) 59 (+/-5) 60 (+/-6) 0.8 
Male  161 (40) 61 (50) 19 (66) 84 (62) <0.001* 
Education category  
Primary 
Secondary 
Tertiary 
 
91 (24) 
203 (54) 
82 (22) 
 
32 (28) 
54 (47) 
28 (25) 
 
6 (21) 
13 (45) 
10 (34) 
 
33 (25) 
58 (43) 
43 (32) 
 
0.2 
IPAQ category  
Low 
Moderate 
High 
 
166 (43) 
122 (32) 
95 (25) 
 
62 (54) 
33 (29) 
19 (17) 
 
12 (41.5) 
5 (17) 
12 (41.5) 
 
72 (56) 
34 (26) 
23 (18) 
 
0.02* 
Smoking Status  
Non-smoker 
Former smoker 
Current smoker 
 
224 (57.5) 
103 (26.5) 
63 (16) 
 
46 (39) 
47 (40) 
24 (21) 
 
17 (61) 
9 (32) 
2 (7) 
 
65 (49) 
43 (32) 
26 (19) 
 
0.02* 
 
 
 
Continued… 
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Table 4.2.1. Continued 
Medical History       
Hypertension  9 (2) 6 (5) 2 (7) 13 (10) 0.03* 
Myocardial Infarction 2 (0.5) 0 (0) 1 (3) 1 (0.7) 0.4 
Stroke 3 (0.8) 1 (0.8) 0 (0) 0 (0) 0.9 
Heart failure  1 (0.3) 1 (0.9) 0 (0) 0 (0) 0.8 
Diabetes 18 (5) 5 (4) 12 (9) 4 (14) 0.05 
Medication      
Cholesterol lowering  104 (26) 35 (29) 7 (24) 41 (30) 0.8 
BMI (kg/m2) 27 (+/-4) 29 (+/-4) 29 (+/-4) 30 (+/-4) <0.001* 
Waist circumference (cm) 92 (+/-12) 98 (+/-11) 97 (+/-11) 102 (+/-13) <0.001* 
LDL (mmol/l) 3.4 (+/-0.8) 3.3 (+/-0.8) 3.4 (+/-1.0) 3.4 (0.9) 0.8 
Creatinine (µmol/l)   69 (+/-13) 69 (+/-13) 75 (+/-15) 73 (+/-14) 0.01* 
eGFR (mls/min)  91 (+/-11) 93 (+/-11) 89 (+/-10) 89 (+/- 12) 0.05 
ACR (mg/mmol)  0.5 (+/-0.9) 0.5 (+/-0.5) 1.0 (+/-2.3) 1.2 (+/-3.1) <0.001* 
Cornell Product (mm x ms) 1332 (+/-557) 1480 (+/-623) 1524 (+/-400) 1585 (+/-549) <0.001* 
ECG LVH  15 (4) 8 (7) 0 (0) 10 (7) 0.2 
* Statistically significant 
 
1
2
1
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Table 4.2.2. Blood pressure levels 
n=685 Normotensive 
 
mean(+/-SD) 
Isolated Daytime 
Hypertension 
mean(+/-SD) 
Isolated Nocturnal 
Hypertension 
mean(+/-SD) 
Day-night Hypertension 
 
mean(+/-SD) 
     
Clinic systolic BP mean (SD) 124 (+/-14) 142 (+/-14)*** 132 (+/-11)** 148 (+/-16)*** 
Clinic diastolic BP mean (SD) 78 (+/-9) 87 (+/-8)*** 83 (+/-8)** 91 (+/-8)*** 
Day systolic mean (SD) 121 (+/-8) 140 (+/-6)*** 128 (+/-5)*** 148 (+/-13)*** 
Day diastolic mean (SD) 73 (+/-7) 83 (+/-6) *** 78 (+/-5) *** 87 (+/-9) *** 
Night systolic mean (SD) 103 (+/-8) 110 (+/-7) *** 121 (+/-5) *** 129 (+/-12) *** 
Night diastolic mean (SD) 58 (+/-5) 61 (+/-5) *** 70 (+/-5) *** 73 (+/-8) *** 
24hr systolic mean (SD) 114 (+/-8) 129 (+/-6) *** 125 (+/-4) *** 141 (+/-11) *** 
24hr diastolic mean (SD) 67 (+/-6) 75 (+/-5) *** 75 (+/-5) *** 82 (+/-8) *** 
Significance of the difference with the normotensive comparison group  
**<0.01 
***<0.001 
1
2
2
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Table 4.2.3. Target organ damage by blood pressure status 
 
 
Normotensive 
 
Isolated Daytime 
Hypertension 
Isolated Nocturnal 
Hypertension 
Day-night 
Hypertension 
 
Urine ACR n = 678 (mg/mmol) (mg/mmol) (mg/mmol) (mg/mmol) 
Model 1: Unadjusted 0.52 0.49 1.01 1.21*** 
Model 2: Sex and age adjusted  0.52 0.49 1.01 1.21*** 
Model 3: Multivariable adjusted 0.53 0.50 1.04 1.20*** 
Cornell Product Voltage n = 684 (mm x ms) (mm x ms) (mm x ms) (mm x ms) 
Model 1: Unadjusted 1332 1480* 1525 1586*** 
Model 2: Sex and age adjusted  1332 1479** 1525 1586*** 
Model 3: Multivariable adjusted 1327 1468* 1520 1585** 
Model 1: unadjusted 
Model 2: adjusted for sex and age  
Model 3: adjusted for sex, age, diabetes mellitus, smoking and BMI 
 
Significance of the difference with the normotensive comparison group  
*<0.05 
**<0.01 
***<0.001 
 
 
1
2
3
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4.2.4. Discussion 
This short report did not find a statistically increased risk of target organ damage 
documented by ACR and ECG Cornell Product voltage criteria in those with isolated 
nocturnal hypertension compared to those who are normotensive. However this 
was a small study with just 29 participants fulfilling the criteria for isolated 
nocturnal hypertension so statistical power is a significant issue, as it was in the 4 
studies included in the systematic review.  Isolated nocturnal hypertension is more 
prevalent in in those of Asian and African ethnicity. (1) Therefore future research 
into this blood pressure profile should focus on such populations to avoid further 
underpowered studies. 
We excluded those on anti-hypertensive medication from this analysis as treatment 
status has a confounding effect on night-time blood pressure profiles as already 
discussed. The prevalence of isolated nocturnal hypertension in the untreated 
group included in this analysis was 4% versus 9% in those who were on treatment. 
This highlights the potential significance of this confounding effect. Therefore we 
recommend that future research examining isolated nocturnal hypertension 
exclude those on anti-hypertensive medication. 
Conclusion: 
The result of this analysis does not address the knowledge deficit identified in our 
systematic review and further research is required. This research should focus on 
untreated individuals in geographical areas where isolated nocturnal hypertension 
is most prevalent. 
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5.1. Abstract 
Introduction 
Valid measurement of target organ damage in epidemiological studies is essential 
to avoid measurement bias. We designed an epidemiological study to assess the 
association of night-time systolic blood pressure with ultrasound markers of 
vascular and cardiac damage. The aim of this study is to describe the quality 
assurance measures applied in order to minimise potential measurement error, 
including description of the ultrasound image acquisition protocol, device and 
personnel evaluation. 
Methods 
Carotid ultrasound and cardiac echocardiogram image acquisition and 
measurement protocols are described. Details of ultrasound phantom scans are 
described. Ten healthy volunteers underwent a carotid ultrasound twice within the 
same week by the same investigator. Carotid intima media thickness (CIMT) was 
measured from the acquired images by the same investigator for intra-observer 
reproducibility. An independent investigator analysed the second set of images for 
inter-observer reproducibility. The images of 10 outpatients undergoing routinely 
indicated echocardiography were analysed by speckle tracking analysis. All 
echocardiograms were carried out by the same operator. Speckle tracking analysis 
was carried out offline to measure global longitudinal strain (GLS). This was 
repeated by the same investigator for intra-observer reproducibility. An 
independent investigator also analysed the images for inter-observer 
reproducibility. Intra- and inter-observer reproducibility was assessed by Bland 
Altman Plots and intra-class correlation coefficients. 
Results 
The intra-observer intra-class coefficient (ICC) for CIMT was 0.91 (95% CI 0.69 – 
0.98). The inter-observer ICC for CIMT was 0.97 (95% CI 0.88 -0.99). The intra-
observer ICC for GLS was 0.93 (95% CI 0.70 - 0.98). The inter-observer ICC for GLS 
was 0.86 (95% CI 0.51 – 0.96). 
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Discussion 
We have demonstrated good intra- and inter-observer reproducibility of CIMT and 
GLS results with standardised imaging and reading protocols. Our findings suggest 
our measurement methods are valid and suitable to be applied in an 
epidemiological study. 
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5.2. Introduction 
The cardiovascular disease continuum highlights the importance of documenting 
target organ damage and clinical trials have clearly demonstrated that intervening 
on risk factors interrupts the continuum and improves clinical outcomes. (1) 
Documenting subclinical stages of organ damage helps to identify individuals who 
will get greater benefit from risk reduction therapy. (2) These intermediate 
surrogate markers must be meticulously measured to ensure accuracy of data. 
Carotid intima media thickness (CIMT) measurement by ultrasound is used to 
document subclinical disease in the carotid vasculature. There is evidence for the 
validity of CIMT as a surrogate measure of atherosclerotic disease. (3, 4) CIMT is 
recognised to be associated with the incidence of myocardial infarction and stroke. 
(5, 6)  The detection of plaques is also important as it improves the predictive 
performance of CIMT. (7)  
Cardiac echocardiography can detect subclinical changes in the heart such as left 
ventricular hypertrophy, left atrial enlargement and early diastolic dysfunction. 
More recently the development of speckle tracking echocardiography has also 
allowed the detection of subtle myocardial dysfunction. (8) The principle of speckle 
tracking echocardiography is the scattering of sound waves by the myocardium 
which generates speckles specific for an area of myocardium. These blocks of 
speckles or kernels can be tracked from frame to frame and provide information on 
deformation or contraction and relaxation (Figure 5.1). Global Longitudinal Strain 
(GLS) is a measure of the myocardial systolic deformation over the longitudinal axis 
measured from the apical views.  
Measurement bias occurs when measurement methods systematically over- or 
under-estimate the actual measurement. We designed a study to assess the 
association of night-time blood pressure with surrogate markers of cardiovascular 
disease including CIMT and GLS in a sample of participants of the Mitchelstown 
Cohort Study. (9) Quality assurance for such a study is essential to ensure valid and 
reliable measurement of target organ damage without systematic error. The aim of 
this manuscript is to describe the quality control measures applied in our study in 
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order to minimise potential measurement error, including description of the 
ultrasound image acquisition protocol, device and personnel evaluation. 
 
Figure 5.1. Tracking of acoustic speckles from frame to frame. Thomas H. Marwick. 
JACC 2006. Reproduced with permission. (10)  
5.3. Methods 
Carotid ultrasound protocol: 
A Philips Cx50 ultrasound machine and a L12-3 3 to 12 MHz extended frequency 
range linear array transducer were used for image acquisition. Subjects were 
examined in the supine position with their head tilted to the opposite side. A Meijer 
arc was used to ensure optimal positioning (Figure 5.2). All imaging was carried out 
at 4 cm depth where possible. A full transverse and longitudinal scan of the extra-
cranial carotid arteries was carried out to assess for the presence of atherosclerotic 
plaques. Ultrasound images of the distal portion of the far wall of both common 
carotid arteries were obtained for assessment of CIMT. Far wall still frames were 
taken from anterior, lateral and posterior angles. Three still frame images were 
taken from each angle. (11) 
The acquired images were saved using digital media and measurement was carried 
out offline using Philips QLAB cardiac and vascular ultrasound quantification border 
detection software version 9.0. This software automatically detects the CIMT 
borders but does allow manual manipulation in cases of suboptimal detection. 
Measurements were made on the 3 still frame images from each angle over a 
length of 1 cm at the distal common carotid artery (CCA) (Figure 5.3). The reference 
point for the commencement of the measurement was where the CCA began to 
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dilate prior to the bifurcation. A mean measurement from the 3 frames for each 
angle was obtained. The mean of these means was obtained to give the 
measurement for each side. The mean of the left and right was used to estimate 
the CIMT. The presence of plaques in the extra-cranial carotid arteries was 
recorded as a binary variable. A plaque was defined according to the Mannheim 
Consensus as a focal protrusion into the blood vessel ≥ 50% of the thickness of the 
adjacent IMT or focal IMT > 1.5 mm. (12) 
 
Figure 5.2. The Meijer Arc. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, 
Mohler ER et al. Journal of the American Society of Echocardiography 2008. 
Reproduced with permission. (11) 
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Figure 5.3. Measurement of CIMT at distal 1 cm of CCA 
Cardiac echocardiography protocol: 
A Philips iE33 ultrasound machine and a S5-1 1 to 5 MHz extended frequency range 
phased array transducer were used for image acquisition. A standard 
echocardiogram protocol was used. Parasternal long and short axis, apical 4-, 2- and 
3-chamber views were obtained. Optimisation of frame rate was carried out by 
reducing the sector depth and width and was above 50 frames/sec in all cases.  
The acquired images were saved using digital media and GLS analysis was carried 
out offline from apical 4-, 2- and 3- chamber views using Philips QLAB cardiac and 
vascular ultrasound quantification software version 9.0. The region of interest was 
selected by the identification of 3 points, one on either side of the mitral valve 
annulus and one at the apex for each view. Adequate tracking was confirmed 
visually and if deemed inadequate the region of interest was edited. GLS average 
was obtained from 17 ventricular segments represented on a bulls-eye plot from 
apical 4-, 2- and 3- chamber views. (Figure 5.4) 
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Figure 5.4. Bullseye plot of global longitudinal strain averaged from apical 4-, 2- and 
3-chamber views 
Ultrasound Phantom scans:  
Routine equipment maintenance was carried out during the scanning period. An 
ultrasound phantom mimics the acoustic properties of tissues and enables 
measurement of ultrasound system accuracy and performance in a standardised 
manner. For this study a general purpose urethane ultrasound phantom (CIRS 
Tissue Simulation & Phantom Technology Model 042 (Figure 5.5)) was used to 
assess ultrasound image quality and distance calibration. It consists of series of 
wires embedded in tissue mimicking gel.  Image uniformity was inspected. Vertical 
and horizontal target distances were measured. Lateral and axial resolution targets 
were inspected. Follow-up phantom scans were performed at 6 month intervals 
throughout the study period to ensure there was no drift in results.  
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Figure 5.5. General purpose urethane ultrasound phantom 
Intra- and inter-observer reproducibility: 
Ten healthy volunteers had a carotid ultrasound twice within the same week in 
2013 carried out by the same investigator (AMOF) who analysed both sets of 
images and compared them for intra-observer reproducibility. An independent 
investigator (EH) analysed the second set of images for inter-observer 
reproducibility.  
Ten outpatients undergoing routinely indicated echocardiography in Cork University 
Hospital in 2013 were asked to consent to have their images analysed by speckle 
tracking analysis. All echocardiograms were carried out by the same operator (IB). 
Speckle tracking analysis was carried out offline by AMOF and repeated for intra-
observer reproducibility. An independent investigator (EH) also analysed the images 
for inter-observer reproducibility. 
AMOF received formal training in CIMT image acquisition. IB is accredited in 
transthoracic echocardiography by the British Society of Echocardiography. Both 
AMOF and EH had formal training in CIMT and speckle tracking echocardiography 
analysis. 
Statistical analysis: 
All statistical analysis was carried out using Stata 12. Mean CIMT and GLS measured 
by AMOF and EH were compared and inspected visually by scatter plots. Mean 
differences were compared using paired t-tests. Exploratory analysis for intra- and 
inter-observer reproducibility was then carried out by Bland Altman Plots. Intra-
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class correlation coefficients for intra- and inter-observer reproducibility were also 
calculated.  
Ethical approval for the study was obtained from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals and all participants provided written 
informed consent.  
5.4. Results 
The phantom scan results are presented in Table 5.1. There was no drift in results 
over the study period. CIMT results of the healthy volunteers who underwent 
carotid ultrasound are presented in Table 5.2. GLS results for the patients 
undergoing echocardiography are presented in Table 5.3.  
Scatter plots of the CIMT and GLS results are presented in figures 5.6-5.9. The mean 
difference in CIMT between examinations observed by investigator 1 was -
0.0004mm (p = 1.0). The mean difference in CIMT between observers was         
0.004 mm (p = 0.2). The mean difference in GLS observed by investigator 1 was        
-0.82% (p = 0.07). The mean difference in GLS between observers was -1.04%  
(p = 0.09).  
Bland Altman Plots for intra- and inter-observer reproducibility are presented in 
figures 5.10-5.13. The intra-observer intra-class correlation coefficient (ICC) for 
CIMT was 0.91 (95% CI 0.69 – 0.98). The inter-observer ICC for CIMT was 0.97 (95% 
CI 0.88 -0.99). The intra-observer ICC for GLS was 0.93 (95% CI 0.70 - 0.98). The 
inter-observer ICC for GLS was 0.86 (95% CI 0.51 – 0.96). 
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Table 5.1. Phantom ultrasound scan results  
Cx50 ultrasound machine and L12-3 linear array transducer 
 Scan 1 Scan 2 Scan 3 
Uniformity Consistent Consistent Consistent 
Vertical distance 2.01 cm 2.01 cm 2.01 cm 
Horizontal distance 1.88 cm 1.88 cm 1.88 cm 
Axial resolution 0.5-1 mm 0.5-1 mm 0.5-1 mm 
Lateral resolution 3 mm 3 mm 3 mm 
iE33 ultrasound machine and S5-1 1 phased array transducer 
 Scan 1 Scan 2 Scan 3 
Uniformity Consistent Consistent Consistent 
Vertical distance 2.01 cm 2.01 cm 2.01 cm 
Horizontal distance 2 cm 2 cm 2 cm 
Axial resolution 0.5-1 mm 0.5-1 mm 0.5-1 mm 
Lateral resolution 2 mm 2 mm 2 mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2. CIMT results 
Subject Sex Age  CIMT mm 
(Investigator 1) 
CIMT mm 
(Investigator 1) 
CIMT mm 
(Investigator 2) 
1 Female 28 0.4628 0.4381 0.4136 
2 Male 19 0.4767 0.4939 0.4961 
3 Male 26 0.5861 0.5411 0.5511 
4 Male 30 0.4783 0.4906 0.4942 
5 Female 25 0.3811 0.3883 0.3697 
6 Female 34 0.4917 0.4878 0.4811 
7 Male 35 0.4511 0.4689 0.4550 
8 Female 33 0.4500 0.4678 0.4678 
9 Female 28 0.4494 0.4500 0.4500 
10 Male 25 0.4356 0.4400 0.4439 
CIMT = Carotid Intima Media Thickness  
Investigator 1 = Anne Marie O’Flynn 
Investigator 2 = Emily Ho 
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Table 5.3. Global longitudinal strain results 
Subject Sex Age Clinical information  GLS % 
(Investigator 1) 
GLS %    
(Investigator 1) 
GLS %  
(Investigator 2) 
1 Male 67 Mild aortic stenosis -22.0 -21.2 -19.6 
2 Male 27 Dilated aortic root -22.1 -22.0 -17.9 
3 Male 62 Mechanical aortic valve and left ventricular ejection fraction 40-50% -16.7 -15.1 -14.8 
4 Female 60 Murmur on clinical examination -19.0 -17.5 -15.9 
5 Male 51 History of non ST elevation myocardial infarction -23.5 -20.1 -22.0 
6 Male 77 Left ventricular ejection fraction 25-35% -14.9 -14.6 -14.0 
7 Male 55 Bicuspid aortic valve -12.7 -11.2 -12.4 
8 Male 45 Dyspnoea with previous chemotherapy   -16.0 -16.6 -14.1 
9 Male 29 Hypertension -17.6 -18.6 -17.2 
10 Male 35 Bicuspid aortic valve -24.1 -23.5 -22.1 
GLS = Global longitudinal strain 
Investigator 1 = Anne Marie O’Flynn 
Investigator 2  = Emily Ho 
1
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Figure 5.6. Scatter plot of CIMT measured by investigator 1  
 
Figure 5.7. Scatter plot of CIMT measured by investigators 1 and 2 
 
Figure 5.8. Scatter plot of GLS measured by investigator 1 
 
Figure 5.9. Scatter plot of GLS measured by investigators 1 and 2 
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Figure 5.10. Bland Altman plot for CIMT intra-observer reproducibility  
 
Figure 5.11. Bland Altman plot for CIMT inter-observer reproducibility 
 
Figure 5.12. Bland Altman plot for GLS intra-observer reproducibility 
 
Figure 5.13. Bland Altman plot for GLS inter-observer reproducibility 
1
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5.5. Discussion 
We have demonstrated good reproducibility of CIMT and GLS with standardised 
imaging and reading protocols. We found high levels of agreement within and 
between investigators with intra-observer and inter-observer ICCs above 0.9 for 
CIMT and intra-observer and inter-observer ICCs above 0.85 for GLS.  
Validity is the degree to which an instrument truly measures that which it is 
supposed to measure while reliability is defined as the degree to which a 
measurement is free from measurement error. A measurement can be valid but 
unreliable and vice versa. (13) Concerns exist regarding measurement quality with 
respect to CIMT. (14) This contributed to the decision not to recommend CIMT in 
routine clinical practice for the assessment of cardiovascular risk in American 
guidelines. (15)  
However, standardised protocols which take multiple measurements increase the 
validity of measurements. (13) Medical residents can be trained to measure CIMT 
using an abbreviated version of the American Society of Echocardiography protocol. 
(16) We have used a standardised CIMT imaging protocol with multiple 
measurements made from different angles on both sides to maximise the likelihood 
of a valid mean estimate and limit measurement error.  
Automated measurements result in less variability of CIMT. (17) Automated 
ultrasound makes it possible for novice operators to accurately assess CIMT after a 
short training period. (18) Automated border detection programmes produce valid 
and reproducible measurements. (19, 20) We used a semi-automated border 
detection programme to detect the CIMT border as recommended by the American 
Society of Echocardiography CIMT task force. (11)  
Our reproducibility results for CIMT are comparable to those reported by others in 
the literature. In the SALPALDIA Cohort Study in Switzerland, Caviezel et al reported 
ICCs of 0.87 to 0.91 for CIMT measured at the distal 1 cm of the CCA far wall and 
read using an automatic border detection programme. (21) An ICC of 0.74 was 
reported for the Rotterdam Study where both near and far wall CIMT of the distal 
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CCA was measured. (22) In the MESA (Multi-Ethnic Study of Atherosclerosis) study 
intra-observer rescan ICC was 0.95 and inter-observer ICC was 0.87. They measured 
the mean of the maximal CIMT of the near and far wall of the distal 1 cm of the 
CCA. (23) The ARIC (Atherosclerosis Risk in Communities) study, on which our image 
acquisition protocol is based, has reported a reliability coefficient of 0.77 for the 
mean CIMT of the distal 1 cm of the CCA. (7) 
Speckle tracking echocardiography myocardial strain is an accurate and angle 
independent measurement of myocardial function and has been validated against 
sonomicrometry and magnetic resonance imaging. (24) GLS appears to be the most 
robust strain measurement. (25) It is also more reproducible than ejection fraction 
and other conventional echocardiographic parameters. (26) It also provides 
superior prognostic information to ejection fraction. (27) To maximise validity we 
used a standardised protocol to acquire the echocardiogram images. As per 
recommendations we ensured a frame rate above 50 frames/sec. (8, 28) In addition 
GLS was averaged from 3 apical views.  
Our GLS reproducibility results compare favourably with those reported in the 
literature. Oxborough et al reported an ICC of 0.807 for intra-observer reliability of 
longitudinal strain measured from the apical 4 chamber view in healthy young 
adults. (29) At the 25 year follow-up examination of the CARDIA (Coronary Artery 
Risk Development in Young Adults) Study Armstrong et al reported an ICC of 0.71 
for 2 chamber longitudinal strain and 0.55 for 4 chamber longitudinal strain for 
inter-reader reproducibility while the ICC values for intra-reader reproducibility 
were 0.87 and 0.79 respectively. (30) Russo et al reported an ICC of 0.85 for inter-
observer reproducibility of GLS measured from 2 and 4 chamber views in a random 
sample of 20 older community based participants of the CABL (Cardiovascular 
Abnormalities and Brain Lesion) Study. (31) In the Framingham Offspring Study 
Cheng et al reported an ICC of 0.89 for 2 chamber longitudinal strain and 0.84 for 4 
chamber longitudinal strain for inter-observer reproducibility in middle-aged to 
older adults. For intra-observer reproducibility the ICC for 2 chamber longitudinal 
strain was 0.92 and for 4 chamber longitudinal strain was also 0.92. (32) 
142 
Inter-vendor variation also needs to be considered in the interpretation of GLS 
studies. Takigiku et al demonstrated poor inter-vendor agreement, however GLS 
reproducibility was better than radial or circumferential strain. Also Philips Medical, 
the vendor used in our work, demonstrated GLS results more in line with results 
from the GE Healthcare system (ICC 0.63) than that of Toshiba (ICC 0.2). (33) Other 
investigators have similarly found GLS to be more reproducible than radial, 
circumferential or transverse strain. (25) A joint initiative from the European 
Association of Cardiovascular Imaging (EACVI), the American Society of 
Echocardiography (ASE) and an industry task force have looked at this in 62 subjects 
using 7 ultrasound machine vendors and 2 software vendors. They found 
endocardial GLS reproducibility to be superior to that of other echocardiographic 
parameters. (26) However there was variability between vendors with a maximum 
absolute difference between vendors of 3.7%. Philips, the vendor used in our work, 
had a maximum absolute difference of 2.7% and correlation coefficients above 0.81 
when compared to the other 8 vendors. Also inter- and intra-observer mean errors 
for endocardial GLS averaged from 2 or 3 apical views were less than that measured 
from the 4 chamber view alone. Software differences have been suggested to be 
the main source of the variation between vendors. (26, 34) 
Ultrasound quality assurance programmes and the use of phantoms to assess image 
based performance measurements is recommended by most authorities including 
the Irish Faculty of Radiologists, Royal College of Surgeons in Ireland. (35-37) In 
addition to routine equipment maintenance we also used an ultrasound phantom 
regularly throughout the study period. This gives an objective assessment of image 
quality and measurement accuracy and our results demonstrate that our 
equipment operated consistently. 
Limitations: 
We designed a study to assess the association of night-time blood pressure with 
CIMT and GLS in a sample of participants from the Mitchelstown Cohort Study. Our 
reproducibility data for CIMT is from a sample of healthy controls (mean age 28, 
50% male) while that for GLS is from a sample of patients referred for clinically 
indicated echocardiography (mean age 51, 90% male). Therefore neither sample in 
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the reproducibility analysis is representative of the Mitchelstown Cohort Study 
participants (mean age 60, 52% male). This approach was taken so we could 
demonstrate sound measurement methods prior to inviting participants to take 
part in the formal study as they had to travel a significant distance to a tertiary 
clinical centre in order to do so. 
Conclusion: 
We have described the imaging and reading protocols and equipment quality 
control measures including the use of phantom ultrasound scans to maximise 
validity of our results. We have also demonstrated good intra- and inter-observer 
reproducibility of CIMT and GLS results. Our findings suggest our measurement 
methods are valid and reliable and suitable to be applied in an epidemiological 
study.  
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6.1. Abstract 
Introduction 
Ambulatory blood pressure monitoring (ABPM) measures blood pressure (BP) over 
a prolonged period and has been shown to be superior to office BP for the 
prediction of clinical events. In particular, night-time systolic BP is a stronger 
predictor than daytime systolic BP. It is not yet clear if night-time BP should be a 
specific therapeutic target although some studies have demonstrated promising 
results. Subclinical cardiovascular disease is a prognostic marker for future 
cardiovascular events. Our aim is to examine the association of night-time systolic 
BP with subclinical cardiac dysfunction measured by global longitudinal strain (GLS) 
and subclinical vascular damage measured by carotid intima media thickness (CIMT) 
and carotid plaques. 
Methods 
In 2014 a random sample of 80 individuals, stratified by BP status at baseline 
recruitment to the Mitchelstown Cohort Study, were invited to undergo 
echocardiogram and carotid ultrasound. GLS was measured by speckle-tracking 
analysis of echocardiogram images carried out on a Philips iE33 ultrasound 
machine. Mean CIMT was measured at the distal 1 cm of the common carotid 
artery. Still images were taken from 3 angles on both sides of the neck using a 
Philips Cx50 ultrasound machine. The presence of carotid plaques was recorded. 
Philips QLAB cardiac and vascular ultrasound quantification software was used for 
analysis. The association of night-time systolic BP with GLS, CIMT and carotid 
plaques was assessed using linear and logistic regression. 
Results 
Fifty (response rate 63%) individuals took part in this study. In univariable models 
night-time systolic BP was significantly associated with GLS (beta coefficient 0.85 
for every 10 mmHg rise, 95% CI 0.3 – 1.4) and carotid plaques (OR 1.9 for every 10 
mmHg rise, 95% CI 1.1 – 3.2). Univariable analysis of daytime systolic BP did not 
demonstrate any statistically significant associations. In age and sex adjusted 
models, the association for night-time systolic BP and GLS remained significant 
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(beta coefficient 0.68 for every 10 mmHg rise, 95% CI 0.1 – 1.3). The association for 
carotid plaques was no longer statistically significant.  In multivariable models 
findings were diminished.  
Discussion 
Our results support an association between night-time systolic BP and subclinical 
cardiac and vascular disease. However this is a small study and the sample size may 
have provided insufficient power to detect true associations between night-time 
systolic BP and target organ damage in multivariable models and for CIMT in 
particular. When assessing ABPM results the absolute night-time BP seems to be 
the most important parameter but ultimately a large randomised controlled trial 
involving chronotherapy is necessary to fully address this. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
6.2. Introduction 
Cardiovascular disease remains the leading cause of mortality worldwide (1) and 
hypertension is the risk factor with the greatest population attributable risk. (2, 3) 
Prevalence rates of hypertension are high while control rates are low. (4)  
Ambulatory blood pressure monitoring (ABPM) measures blood pressure over 24 to 
48 hours and has been shown to be superior to office blood pressure for the 
prediction of clinical events. (5, 6) Night-time systolic blood pressure is a stronger 
predictor of events than daytime systolic blood pressure. (7)  
Though it is unclear if night-time blood pressure should be a specific therapeutic 
target, chronotherapy has demonstrated some promising results. In one study 
patients were randomised to either take all of their anti-hypertensive medications 
in the morning or to take at least 1 of them at night. The decrease in nocturnal 
blood pressure was associated with a reduced risk of total cardiovascular events. 
Similarly patients with chronic kidney disease who took at least one anti-
hypertensive at night had a lower hazard ratio of total cardiovascular events than 
those taking all of their medications in the morning. (8, 9) 
The association of night-time blood pressure with subclinical target organ damage 
has been investigated. (10, 11) This would seem intuitive given the greater 
association of night-time blood pressure with clinical events, the continuum of 
cardiovascular disease, (12) and subclinical disease being a prognostic marker for 
future cardiovascular events. (13) Many studies have focused on dipping status 
rather than the absolute blood pressure level. (14-16) We have previously shown 
that absolute night-time systolic blood pressure is better associated than dipping 
status with subclinical cardiac and vascular damage documented by 
electrocardiogram left ventricular hypertrophy voltage criteria and 
microalbuminura in the Mitchelstown Cohort Study . (17) 
Echocardiography can measure the subclinical cardiac consequences of 
hypertension such as increased left atrial (LA) size and left ventricular hypertrophy 
(LVH). Speckle tracking echocardiography has enabled the quantification of strain 
which is a dimensionless measure of myocardial deformation. Global longitudinal 
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strain (GLS) is a measure of the myocardial systolic deformation over the 
longitudinal axis. (18) There is emerging evidence for the prognostic importance of 
this measure. (19, 20) It offers incremental prognostic information in the 
assessment of left ventricular function particularly when the ejection fraction is 
near normal. (21) Few studies have examined the association of night-time blood 
pressure and GLS measured by speckle tracking analysis. (22, 23) 
Carotid intima-media thickness (CIMT) measured by ultrasound is a marker of 
subclinical vascular damage and is recognised to be associated with cardiovascular 
risk factors and with the incidence of myocardial infarction and stroke. (24, 25) 
There is evidence for the validity of CIMT as a suitable surrogate measure of 
atherosclerotic disease. (26, 27) The addition of carotid plaques to risk prediction 
models including CIMT improves performance. (28, 29)  
The present study aims to build on previous work by examining the association of 
night-time systolic blood pressure with ultrasound markers of subclinical 
cardiovascular disease including abnormal GLS, CIMT and carotid plaques in a 
sample from the Mitchelstown Cohort Study.  
6.3. Methods 
In 2010 the Mitchelstown Cohort Study recruited 2047 participants from a single 
large primary care centre, the Livinghealth Clinic in Mitchelstown, a town in the 
south of Ireland. (30) Of these, 1207 (response rate 59%) also underwent 24 hour 
ambulatory blood pressure monitoring (ABPM). These individuals provide the 
sample for the present study. Based on the initial ABPM results the sample was 
divided into 4 groups: normotension, isolated daytime hypertension, isolated 
nocturnal hypertension and day-night hypertension. Twenty participants were 
randomly selected from each group and invited to attend for echocardiogram and 
carotid ultrasound in 2014. This study therefore includes analysis of baseline ABPM 
data and follow-up imaging data.  
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Height and weight measurements: 
A trained researcher carried out the physical measures. Height and weight were 
measured without foot-ware using a Seca measuring and weighing station. Body 
mass index (BMI) and body surface area (BSA) were calculated. 
Study blood pressure: 
At the baseline visit after the participant had been in a relaxed seated position for 
at least 5 minutes three blood pressure readings were taken on the right arm, 1 
minute apart, using an OMRON M7 digital automatic blood pressure monitor.  The 
average of the second and third blood pressure reading was defined as the study 
blood pressure. 
ABPM: 
ABPM measurements were performed at baseline using the MEDITECH ABPM-05 
and data was stored using the dabl ABPM system. The monitors were programmed 
to record the blood pressure every 30 minutes throughout the 24 hour period. 
Participants kept a diary of the times they went to bed and got up. Diary times were 
used to calculate mean daytime and night-time blood pressures. Mean 24 hour 
blood pressure was calculated as the mean of all the readings throughout the 24 
hour period. 
Echocardiography: 
A Philips iE33 ultrasound machine and a S5-1 phased array transducer were used 
for image acquisition. All scans were carried out by the same operator (IB). IB is 
accredited in transthoracic echocardiography by the British Society of 
Echocardiography.  A standard echocardiogram protocol was used. Parasternal long 
and short axis, apical 4-, 2- and 3-chamber views were obtained. Optimisation of 
frame rate was carried out by reducing the sector depth and width.  
Left ventricular (LV) wall thickness and diameters were measured from the 
parasternal long axis view. LV mass was calculated using the Devereux formula. (31) 
LV mass was indexed for BSA. LVH was defined as LV mass > 115 g/m2 in males and 
> 95 g/m2 in females. (32) LV volumes and ejection fraction were calculated from 
the apical 4 chamber view using the single plane method of discs. (33) LV volumes 
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were indexed for body surface area. LA volume was calculated from the apical 4 
chamber view using the single plane method of discs. LA volume was indexed for 
body surface area. (32) 
Diastolic function parameters were measured in the apical 4 chamber view. Mitral 
inflow early (E) and late (A) velocities and E wave deceleration time were obtained 
by pulse-wave Doppler with the sample volume at the mitral valve tips. Peak 
diastolic mitral annular (e’) velocity was measured from the septal and lateral mitral 
annulus and averaged. The E/e’ ratio was then calculated. Diastolic dysfunction was 
defined as E/A ≤ 0.7 or deceleration time > 260 ms; or E/A ratio > 0.7 and ≤ 1.5 and 
e’ velocity < 7 cm/s; or E/A ratio > 1.5 and e’ velocity < 7 cm/s or deceleration time 
< 140 ms. (34) 
The acquired images were saved using digital media and speckle tracking GLS 
analysis was carried out offline by a single reader (AMOF) from apical 4-, 2- and 3- 
chamber views using Philips QLAB cardiac and vascular ultrasound quantification 
software version 9.0. The region of interest was identified by the selection of 3 
points, one on either side of the mitral valve annulus and one at the apex for each 
view. Adequate tracking was confirmed visually and if deemed inadequate the 
region of interest was edited. If inadequate tracking persisted problematic 
segments were excluded. If more than 2 segments in a single view had to be 
excluded the entire study was excluded from speckle tracking analysis. (32) GLS 
average was obtained from 17 ventricular segments represented on a bulls-eye plot 
from apical 4-, 2- and 3- chamber views. Normal cut-off was taken as -19.7%. (35) 
Carotid ultrasound: 
A Philips Cx50 portable ultrasound machine and a L12-3 linear array transducer 
were used for image acquisition. All scans were carried out by the same operator 
(AMOF). AMOF received formal training in CIMT image acquisition. Subjects were 
examined in the supine position with their head tilted to the opposite side. A Meijer 
arc was used to ensure optimal positioning. A thorough transverse and longitudinal 
scan of the extra-cranial carotid arteries was carried out to evaluate for the 
presence of atherosclerotic plaques. Ultrasound images of the distal portion of the 
156 
far wall of both common carotid arteries were obtained for assessment of CIMT. Far 
wall still frames were taken from anterior, lateral and posterior angles. Three still 
frame images were taken from each angle. (36) 
The acquired images were saved using digital media and measurement was carried 
out offline by a single reader (AMOF) using Philips QLAB cardiac and vascular 
ultrasound quantification software version 9.0. Measurements were made on the 3 
still frame images from each angle over a length of 1 cm at the distal common 
carotid artery (CCA). The reference point for the commencement of the 
measurement was where the CCA began to dilate prior to the bifurcation. A mean 
measurement from each angle was obtained. The mean of these means was 
obtained to give the measurement for each side. The mean of the left and right was 
then taken as the CIMT. Normal cut-off was taken as the 75th percentile. (37) The 
presence of plaques in the extra-cranial carotid arteries was recorded as a binary 
variable. A plaque was defined according to the Mannheim Consensus as a focal 
protrusion into the blood vessel ≥ 50% of the thickness of the adjacent IMT or focal 
IMT > 1.5 mm. (38) 
Reproducibility: 
Intra- and inter-observer reproducibility was assessed prior to undertaking the 
study. Ten patients undergoing routinely indicated echocardiography were asked to 
consent to have their images analysed by speckle tracking analysis. All 
echocardiograms were carried out by the same operator (IB). Speckle tracking 
analysis was carried out offline by AMOF and repeated for intra-observer 
reproducibility. An independent observer (EH) also analysed the images for inter-
observer reproducibility. Ten healthy volunteers had a carotid ultrasound twice 
within the same week carried out by the same investigator (AMOF) who also 
analysed the images for intra-observer reproducibility. An independent observer 
(EH) analysed the second set of images for inter-observer reproducibility.  
The intra-observer intra-class coefficient (ICC) for GLS was 0.93 (95% CI 0.70 - 0.98). 
The inter-observer ICC was 0.86 (95% CI 0.51 – 0.96). The intra-observer ICC for 
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CIMT was 0.91 (95% CI 0.69 – 0.98). The inter-observer ICC was 0.97 (95% CI 0.88 -
0.99).  
Statistical analysis: 
Statistical analysis was carried out using Stata 12. Continuous variables are 
described by means +/- standard deviation. Categorical variables are described 
using proportions.  
The association of baseline night-time, daytime and study systolic blood pressure 
with GLS and CIMT was assessed using univariable and multi-variable linear 
regression. The association of baseline night-time, daytime and study systolic blood 
pressure with carotid plaques was assessed using logistic regression. Regression 
models were initially adjusted for sex and age. Multi-variable regression analysis 
was also carried out with adjustments applied for sex, age, BMI, smoking status, 
diabetes mellitus and total cholesterol. Interaction terms including antihypertensive 
medications with night-time, daytime and study systolic blood pressures 
respectively were also included in the models.  
6.4. Results 
Fifty individuals took part in this study (Overall response rate 63%). The mean 
period of follow up was 3.9 years. The mean age of participants was 60 and 26 
(52%) were male. Baseline characteristics are presented in table 6.1 together with 
the baseline characteristics of the full cohort and those who underwent ABPM.  
The echocardiogram and carotid ultrasound findings by blood pressure strata are 
presented in table 6.2. Speckle tracking echocardiography analysis was not possible 
in 1 study due to poor image quality. In univariable models night-time systolic blood 
pressure was significantly associated with GLS (beta coefficient 0.85 for every 10 
mmHg rise, 95% CI 0.3 – 1.4) and carotid plaques (OR 1.9 for every 10 mmHg rise, 
95% CI 1.1 – 3.2). Univariable analysis of daytime systolic blood pressure did not 
demonstrate any statistically significant associations. Table 6.3. In age and sex 
adjusted models, the association for night-time systolic blood pressure and GLS 
remained significant (beta coefficient 0.68 for every 10 mmHg rise, 95% CI 0.11 – 
1.25). The association for carotid plaques was no longer statistically significant. 
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Table 6.4. In multivariable models findings were attenuated. Table 6.5. Interaction 
terms including antihypertensive medications with night-time, daytime and study 
systolic blood pressures respectively were included in the models but were not 
statistically significant (data not shown).  
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Table 6.1. Baseline characteristics 
 Total cohort n =2047 Sample with satisfactory 
ABPM n =1072 
Sample n =50 
 N (%) /mean +/-SD N (%) /mean +/-SD N (%) /mean +/-SD 
Age 59 (+/-6) 60 (+/-6) 60 (+/-5) 
Male 1008 (49) 567 (47) 26 (52) 
Education category     
Primary 537 (28) 335 (30) 7 (15.5) 
Secondary 936 (49) 547 (48) 22 (49) 
Tertiary 435 (23) 253 (22) 16 (35.5) 
IPAQ category     
Low 932 (49) 571 (50) 31 (62) 
Moderate 566 (30) 318 (28) 19 (38) 
High 420 (22) 248 (22) 0 (0) 
Smoking Status     
Non-smoker 1002 (51) 615 (53) 27 (54) 
Former smoker 671 (34) 378 (32) 18 (36) 
Current smoker 292 (15) 175 (15) 5 (10) 
Medical History    
Hypertension 567 (29) 407 (34) 19 (40) 
Myocardial Infarction 49 (2) 33 (3) 2 (4) 
Stroke 22 (1) 13 (1) 0 (0) 
Heart failure 8 (0.4) 6 (0.5) 1 (2) 
Diabetes 174 (9) 114 (10) 5 (10) 
Medication    
Anti-hypertensive 584 (29) 405 (35) 21 (42)  
Cholesterol lowering  711 (36) 457 (39) 21 (42) 
BMI (kg/ m2) 29 (+/-5) 30 (+/-5) 29 (+/-5) 
Waist circumference 97 (+/-13) 97 (+/-14) 100 (+/-13) 
LDL (mmol/l) 3.2 (+/-0.9) 3.2 (+/-0.9) 3.2 (+/-0.8) 
Creatinine (µmol/l) 71 (+/-16) 72 (+/-16) 74 (+/-17) 
ACR (mg/mmol) 0.7 (+/-2.1) 0.8 (+/-2.1) 0.6 (+/-0.7) 
eGFR (mls/min) 90 (+/-13) 89 (+/-13) 87 (+/-13) 
Cystatin C 0.83 (+/-0.18) 0.83 (+/-0.18) 0.87 (+/-0.14) 
Study systolic  130 (+/-17) 134 (+/- 18) 134 (+/-16) 
Study diastolic 80 (+/-10) 83 (+/- 10) 82 (+/-10) 
Daytime systolic   131 (+/-14) 132 (+/-12) 
Daytime diastolic  77 (+/-9) 78 (+/-9) 
Night-time systolic  112 (+/-14) 117 (+/-14) 
Night-time diastolic  63 (+/-8) 66 (+/-9) 
Twenty four systolic  124 (+/-13) 126 (+/- 11) 
Twenty four diastolic  72 (+/-8) 74 (+/- 8) 
    
Note some missing data  
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Table 6.2. Echocardiogram and carotid ultrasound characteristics 
 Total sample 
 
n= 50 
mean (+/- SD)/ n(%) 
Normotension 
 
n=11 
mean (+/- SD)/ n(%) 
Isolated daytime 
hypertension 
n=14 
mean (+/- SD)/ n(%) 
Isolated nocturnal 
hypertension 
n=14 
mean (+/- SD)/ n(%) 
Sustained day-night 
hypertension 
n=11 
mean (+/- SD)/ n(%) 
 
Echocardiogram  
     
LA volume index, ml/m2 32.0 (+/-9.4) 27.7 (+/-7.3) 31.3 (+/-7.7) 32.6 (+/-9.7) 36.2 (+/-12.0) 
LV mass index , g/m2  99.3 (+/-24.2) 85.5 (+/-19.7) 97.8 (+/-17.5) 101.5 (+/-24.7) 112.4 (+/-29.9) 
Left ventricular hypertrophy 16 (32) 2 (18) 4 (29) 5 (36) 5 (45) 
LV end diastolic volume, ml/m2 48.3 (+/-8.4) 45.8 (+/-7.6) 48.2 (+/-7.0) 48.6 (+/-10.3) 50.5 (+/-8.7) 
LV end systolic volume, ml/m2 17.2 (+/-5.2) 17.7 (+/-6.8) 16.3 (+/-2.9) 17.5 (+/-7.0) 17.6 (+/-3.6) 
LV ejection fraction, % 65.1 (+/-6.2) 64.5 (+/-7.2) 66.0 (+/-5.0) 64.9 (+/-7.5) 65.0 (+/-5.3) 
Global longitudinal strain,% -21.2 (+/-3.0) -22.6 (+/-2.9) -21.9 (+/-2.8) -21.0 (+/-2.9) -19.2 (+/-2.6) 
Abnormal GLS 16 (33) 1 (10) 3 (21) 5 (36) 7 (64) 
E/A 0.98 (+/-0.3) 1.04 (+/-0.2) 0.89 (+/-0.2) 0.95 (+/-0.4) 1.05 (+/-0.3) 
E wave deceleration time, ms 253.9 (+/-74.2) 224 (+/-54) 255.4 (+/-60.0) 282 (+/-90.1) 246 (+/- 80.3) 
E’, cm/s 7.7 (+/-1.8) 8.2 (+/-1.0) 7.8 (+/-2.2) 7.3 (+/-2.0) 7.9 (+/-1.6) 
E/e’  9.5 (+/-1.9) 9.4 (+/-0.9) 8.6 (+/-2.1) 9.9 (+/-1.9) 10.2 (+/-2.3) 
Diastolic dysfunction 30 (60) 4 (36) 10(71) 10 (71) 6 (55) 
      
Carotid ultrasound       
Common carotid IMT, mm 0.72 (+/-0.13) 0.64 (+/-0.10) 0.71 (+/-0.14) 0.76 (+/-0.14) 0.76 (+/-0.12) 
Common carotid IMT > 75th percentile 12 (24) 1 (9) 3 (21) 4 (29) 4 (36) 
Plaques 33 (66) 5 (45) 8 (57) 12 (86) 8 (73) 
GLS analysis not possible in 1 study due to poor image quality 
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Table 6.3. Univariable linear and logistic regression results 
 GLS 
 
Beta Coef  (95% CI) 
 
 
p-value 
CIMT 
 
Beta Coef  (95% CI) 
 
 
p-value 
Plaques 
 
OR (95% CI) 
 
 
p-value 
Sex (male v female) 2.70  (1.15 – 4.24) 0.001 0.09 (0.02 – 0.16) 0.02 6.5 (1.7 – 24.7) 0.006 
Age 0.05 (-0.11 – 0.21) 0.5 0.009 (0.002 – 0.015) 0.009 1.2 (1.0 – 1.3) 0.03 
Antihypertensives (yes v no) -0.91 (-2.65 – 0.84) 0.3 -0.03 (-0.11 – 0.05) 0.4 0.3 (0.1 – 1.1) 0.06 
BMI 0.20 (0.03 – 0.37) 0.02 -0.004 (-001 – 0.004) 0.3 1.1 (0.96 – 1.2) 0.2 
Smoking status (current v non/ex)  -0.18 (-3.05 – 2.69) 0.9 0.18 (0.06 – 0.29) 0.004 2.2 (0.2 – 21.4) 0.5 
Diabetes mellitus (yes v no) 3.16 (0.43 – 5.88) 0.02 0.02 (-0.11 – 0.15) 0.7 2.1 (0.2 – 20.9) 0.5 
Total cholesterol 0.05 (-0.89 – 0.99) 0.9 -0.02 (-0.06 – 0.03) 0.4 0.67 (0.34 – 1.3) 0.2 
Night–time SBP 0.85 (0.3 – 1.4) 0.003 0.02 (-0.002 – 0.05) 0.08 1.9 (1.1 – 3.2) 0.03 
Daytime SBP 0.47 (-0.24 – 1.17) 0.2 0.02 (-0.01 – 0.05) 0.3 1.2 (0.7 – 2.0) 0.4 
Study SBP 0.53 (0.01 – 1.06) 0.05 0.01 (-0.01 – 0.03) 0.4 1.16 (0.8 – 1.7) 0.4 
Beta coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg rise 
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Table 6.4. Sex and age adjusted linear and logistic regression results 
 GLS 
Model 1 
Beta Coef  (95% CI) 
 
 
p-value 
GLS 
Model 2 
Beta Coef  (95% CI) 
 
 
p-value 
GLS 
Model 3 
Beta Coef    (95% CI) 
 
 
p-value 
Sex (male v female) 2.21 (0.64 – 3.77) 0.007 2.61 (0.89 – 4.33) 0.004 2.44 (0.64 – 4.23) 0.009 
Age -0..5 (-0.20 – 0.10) 0.5 0.01 (-0.14 – 0.16) 0.9 0.002 (-0.15 – 0.15) 1.0 
Night-time SBP  0.68 (0.11 – 1.25) 0.02 - - - - 
Daytime SBP - - 0.08 (-0.61 – 0.78) 0.8 - - 
Study SBP - -   0.17 (-0.40 – 0.74) 0.6 
 CIMT 
Model 1 
Beta Coef  (95% CI) 
 
 
p-value 
CIMT 
Model 2 
Beta Coef  (95% CI) 
 
 
p-value 
CIMT 
Model 3 
Beta Coef    (95% CI) 
 
 
p-value 
Sex (male v female) 0.07 (-0.01 – 0.14) 0.07 0.07 (-0.01 – 0.14) 0.09 0.08 (-0.0003 – 0.16) 0.05 
Age 0.01 (0.0001 – 0.01) 0.05 0.01 (0.001 – 0.01) 0.02 0.01 (0.001 – 0.01) 0.02 
Night-time SBP  0.01 (-0.02 – 0.03) 0.6 - - - - 
Daytime SBP - - 0.01 (-0.02 – 0.04) 0.6 - - 
Study SBP - - - - -0.005 (-0.03 – 0.02) 0.7 
 Plaques 
Model 1 
OR (95% CI) 
 
 
p-value 
Plaques 
Model 2 
OR  (95% CI) 
 
 
p-value 
Plaques 
Model 3 
OR    (95% CI) 
 
 
p-value 
Sex (male v female) 4.8 (1.16 – 19.86) 0.03 6.11 (1.39 – 26.75) 0.02 8.4 (1.64 – 43.01) 0.01 
Age 1.11 (0.97 – 1.28) 0.1 1.14 (0.99 – 1.31) 0.06 1.15 (1.00 – 1.32) 0.05 
Night-time SBP  1.47 (0.80 – 2.69) 0.2 - - - - 
Daytime SBP - - 0.95 (0.55 – 1.65) 0.9 - - 
Study SBP - - - - 0.80 (0.49 – 1.30) 0.4 
Model 1 Night-time SBP adjusted for sex and age  
Model 2 Daytime SBP adjusted for sex and age  
Model 3 Study SBP adjusted for sex and age  
Beta coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg rise 
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Table 6.5. Multivariable adjusted linear and logistic regression results 
 GLS 
Model 1 
Beta Coef (95% CI) 
 
 
p-value 
GLS 
Model 2 
Beta Coef (95% CI) 
 
 
p-value 
GLS  
Model 3 
Beta Coef   (95% CI) 
 
 
p-value 
 
Sex (male v female) 1.79 (-0.03 – 3.6) 0.05 1.97 (0.03 – 3.9) 0.05 2.02 (0.03 – 4.01) 0.05  
Age 0.002 (-0.17 – 0.17) 1.0 0.06 (-0.10 – 0.21) 0.5 0.06 (-0.10 – 0.22) 0.5  
BMI 0.06 (-0.13 – 0.26) 0.5 0.11 (-0.08 – 0.30) 0.2 0.11 (-0.08 – 0.30) 0.2  
Smoking (current v non/ex) -0.01 (-2.82 – 2.80) 1.0 0.27 (-2.61 – 3.15) 0.9 0.28 (-2.60 – 3.16) 0.8  
Diabetes mellitus (yes v no) 1.91 (-0.75 – 4.56) 0.2 2.16 (-0.57 – 4.89) 0.1 2.16 (-0.61 – 4.93) 0.1  
Total cholesterol 0.28 (-0.62 – 1.17) 0.5 0.38 (-0.54 – 1.29) 0.4 0.38 (-0.54 – 1.31) 0.4  
Night-time SBP  0.52 (-0.13 – 1.16) 0.1 - - - -  
Daytime SBP - - 0.04 (-0.66 – 0.75) 0.9 - -  
Study SBP - - - - -0.01 (-0.61 – 0.58) 1.0  
 CIMT 
Model 1 
Beta Coef (95% CI) 
 
 
p-value 
CIMT 
Model 2 
Beta Coef  (95% CI) 
 
 
p-value 
CIMT 
Model 3 
Beta Coef    (95% CI) 
 
 
p-value 
 
Sex (male v female) 0.07 (-0.01 – 0.15) 0.07 0.07 (-0.01 – 0.15) 0.1 0.07 (-0.01 – 0.16) 0.08  
Age 0.01 (-0.001 – 0.01) 0.08 0.01 (0.004 – 0.01) 0.04 0.01 (0.0003 – 0.1) 0.04  
BMI -0.003 (-0.01 – 0.004) 0.4 -0.003 (-0.01 – 0.004) 0.4 -0..003 (-0.01 – 0.004) 0.5  
Smoking (current v non/ex) 0.15 (0.03 – 0.27) 0.02 0.16 (0.04 – 0.28) 0.01 0.16 (0.04 – 0.28) 0.01  
Diabetes mellitus (yes v no) 0.02 (-0.10 – 0.13) 0.8 0.02 (-0.09 – 0.14) 0.7 0.02 (-0.10 – 0.14) 0.7  
Total cholesterol -0.01 (-0.05 – 0.03) 0.5 -0.01 (-0.05 – 0.03) 0.6 -0.01 (-0.05 – 0.03) 0.6  
Night-time SBP  0.01 (-0.02 – 0.03) 0.5 - - - -  
Daytime SBP - - 0.01 (-0.02 – 0.04) 0.5 - -  
Study SBP - - - - 0.001 (-0.02 – 0.95) 0.2  
Continued… 
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Table 6.5. Continued 
 Plaques 
Model 1 
OR (95% CI) 
 
 
p-value 
Plaques 
Model 2 
OR  (95% CI) 
 
 
p-value 
Plaques  
Model 3 
OR    (95% CI) 
 
 
p-value 
 
Sex (male v female) 4.66 (0.78 – 27.80) 0.09 5.70 (0.84 – 38.50) 0.07 6.57 (0.93 – 46.49) 0.06  
Age 1.17 (0.99 – 1.38) 0.07 1.19 (1.01 – 1.40) 0.03 1.21 (1.02 – 1.42) 0.03  
BMI 1.10 (0.93 – 1.30) 0.3 1.13 (0.95 – 1.33) 0.2 1.13 (0.96 – 1.34) 0.1  
Smoking (current v non/ex) 6.81 (0.30 – 157.32) 0.2 10.28 (0.38 – 280.48) 0.2 9.16 (0.39 – 217.16) 0.2  
Diabetes mellitus (yes v no) 0.61 (0.04 – 10.57) 0.7 0.74 (0.04 – 12.38) 0.8 0.93 (0.05 – 16.23) 1.0  
Total cholesterol 0.63 (0.25 – 1.56) 0.3 0.69 (0.29 – 1.64) 0.4 0.70 (0.29 – 1.70) 0.4  
Night-time SBP  1.31 (0.65 – 2.66) 0.5 - - - -  
Daytime SBP - - 0.86 (0.46 – 1.62) 0.6 - -  
Study SBP - - - - 0.78 (0.45 – 1.37) 0.4  
Model 1 Night-time SBP adjusted for sex, age, BMI, smoking, diabetes mellitus and total cholesterol  
Model 2 Daytime SBP adjusted for sex, age , BMI, smoking, diabetes mellitus and total cholesterol  
Model 3 Study SBP adjusted for sex, age , BMI, smoking, diabetes mellitus and total cholesterol 
Beta coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg rise 
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6.5. Discussion 
We have demonstrated an association of night-time systolic blood pressure with 2 
measures of subclinical cardiovascular disease, GLS and carotid plaques, in a 
community based middle-aged population sample. These associations were 
attenuated in multivariable models. No such associations were seen for daytime or 
study systolic blood pressures and subclinical cardiovascular disease.  
Cumulative blood pressure exposure over a 25 year period is associated with 
subclinical systolic and diastolic dysfunction assessed by speckle tracking 
echocardiography in middle age. (39) Uncontrolled 24 hour blood pressure has also 
been shown to be associated with abnormal GLS, while uncontrolled office blood 
pressure was not, in treated hypertensive patients. (40) Few studies have 
specifically addressed the association of night-time blood pressure and GLS. 
Kalaycioglu et al found a significant reduction in GLS in non-dippers compared to 
dippers in a sample of 86 treated hypertensive diabetic patients with mean age 
57.8 years. They also reported night-time systolic blood pressure to be 
independently associated with GLS and global longitudinal strain rate (GLSR) in 
linear regression models adjusted for age, sex and left ventricular mass index. (22) 
In untreated hypertensive patients Tadic et al found reduced 2D and 3D left 
ventricular GLS and reduced atrial longitudinal strain in non-dippers compared to 
dippers. (23) Açar et al also examined left atrial strain in dippers and non-dippers 
and found reduced atrial function in non-dippers. (41) Others have examined right 
heart mechanics and found reduced function in non-dippers. (42) Our results 
suggest an association between increased night-time systolic blood pressure and 
subclinical left ventricular systolic dysfunction. We also found night-time systolic 
blood pressure to have a stronger association than daytime systolic blood pressure 
and study blood pressure with other echocardiographic markers of subclinical 
cardiac damage such as LA volume and LV mass. (Data not shown) 
CIMT does improve cardiovascular risk prediction models but the overall impact is 
small. (43) There are concerns regarding measurement methods. (44) Moreover, 
increasing IMT is recognised as a normal ageing phenomenon which further 
complicates interpretation of CIMT measurements. (45-47) The use of CIMT is 
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therefore not without controversy and while the European cardiovascular 
prevention guidelines continue to give it a IIa level of recommendation for risk 
assessment in those at moderate overall risk, (48) American guidelines no longer 
recommend routine measurement of CIMT in clinical practice for the assessment of 
cardiovascular risk. (49) The addition of plaques has been shown to improve the 
predictive performance of CIMT. (28, 50) Findings on the association of night-time 
blood pressure and CIMT are conflicting. Cuspidi et al reported no difference in 
CIMT or plaques between those with nocturnal normotension and nocturnal 
hypertension. (10) On the other hand, Wang et al reported an association between 
nocturnal hypertension and CIMT in patients with chronic kidney disease. (51) 
Cuspidi and colleagues have recently reported the results of a meta-analysis that 
examined the association of non-dipping with carotid atherosclerosis and found 
higher CIMT and greater prevalence of plaques in non-dippers. (52) While we found 
no association between night-time systolic blood pressure and CIMT we did find an 
association with carotid plaques in univariable analysis. We measured CIMT at the 
distal 1 cm of the common carotid artery as guidelines recommend, while we 
assessed all of the extracranial carotid vessels for plaques. (36) This may have 
contributed to the differential findings for CIMT and plaques as they likely reflect 
different stages of atherosclerosis and plaques are more likely to develop in areas 
of turbulent flow such as the bifurcation. (53) In addition we may not have had 
sufficient power to detect an association between night-time blood pressure and 
CIMT. 
The evidence for the prognostic importance of night-time blood pressure is 
compelling. (7) However the potential underlying mechanisms are unclear and 
include altered sympathetic nervous system activity, disturbed baroreflex 
sensitivity, increased sodium sensitivity and obstructive sleep apnoea. (7) It may be 
that night-time blood pressure is subject to less variability and more accurately 
represents true blood pressure. (54) Reverse causality is also possible and elevated 
night-time blood pressure may merely be a marker of more severe end organ 
damage. Cuspidi and colleagues have recently carried out a systematic review and 
meta-analysis on the association of nocturnal hypertension with subclinical cardiac 
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and carotid disease documented by ultrasound and found increased left ventricular 
mass index and CIMT in those with nocturnal hypertension compared to those with 
nocturnal normotension. (55) They acknowledge the cross-sectional nature of 
existing data and that the causal relationship between nocturnal hypertension and 
subclinical cardiovascular disease remains unproven. Our study provides some 
prospective data on subclinical target organ damage and our results suggest that 
elevated night-time blood pressure may contribute more than daytime or office 
blood pressure to cardiac and vascular end organ damage. However large 
prospective randomised trials with interventions aimed at normalising night-time 
blood pressure are required to resolve the questions that remain regarding the 
importance of night-time blood pressure as a therapeutic target. The methods of a 
large prospective open-label blinded randomised controlled trial have recently 
been published which will answer this question. The TIME (Treatment In Morning 
versus Evening) trial aims to randomise 10,269 hypertensive patients to either 
morning or evening dosing of anti-hypertensive medications. The primary end-point 
is vascular death or hospitalisation for the composite of non-fatal myocardial 
infarction or non-fatal stroke. (56) 
Limitations: 
This is a small study and the sample size may have provided insufficient power to 
detect true associations between night-time systolic blood pressure and target 
organ damage in multivariable models and for CIMT in particular. The ultrasound 
machines used were in fulltime clinical use and could only be used for research 
scans at the end of the working day therefore collection of imaging data was limited 
by access to the ultrasound machines. This resulted in a prolonged data collection 
period. Given these feasibility issues a decision was taken after 50 participants had 
been recruited to proceed with data analysis. Based on our results we had 86% 
power to detect a true association between night-time blood pressure and GLS. 
However for CIMT we had just 33% power and would have required a sample size 
of 162 to avoid a type II error. (57) 
Selection bias is another limitation as those who took part in this study were more 
likely to self-report a history of hypertension therefore the sample is not 
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representative of the full Mitchelstown Cohort (40% v 29% previous doctor 
diagnosis of hypertension). Similarly they were more likely to report being on anti-
hypertensive medication at baseline (42% versus 29%). In addition the use of 
antihypertensive medications in the sample increased between 2010 and 2014 
from 42% (n = 21) to 61% (n = 30) which may have impacted results although one 
would expect that increased use of anti-hypertensive medications would be more 
likely to influence results towards the null hypothesis. While our study provides 
some prospective imaging data in a community based sample the lack of ultrasound 
data at baseline recruitment means it is not possible to draw inference on the 
temporal relationship for the observed associations of night-time systolic blood 
pressure with GLS and carotid plaques.  
In addition night-time blood pressure profiles are not fully reproducible. (58, 59) 
We were able to assess the reproducibility of blood pressure profiles in 47 of those 
who took part in this study. There were no significant differences in mean blood 
pressure levels between 2010 and 2014. However the reproducibility of dipping 
status was poor with just 24% maintaining the same profile after 4 years. The 
reproducibility of blood pressure profiles defined by the absolute blood pressure 
level was better but still just 40% (Appendix 6). These findings highlight the 
limitations of applying thresholds and categories to continuously distributed risk 
factors but also the need to be cautious when interpreting results of studies 
examining nocturnal blood pressure profiles based on a single ABPM recording.  
The strength of this study lies in the novel question addressed as limited studies 
have assessed the association of night-time blood pressure and GLS. (22, 23) In 
addition these participants will continue to be followed up for the Mitchelstown 
Cohort Study so further prospective data will be available over time. 
Conclusion: 
This study supports an association of night-time systolic blood pressure with 
markers of subclinical cardiac and vascular disease.  We didn’t find a significant 
association between these markers and daytime systolic blood pressure. When 
assessing ABPM results the absolute night-time systolic blood pressure seems to be 
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the most important prognostic parameter. However whether normalising night-
time blood pressure improves prognosis remains unanswered and only a large 
randomised controlled trial involving chronotherapy can address this.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
170 
6.6. References 
1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, 
and national age–sex specific all-cause and cause-specific mortality for 240 causes 
of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 
2013. The Lancet. 2015;385(9963):117-71. 
2. Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray CJL. 
Estimates of Global and Regional Premature Cardiovascular Mortality in 2025. 
Circulation. 2015;132(13):1270-82. 
3. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. The Lancet. 
2015;386(9995):801-12. 
4. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, 
and control of hypertension in rural and urban communities in high-, middle-, and 
low-income countries. The Journal of the American Medical Association. 
2013;310(9):959-68. 
5. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of 
Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The 
Dublin Outcome Study. Hypertension. 2005;46(1):156-61. 
6. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, 
Fagard RH, et al. Prognostic Value of Ambulatory Blood-Pressure Recordings in 
Patients with Treated Hypertension. New England Journal of Medicine. 
2003;348(24):2407-15. 
7. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive Role of 
the Nighttime Blood Pressure. Hypertension. 2011;57(1):3-10. 
8. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing Sleep-Time Blood 
Pressure Determined by Ambulatory Monitoring Reduces Cardiovascular Risk. 
Journal of the American College of Cardiology. 2011;58(11):1165-73. 
9. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime Dosing of 
Antihypertensive Medications Reduces Cardiovascular Risk in CKD. Journal of the 
American Society of Nephrology. 2011;22(12):2313-21. 
10. Cuspidi C, Sala C, Valerio C, Negri F, Mancia G. Nocturnal blood pressure in 
untreated essential hypertensives. Blood Pressure. 2011;20(6):335-41. 
171 
11. Perez-Lloret S, Toblli JE, Cardinali DP, Malateste JC, Milei J. Nocturnal 
hypertension defined by fixed cut-off limits is a better predictor of left ventricular 
hypertrophy than non-dipping. International Journal of Cardiology. 
2008;127(3):387-9. 
12. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The 
Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient 
Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through 
Stable Coronary Artery Disease). Circulation. 2006;114(25):2850-70. 
13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 
ESH/ESC guidelines for the management of arterial hypertension: the Task Force for 
the Management of Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 
2013;34(28):2159-219. 
14. Cuspidi C, Giudici V, Negri F, Sala C. Nocturnal nondipping and left 
ventricular hypertrophy in hypertension: an updated review. Expert Review of 
Cardiovascular Therapy. 2010;8(6):781-92. 
15. Pierdomenico SD, Lapenna D, Guglielmi MD, Costantini F, Romano F, 
Schiavone C, et al. Arterial disease in dipper and nondipper hypertensive patients. 
American Journal of Hypertension. 1997;10(5 Pt 1):511-8. 
16. Roman MJ, Pickering TG, Schwartz JE, Cavallini MC, Pini R, Devereux RB. Is 
the absence of a normal nocturnal fall in blood pressure (nondipping) associated 
with cardiovascular target organ damage? Journal of Hypertension. 1997;15(9):969-
78. 
17. O’Flynn AM, Dolan E, Curtin RJ, O’Brien E, Perry IJ, Kearney PM. Night-time 
blood pressure and target organ damage: a comparative analysis of absolute blood 
pressure and dipping status. Journal of Hypertension. 2015;33(11):2257-64. 
18. Blessberger H, Binder T. Non-invasive imaging: Two dimensional speckle 
tracking echocardiography: basic principles. Heart. 2010;96(9):716-22. 
19. Russo C, Jin Z, Elkind MS, Rundek T, Homma S, Sacco RL, et al. Prevalence 
and prognostic value of subclinical left ventricular systolic dysfunction by global 
longitudinal strain in a community-based cohort. European Journal of Heart Failure. 
2014;16(12):1301-9. 
172 
20. Holland DJ, Marwick TH, Haluska BA, Leano R, Hordern MD, Hare JL, et al. 
Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart. 
2015;101(13):1061-6. 
21. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV 
dysfunction: a systematic review and meta-analysis of global longitudinal strain and 
ejection fraction. Heart. 2014;100(21):1673-80. 
22. Kalaycioglu E, Gokdeniz T, Aykan AC, Gul I, Ugur M, Gursoy OM, et al. The 
influence of dipper/nondipper blood pressure patterns on global left ventricular 
systolic function in hypertensive diabetic patients: a speckle tracking study. Blood 
Pressure Monitoring. 2014;19(5):263-70. 
23. Tadic M, Cuspidi C, Majstorovic A, Sljivic A, Pencic B, Ivanovic B, et al. Does a 
nondipping pattern influence left ventricular and left atrial mechanics in 
hypertensive patients? Journal of Hypertension. 2013;31(12):2438-46. 
24. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. 
Carotid-artery intima and media thickness as a risk factor for myocardial infarction 
and stroke in older adults. Cardiovascular Health Study Collaborative Research 
Group. The New England Journal of Medicine. 1999;340(1):14-22. 
25. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. 
Association of Coronary Heart Disease Incidence with Carotid Arterial Wall 
Thickness and Major Risk Factors: The Atherosclerosis Risk in Communities (ARIC) 
Study, 1987–1993. American Journal of Epidemiology. 1997;146(6):483-94. 
26. Peters SA, Grobbee DE, Bots ML. Carotid intima–media thickness: a suitable 
alternative for cardiovascular risk as outcome? European Journal of Cardiovascular 
Prevention & Rehabilitation. 2011;18(2):167-74. 
27. Iwakiri T, Yano Y, Sato Y, Hatakeyama K, Marutsuka K, Fujimoto S, et al. 
Usefulness of Carotid Intima Media Thickness Measurement as an Indicator of 
Atherosclerosis: Findings from Autopsy Analysis. Atherosclerosis. 2012;225(2):359-
62. 
28. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid 
intima-media thickness and presence or absence of plaque improves prediction of 
coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. 
Journal of the American College of Cardiology. 2010;55(15):1600-7. 
173 
29. Polak JF, Szklo M, Kronmal RA, Burke GL, Shea S, Zavodni AEH, et al. The 
Value of Carotid Artery Plaque and Intima‐Media Thickness for Incident 
Cardiovascular Disease: The Multi‐Ethnic Study of Atherosclerosis. Journal of the 
American Heart Association. 2013;2(2):e000087. 
30. Kearney PM, Harrington JM, Mc Carthy VJ, Fitzgerald AP, Perry IJ. Cohort 
Profile: The Cork and Kerry Diabetes and Heart Disease Study. International Journal 
of Epidemiology. 2013;42(5):1253-62. 
31. Devereux RB, Reichek N. Echocardiographic determination of left ventricular 
mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-8. 
32. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 
Recommendations for cardiac chamber quantification by echocardiography in 
adults: an update from the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. European Heart Journal - 
Cardiovascular Imaging. 2015;16(3):233-70. 
33. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. 
Recommendations for chamber quantification. European Journal of 
Echocardiography. 2006;7(2):79-108. 
34. Russo C, Jin Z, Sera F, Lee ES, Homma S, Rundek T, et al. Left Ventricular 
Systolic Dysfunction by Longitudinal Strain Is an Independent Predictor of Incident 
Atrial Fibrillation: A Community-Based Cohort Study. Circulation: Cardiovascular 
Imaging. 2015;8(8):e003520. 
35. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of 
left ventricular strain: a meta-analysis. Journal of the American Society of 
Echocardiography. 2013;26(2):185-91. 
36. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of 
carotid ultrasound to identify subclinical vascular disease and evaluate 
cardiovascular disease risk: a consensus statement from the American Society of 
Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the 
Society for Vascular Medicine. Journal of the American Society of 
Echocardiography. 2008;21(2):93-111. 
174 
37. Aminbakhsh A, Mancini GB. Carotid intima-media thickness measurements: 
what defines an abnormality? A systematic review. Clinical and Investigative 
Medicine. 1999 Aug;22(4):149-57. 
38. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et 
al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-
2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching 
the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, 
Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 
2011. Cerebrovascular Diseases. 2012;34(4):290-6. 
39. Kishi S, Teixido-Tura G, Ning H, Venkatesh BA, Wu C, Almeida A, et al. 
Cumulative Blood Pressure in Early Adulthood and Cardiac Dysfunction in Middle 
Age: The CARDIA Study. Journal of the American College of Cardiology. 
2015;65(25):2679-87. 
40. Sera F, Jin Z, Russo C, Lee ES, Schwartz JE, Rundek T, et al. Ambulatory Blood 
Pressure Control and Subclinical Left Ventricular Dysfunction in Treated 
Hypertensive Subjects. Journal of the American College of Cardiology. 
2015;66(12):1408-9. 
41. Acar G, Bulut M, Arslan K, Alizade E, Ozkan B, Alici G, et al. Comparison of 
left atrial mechanical function in nondipper versus dipper hypertensive patients: a 
speckle tracking study. Echocardiography. 2013;30(2):164-70. 
42. Tadic M, Cuspidi C, Pencic B, Ivanovic B, Scepanovic R, Marjanovic T, et al. 
Circadian blood pressure pattern and right ventricular and right atrial mechanics: A 
two- and three-dimensional echocardiographic study. Journal of the American 
Society of Hypertension. 2014;8(1):45-53. 
43. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans 
MJ, et al. Common carotid intima-media thickness measurements in cardiovascular 
risk prediction: a meta-analysis. The Journal of the American Medical Association. 
2012;308(8):796-803. 
44. Peters SA, Bots ML. Carotid Intima-Media Thickness Studies: Study Design 
and Data Analysis. Journal of Stroke. 2013;15(1):38-48. 
45. Mancini GBJ, Dahlöf B, Díez J. Surrogate Markers for Cardiovascular Disease: 
Structural Markers. Circulation. 2004;109(25 suppl 1):IV22-30. 
175 
46. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in 
cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular 
disease. Circulation. 2003;107(1):139-46. 
47. Najjar SS, Scuteri A, Lakatta EG. Arterial Aging: Is It an Immutable 
Cardiovascular Risk Factor? Hypertension. 2005;46(3):454-62. 
48. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. 
European Guidelines on cardiovascular disease prevention in clinical practice 
(version 2012). The Fifth Joint Task Force of the European Society of Cardiology and 
Other Societies on Cardiovascular Disease Prevention in Clinical Practice 
(constituted by representatives of nine societies and by invited experts). European 
Heart Journal. 2012;33(13):1635-701. 
49. Goff Jr DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino Sr RB, Gibbons 
R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A 
Report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. Journal of the American College of Cardiology. 
2014;63(25, Part B):2935-59. 
50. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid 
intima-media thickness, more accurately predicts coronary artery disease events: a 
meta-analysis. Atherosclerosis. 2012;220(1):128-33. 
51. Wang C, Deng W-J, Gong W-Y, Zhang J, Zhang Q-Z, Ye ZC, et al. Nocturnal 
Hypertension Correlates Better With Target Organ Damage in Patients With Chronic 
Kidney Disease than a Nondipping Pattern. The Journal of Clinical Hypertension. 
2015;17(10):792-801. 
52. Cuspidi C, Sala C, Tadic M, Gherbesi E, Grassi G, Mancia G. Nondipping 
pattern and carotid atherosclerosis: a systematic review and meta-analysis. Journal 
of Hypertension. 2016;34(3):385-92. 
53. Finn AV, Kolodgie FD, Virmani R. Correlation Between Carotid 
Intimal/Medial Thickness and Atherosclerosis A Point of View From Pathology. 
Arteriosclerosis Thrombosis and Vascular Biology. 2010;30(2):177-81. 
54. Pickering TG. What Is the True Blood Pressure? Smirk Revisited. The Journal 
of Clinical Hypertension. 2005;7(7):421-4. 
176 
55. Cuspidi C, Sala C, Tadic M, Gherbesi E, Grassi G, Mancia G. Nocturnal 
Hypertension and Subclinical Cardiac and Carotid Damage: An Updated Review and 
Meta-Analysis of Echocardiographic Studies. Journal of Clinical Hypertension 
(Greenwich, Conn). 2016. Epub Feb 18  
56. Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Willams B, et al. Methods 
of a large prospective, randomised, open-label, blinded end-point study comparing 
morning versus evening dosing in hypertensive patients: the Treatment In Morning 
versus Evening (TIME) study. British Medical Journal Open. 2016;6(2):e010313. 
57. Dupont WD, Plummer WD, Jr. Power and sample size calculations for studies 
involving linear regression. Controlled clinical trials. 1998;19(6):589-601. 
58. Cuspidi C, Meani S, Salerno M, Valerio C, Fusi V, Severgnini B, et al. 
Reproducibility of nocturnal blood pressure fall in early phases of untreated 
essential hypertension: a prospective observational study. Journal of Human 
hypertension. 2004;18(7):503-9. 
59. White WB, Larocca GM. Improving the utility of the nocturnal hypertension 
definition by using absolute sleep blood pressure rather than the “dipping” 
proportion. The American Journal of Cardiology. 2003;92(12):1439-41. 
 
 
 
 
 
 
 
 
 
 
177 
7. Discussion 
The overall aim of this thesis was to investigate how ambulatory blood pressure 
monitoring (ABPM) refines blood pressure measurement and to explore the 
association of night-time blood pressure with subclinical target organ damage. This 
was achieved through primary and secondary data analysis and a systematic 
review. 
7.1. Summary of findings 
Using ABPM to assess blood pressure clarifies diagnosis and management decisions 
for hypertension. In addition it allows examination of the night-time blood pressure 
window, and, as we have shown elevated night-time systolic blood pressure is 
better associated with subclinical target organ damage than daytime systolic blood 
pressure or dipping status. Therefore when interpreting ABPM results the night-
time systolic blood pressure mean seems to be the most important prognostic 
marker.  
The first objective of this thesis was to examine how ABPM refines office blood 
pressure measurement. We demonstrated that overall hypertension prevalence 
was similar when blood pressure was measured in a standardised fashion in the 
office or by ABPM, however at an individual level ABPM resulted in the 
reclassification of approximately a quarter of patients, with prevalence rates of 
white coat and masked hypertension in untreated individuals of 11% and 13% 
respectively (Chapter 2).  
Having demonstrated the utility of ABPM in the assessment of blood pressure we 
then sought to explore the nocturnal blood pressure window and its association 
with target organ damage. The second objective was to determine whether dipping 
status or the absolute night-time blood pressure level is more important. We found 
absolute night-time blood pressure to be better associated with ECG LVH and 
microalbuminuria than dipping status (Chapter 3). The third objective was to 
explore the association of isolated nocturnal hypertension, a classification based on 
the absolute blood pressure level, and target organ damage. A systematic review of 
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the literature demonstrated the evidence for the association to be inconclusive as 
did analysis of data from the Mitchelstown Cohort Study (Chapter 4).  
The final objective was to build on the findings of chapter 3 and investigate the 
association of night-time systolic blood pressure with ultrasound markers of cardiac 
and vascular damage. We first outlined the image acquisition protocols and quality 
control methods used to acquire the ultrasound data (Chapter 5). We then 
examined the association of night-time blood pressure with global longitudinal 
strain (GLS) measured by speckle tracking echocardiography, carotid intima media 
thickness (CIMT) and carotid plaques (Chapter 6). The results demonstrated an 
association for night-time systolic blood pressure with GLS and carotid plaques in 
unadjusted analysis. The findings persisted for GLS in sex and age adjusted analysis 
but were attenuated in fully adjusted models.  
7.2. Where findings fit in the literature 
Few population studies have used ABPM to quantify the burden of hypertension at 
a population level. In a random sample of adults aged 60 years or older in Spain 
Banegas et al found hypertension prevalence was lower when the 24 hour ABPM 
threshold was compared to casual blood pressure measured in the home (62.1% 
versus 68.8%) while control rates were higher (54.1% versus 37.4%). (1) When they 
used the daytime threshold they had similar results (60.6% versus 68.8% prevalence 
and 59.7% versus 37.4% control). We found the prevalence rates using the daytime 
ABPM threshold compared to the study blood pressure were similar to one another 
(61% versus 60%) although control rates were higher (54% versus 46%). Similar to 
Banegas et al we found the 24 hour ABPM threshold resulted in lower prevalence of 
hypertension (50% versus 60%) and higher control rates (68% versus 46%) 
compared to study blood pressure (chapter 2). Like us Banegas et al found over a 
quarter of people had their hypertensive status reclassified by ABPM and conclude 
that using ABPM would facilitate more appropriate management decisions.  
Some have advocated for the routine use of ABPM in research settings. (2, 3) The 
recent controversy surrounding renal artery denervation supports the use of 24 
hour ABPM in clinical trials particularly when new procedures are being tested. (4) 
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However for population prevalence studies particularly in developing countries the 
routine use of ABPM is unlikely to be feasible. In addition the results of chapter 2 
suggest that overall prevalence rates may not be dramatically impacted on by using 
ABPM depending on the threshold chosen although this does require further study. 
However it is clear that at the individual level a large proportion of people are 
reclassified by ABPM and it should be routinely used to guide management 
decisions in clinical practice. It should also be noted that chosen thresholds do have 
an impact on white coat and masked hypertension prevalence rates as the IDACO 
investigators have also shown with ranges from 6.3% to 12.5% and 9.7% to 19.6% 
respectively. (5) 
A cost-effective analysis of using ABPM to diagnose hypertension found that 
additional costs related to using ABPM are offset by savings on antihypertensive 
therapy.  (6) The National Institute for Health and Care Excellence (NICE) in the 
United Kingdom recommend ABPM to confirm the diagnosis of hypertension. (7) A 
recent statement from the United States Preventive Services Task Force makes a 
similar recommendation. (8) The European Society of Cardiology hypertension 
guidelines recommend office blood pressure as the gold standard for screening, 
diagnosis and management of hypertension but acknowledge the important role of 
out of office blood pressure in hypertension management. (9) A position paper 
from the European Society of Hypertension outline a list of clinical indications for 
the use of ABPM including identifying white coat and masked phenomena. (10) The 
routine use of ABPM will guide appropriate management and may help address 
therapeutic inertia as demonstrated by one Irish study. (11) However despite the 
recommendations of a number of guideline authorities some have urged caution 
prior to the routine adoption of ABPM for the diagnosis of hypertension citing lack 
of evidence and that cost savings should not be the primary motivating factor. (12) 
The prognostic importance of night-time blood pressure is well recognised. (13, 14) 
The night-time blood pressure dipping phenomenon has been the subject of much 
investigation and comment, (15-19) but 28 years after it was first described, (20) it 
is still not clear if non-dipping should be a therapeutic target. Some investigators 
have concluded that the absolute night-time blood pressure is better associated 
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with clinical outcomes than non-dipping. (21, 22) Perez-Lloret et al addressed the 
comparative role of nocturnal hypertension and non-dipping and their association 
with target organ damage in 2008 and concluded that nocturnal hypertension was 
better associated with LVH. More recently there has been increasing interest in the 
comparative roles of nocturnal hypertension and non-dipping and others have 
similarly concluded that nocturnal hypertension rather than non-dipping is better 
associated with target organ damage. (23-27) We explored night-time blood 
pressure and its association with ECG LVH and microalbuminuria and found the 
association for the absolute night-time blood pressure level was greater than that 
for dipping status in multivariable models (Chapter 3). We concluded that review of 
the absolute night-time blood pressure prior to considering dipping status may be 
the optimal approach when assessing night-time blood pressure. Others have also 
proposed that the absolute nocturnal blood pressure is better related to risk and 
that the circadian variability or dipping status can refine risk evaluation in 
hypertension. (28)  
There are a number of issues that require consideration in relation to this. Firstly 
blood pressure is a continuous variable and categorising it in any way including 
dipping is not ideal. However this is true for every blood pressure definition and as 
already discussed physicians require diagnostic thresholds that define normal and 
abnormal when managing patients. The analysis in chapter 3 was repeated using 
dipping as a continuous variable with similar findings (Appendix 4). Secondly night-
time blood pressure profiles are not fully reproducible. (16) However definitions 
that use absolute blood pressure levels rather than dipping status seem to be more 
reproducible (Appendix 7). (29) Thirdly when non-dipping and nocturnal 
hypertension co-exist the cardiovascular risk profile of an individual seems to be 
worse when compared to those who have either profile alone. (23) The presence of 
both profiles together may therefore represent more advanced hypertensive 
disease. On the other hand these phenomena frequently exist independently of 
eachother and may actually represent different underlying processes. (28) It has 
also been suggested that trying to separate their underlying significance may be 
difficult. (22, 28) What we need are further intervention trials of chronotherapy to 
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elucidate if normalising night-time blood pressure profiles improves prognosis. Our 
work and that of others would suggest that the absolute night-time blood pressure 
mean should be the primary therapeutic target of such trials. The methods of the 
TIME (Treatment In Morning versus Evening) study, have recently been published. 
(30) This is a large prospective randomised open label trial which will address 
whether evening or morning dosing of antihypertensive medications improves 
cardiovascular outcome. However the trial design doesn’t allow for ABPM data 
collection so even if the trial has a positive outcome questions will still remain on 
mechanisms. 
A systematic review was undertaken in chapter 4 to explore the association of 
isolated nocturnal hypertension with target organ damage. Isolated nocturnal 
hypertension is a very interesting phenomenon and has been shown to be 
associated with increased risk of mortality and cardiovascular events. (31) It may 
offer some insight into the pathophysiological basis of the prognostic importance of 
night-time blood pressure. Just 4 studies addressed the association with target 
organ damage and different markers were used in each of these so a narrative 
synthesis was carried out from which no definitive conclusions could be drawn. An 
updated search carried out in February 2016 revealed no new studies that satisfied 
the inclusion criteria (Appendix 5). We also carried out an analysis on the 
association of isolated nocturnal hypertension and its association with 
microalbuminuria and ECG Cornell Product Voltage in the baseline data from the 
Mitchelstown Cohort Study. There was no statistically significant increase in either 
marker of target organ damage in those with isolated nocturnal hypertension 
compared to those who are normotensive. However the sample size was small with 
just 29 individuals with isolated nocturnal hypertension so the results may 
represent a type II error. We focused our analysis on untreated individuals in order 
to avoid the confounding effect of anti-hypertensive medication. 
Some interesting observations can be made on isolated nocturnal hypertension. If 
night-time blood pressure carries greater prognostic significance as it seems to, one 
could expect more target organ damage in those with isolated nocturnal 
hypertension compared to normotensives. We were unable to draw a definite 
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conclusion on this but examining this profile in more detail in future research 
studies may help provide some explanation on the greater prognostic importance 
of night-time blood pressure. On the other hand the reproducibility of isolated 
nocturnal hypertension has been questioned in a recent study. (32) We examined 
reproducibility of blood pressure profiles categorised by absolute blood pressure in 
47 of the participants who took part in the ultrasound study in chapter 6. We found 
only modest reproducibility although this was better than that of dipping status 
(Appendix 6). 
The prevalence of isolated nocturnal hypertension varies according to ethnicity and 
seems to be lowest in Caucasian populations and higher in those of Asian and 
African ethnicity. (33) If isolated nocturnal hypertension is to be further developed 
as a research topic, focusing the research on these geographical regions is likely to 
provide the most impactful results for clinical practice.  In addition these areas have 
different relative contributions of stroke and coronary heart disease to mortality 
rates with a higher contribution from stroke in China, Africa, and South America. 
(34) China also has high levels of dietary salt intake and salt sensitivity has been 
postulated as a potential mechanism for elevated night-time blood pressure. (35, 
36) These are interesting research topics to further explore in those with isolated 
nocturnal hypertension.  
Measurement is a key element of medical research and clinical practice. What we 
measure needs to be a valid and reliable reflection of the true measurement. 
Chapter 5 focused on the imaging protocols and quality control processes applied 
to the acquisition and reading of GLS and CIMT. We demonstrated good 
reproducibility of results which compare favourably with the work of other 
investigators. (37-44) We were therefore able to apply these methods in chapter 6 
which built on chapter 3 and focused on the association of night-time systolic blood 
pressure with GLS measured by speckle tracking echocardiography, CIMT and 
carotid plaques.  
In chapter 6 we demonstrated an association of night-time systolic blood pressure 
with subclinical left ventricular systolic dysfunction documented by GLS and carotid 
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plaques in unadjusted models. Findings for GLS persisted in sex and age adjusted 
models but were attenuated in fully adjusted models. No such associations were 
seen for daytime systolic blood pressure. To the best of our knowledge Kalaycioglu 
et al are the only other investigators to specifically address the association of 
absolute night-time blood pressure and left ventricular GLS measured by speckle 
tracking echocardiography. They focused on dipping status but also found night-
time systolic blood pressure to be associated with GLS in linear regression models 
adjusted for age, sex and left ventricular mass index. (45) Their total sample size 
was 86 and included patients treated for hypertension and type II diabetes mellitus. 
Similarly in 147 recently diagnosed untreated hypertensive patients Tadic et al 
demonstrated reduced GLS in non-dippers compared to dippers. They found the 
mean twenty four blood pressure level to be a significant predictor of GLS. (46) Our 
study is the first study to specifically address the association of night-time blood 
pressure level and GLS in a community based sample using speckle tracking 
echocardiography and supports the findings of others but requires corroboration in 
larger prospective studies.  
Many of the studies that have examined the association of night-time blood 
pressure with target organ damage are cross-sectional in nature which limits 
interpretation. (47-50) Chapter 6 provides some follow-up data on target organ 
damage but the lack of baseline ultrasound data is a limitation. However these 
patients will continue to be followed up through the Mitchelstown Cohort Study 
which strengthens the work as there is potential for follow-up imaging studies.  
7.3. Implications for research 
Some of the research implications of this work have already been discussed such as 
the use of ABPM in research studies, targeting the absolute night-time blood 
pressure mean in therapeutic trials, focusing research on isolated nocturnal 
hypertension studies in geographical areas where it is most prevalent and the need 
for further adequately powered prospective studies examining the association of 
night-time blood pressure and subclinical cardiac dysfunction documented by 
speckle tracking echocardiography. In particular such studies should focus on 
184 
untreated individuals in order to avoid the significant confounding effect of anti-
hypertensive medications on night-time blood pressure. 
The potential mechanisms behind the importance of night-time blood pressure are 
not well understood but include altered sympathetic nervous system activity, 
disturbed baroreflex sensitivity, increased sodium sensitivity and sleep quality. (13, 
51, 52) In shift workers it has been shown that the average night-time blood 
pressure during the day shift is similar to the average daytime blood pressure 
during the night shift. The mean sleep blood pressure was similar during both shift 
periods. (53) The diurnal variations in blood pressure therefore seem to be 
determined by activity/sleep cycles rather than any inbuilt rhythm. There is 
epidemiological evidence supporting an association between obstructive sleep 
apnoea and hypertension and blunted night-time dip. (54)  
Few researchers have addressed the issue of sleep quality and its association with 
night-time blood pressure. Manning et al examined sleep quality by questionnaire 
in 79 untreated hypertensive patients. Those who reported good sleep quality had 
lower mean systolic blood pressure during sleep and were more likely to be 
dippers. (16) Verdecchia et al again used a questionnaire to assess sleep deprivation 
in 2934 untreated individuals with hypertension and followed patients up for a 
median of 7 years. They found night-time systolic blood pressure to be a significant 
predictor of prognosis when reported sleep deprivation while wearing the ABPM 
device was less than 2 hours but it lost significance when more than 2 hours sleep 
deprivation was reported. (55) Similarly increased sleep disturbance assessed 
subjectively resulted in higher night-time blood pressure and attenuated the 
association with subclinical cardiac disease documented by echocardiography. (56) 
Others have found differences between sleep assessed subjectively and objectively. 
When measured objectively by wrist actigraphy there was no difference in sleep 
quality while wearing an ABPM device while subjectively good sleepers reported an 
adverse impact on sleep quality when wearing the device. (57) Evolving technology 
such as low stress devices may help reduce any impact of ABPM on sleep quality 
and make wearing the monitors more amenable to individuals but any new devices 
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will require formal validation prior to being adopted into clinical practice. (58) The 
whole area of sleep quality and its impact on the prognostic importance of night-
time blood pressure warrants further investigation. 
Precision medicine is gaining steady momentum. This is a concept for disease 
treatment and prevention that takes into account individual variability in molecular, 
genomic, cellular, clinical, behavioural, physiological, and environmental 
parameters for each person. (59) The USA have committed to building a national 
cohort with the aim of carrying out research to improve health outcomes through 
precision medicine. (60) A recent editorial in the Journal of the American Medical 
Association discussed how precision medicine might be applied to hypertension. 
(59) We propose that ABPM combined with markers of target organ damage, along 
with existing cardiovascular risk prediction tools, already offer the opportunity to 
profile patients and apply precision medicine to hypertension. Despite this and the 
inclusion of these tools in clinical guidelines, treatment and control rates of 
hypertension remain inadequate worldwide. (61) Therefore work aimed to 
investigate how existing knowledge in the hypertension field should be adequately 
implemented may be prudent in the first instance.  The World Heart Federation’s 
Roadmap for raised blood pressure takes such a practical approach to applying 
existing knowledge into strategies for improved cardiovascular outcomes. (62) 
Roadmaps go beyond the evidence to the real world where patients live and 
healthcare professionals practise in different resource environments. 
7.4. Implications for practice 
It seems clear that ABPM should be used routinely in the management of 
hypertension. The routine use of ABPM in clinical practice has been recommended 
by some experts for many years. (63-65) Without it over a quarter of individuals 
receive suboptimal care with medications being unnecessarily commenced or 
titrated in the case of white coat hypertension, or the opposite for masked 
hypertension. Not only that but it is cost-effective. In addition the prognostic 
information that night-time blood pressure offers is only available through ABPM. 
The benefit of normalising night-time blood pressure profiles through therapeutic 
intervention remains to be fully proven but the initial studies have been promising. 
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(66-69) However the concept of chronotherapy has yet to be universally adopted 
into clinical practice guidelines although the American Diabetes Association did give 
the administration of one or more anti-hypertensives at bedtime a level A 
recommendation in 2013. (70) The TIME study may change guideline 
recommendations when its results are available in the future. (30) 
Searching for asymptomatic organ damage is recommended in guidelines as part of 
the work-up of patients with hypertension. Routine evaluation should include a 
urine sample and ECG. (7, 9) Echocardiography and carotid ultrasound are 
recommended in the European Society of Cardiology guidelines as additional tests 
based on history, physical examination and routine laboratory tests. (9) While not 
yet mainstream, speckle tracking echocardiography, and GLS in particular, is 
increasingly being adopted into routine clinical use and offers additional prognostic 
information that can help further guide treatment decisions.  
In Ireland the feasibility of using pharmacists to make ABPM more accessible in the 
community has been shown. (71) Involving community pharmacists in hypertension 
management has also been shown to improve adherence and control rates. (72) 
This seems a sensible approach but would require careful planning with 
engagement of all stakeholders given recent controversies in both Ireland and the 
UK when plans for pharmacists to administer the flu vaccination were introduced. 
(73-75) The Pharmaceutical Society of Ireland has engaged in such a consultation 
process regarding the wider role of pharmacists in the care of patients in the Irish 
healthcare setting through the Future Pharmacy Practice Project. They are due to 
publish a report shortly which may offer a position on the future potential input of 
pharmacists into hypertension management in Ireland. (76) 
7.5. Implications for policy 
Up until now GPs in Ireland have not been reimbursed to provide ABPM in their 
general medical services (GMS) contract. Therefore the only way for patients who 
have a medical card, and are therefore entitled to free healthcare, to access ABPM 
is through referral to secondary care or out of their own pocket. For the 
approximately 60% of the population who don’t have a medical card this is also 
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how the system operates. The National Cardiovascular Health Policy 2010-2019 
document published in 2010 states that the “overall contribution of ambulatory 
blood pressure monitoring to primary care detection and management of high 
blood pressure has yet to be fully ascertained” and suggests that practices be 
encouraged to invest in the technology. (77) This is outdated given the clinical and 
cost-effectiveness evidence that now exists. (6, 78) Policy makers have responded, 
and as of May 1st 2016 GPs will be reimbursed €60 to provide ABPM to patients on 
the GMS contract. It must be acknowledged that this is a big step forward in the 
care of those with hypertension in this country. However those without a medical 
card will continue to face access and financial barriers to ABPM. This is likely to 
have consequences given results from the Irish Longitudinal Study on Ageing which 
demonstrated these people are less likely to be on anti-hypertensive medication 
compared to those with a medical card. (79)  
Other policy implications were discussed in chapter 2 such as the importance of 
investment in health information technology and incentives for data coding. 
Chronic disease registries are increasingly important in surveillance and measuring 
healthcare quality. The Spanish have successfully implemented a national ABPM 
registry. (80) An ABPM database exists in Ireland but has limited information 
outside of the raw ABPM data. Nonetheless it has been a source of important and 
fruitful research. (71, 81, 82) There are difficulties that would need to be overcome 
in order to establish a national ABPM registry in Ireland. Funding is the first obvious 
difficulty but even if funding were available the establishment of a national registry 
requires special legislation to be passed. (83) Competing interests from other 
clinical fields for their own registries will add to the difficulties. Therefore the 
establishment of a formal national ABPM clinical registry will require visionary and 
innovative leadership to drive it from a policy and clinical perspective. 
7.6. Limitations 
The limitations of each of the individual studies included in this thesis have already 
been discussed and will not be repeated. We have demonstrated an association 
between night-time blood pressure and a number of markers of target organ 
damage but we have not resolved the issue of reverse causality. I consider this to 
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be the main limitation of this work. Elevated night-time blood pressure may merely 
be a marker of more severe target organ damage rather than a cause of it. This is an 
inherent problem with cross-sectional data. While chapter 6 provides some 
prospective data the lack of ultrasound data at baseline recruitment means it is not 
possible to draw inference on the temporal relationship for the observed 
associations of night-time systolic blood pressure with GLS and carotid plaques. 
These may also have been evident at baseline had that data been available.  
7.7. Conclusion 
I believe hypertension cannot be effectively managed at the individual level without 
using ABPM. In particular night-time blood pressure offers vital prognostic 
information that can only be gleaned by using ABPM. The absolute night-time blood 
pressure level seems to be better associated with target organ damage than 
dipping and may be a better therapeutic target in future chronotherapy studies. 
Using ABPM to examine the full twenty four hour blood pressure profile is the way 
forward in guiding hypertension treatment decisions. However the results of large 
prospective studies are necessary before chronotherapy can be adopted into 
guidelines and routine clinical practice.   
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Appendix 1: Research training 
Modules for credit University College Cork 
 Advanced Epidemiology (EH6031) (10 credits) 
 Advanced Biostatistics (ST6011) (5 credits) 
 Survival Analysis (ST6012) (5 credits) 
 Systematic Reviews for the Health Sciences (PG7016) (5 credits) 
 The PhD II: From Development to Completion (PG7003) (5 credits) 
 
Other relevant training 
 Good Clinical Practice   
University College Cork, Ireland 2013, updated 2015 
 
 The International Society for Cardiovascular Disease Epidemiology and 
Prevention 46th 10 day international teaching seminar on cardiovascular 
disease epidemiology and prevention 
Mysore, India 2014 
 
 Fundamentals of Clinical Trials 
Online course from Harvard School of Public Health and Harvard Medical 
School 2013 – 2014 
 An Introduction to  Cochrane Systematic Reviews  
University College Galway, Ireland 2013 
 
 Workshop on Scientific Writing  
University College Cork, Ireland 2013 
 
 Health in Numbers: Quantitative Methods in Clinical and Public Health 
Research  
Online course from Harvard School of Public Health 2012 – 2013 
 
 “Speckle tracking imaging and analysis” Meet the experts - Advanced 
Training Course 
Leiden University Medical Centre, Leiden, The Netherlands 2013 
 
 Speckle Tracking Echocardiography training 
Leiden University Medical Centre, Leiden, The Netherlands 2012 
 
 Hands-on CIMT Training 
Amsterdam Medical Centre, The Netherlands 2012  
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 Basic Statistics for Researchers 
University of Limerick 2012 
 
 Hypertension Summer School 
European Society of Hypertension, Dublin, Ireland 2012 
 
 Carotid IMT Clinical Training Course 
University of Wisconsin Atherosclerosis Imaging Research Program Lab, USA 
2011 
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 O'Flynn AM, Curtin RJ, Perry IJ, Kearney PM. Hypertension Prevalence, 
Awareness, Treatment and Control. Should 24 hour Ambulatory Blood 
Pressure Monitoring be the Tool of Choice? Journal of Clinical Hypertension. 
2016;18(7):697-702 
 
 O'Flynn AM, Dolan E, Curtin RJ, O’Brien E, Perry IJ, Kearney PM. Night-time 
blood pressure and target organ damage: A comparative analysis of 
absolute blood pressure and dipping status. Journal of Hypertension. 
2015;33(11):2257-64. 
 
 O'Flynn AM, Madden JM, Russell AJ, Curtin RJ, Kearney PM. Isolated 
nocturnal hypertension and subclinical target organ damage: a systematic 
review of the literature. Hypertension Research. 2015;38(8):570-5 
 
Other original manuscript publications 
 O'Flynn AM, McHugh SM, Madden JM, Harrington JM, Perry IJ, Kearney PM. 
Applying the ideal cardiovascular health metrics to couples: a cross-sectional 
study in primary care. Clinical Cardiology. 2015;38(1):32-8. 
 
 Madden JM, O'Flynn AM, Fitzgerald, AP, Kearney PM. Correlation between 
Short-Term Blood Pressure Variability and Left Ventricular Mass Index: A 
Meta-Analysis. Hypertension Research. 2016;39(3):171-7 
 
 Madden JM, O'Flynn AM, Dolan E, Fitzgerald AP, Kearney PM. Short-term 
blood pressure variability over 24 h and target organ damage in middle-aged 
men and women. Journal of Human Hypertension. 2015;29(12):719-25 
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Applying the ideal cardiovascular health metrics to couples: a cross-sectional 
study in primary care. National Institute of Health Sciences Research 
Bulletin. Volume 7, Issue 3, page 21, February 2016 
 
 O’Flynn AM, Curtin RJ, Perry IJ, Kearney PM. Hypertension prevalence, 
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 O'Flynn AM, McHugh SM, Madden JM, Harrington JM, Perry IJ, Kearney PM. 
Spousal concordance for cardiovascular health in a primary care based 
sample. Irish Journal of Medical Science. Volume 183 Supplement 8: 389-
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 O'Flynn AM, Madden JM, Russell AJ, Curtin RJ, Kearney PM. Isolated 
nocturnal hypertension and subclinical target organ damage: a systematic 
review of the literature. Journal of Hypertension. 2014 Volume 32 e-
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Oral presentations 
 Applying the ideal cardiovascular health metrics to couples: a cross-sectional 
study in primary care.  
Jacqueline Horgan Bronze Medal Prize meeting, Royal College of Physicians 
of Ireland, Dublin, 2015.  
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 Night-time Blood Pressure and Subclinical Target Organ Damage: Findings 
from an Irish Primary Care Based Population Sample.  
Annual Scientific Meeting of the Association of Departments of General 
Practice in Ireland, University College Cork, 2014 
 
 Hypertension Prevalence, Awareness, Treatment and Control: The Impact of 
Ambulatory Blood Pressure Monitoring. 
Annual Scientific Meeting of the Association of Departments of General 
Practice in Ireland, University College Cork, 2014 
 
Poster presentations 
 The Association of Night-time Systolic Blood Pressure with Ultrasound 
Markers of Subclinical Cardiac and Vascular Damage. The British 
Cardiovascular Society Annual Conference, Manchester, UK, 2016. 
 
 The Association of Night-time Systolic Blood Pressure with Ultrasound 
Markers of Subclinical Cardiac and Vascular Damage. New Horizons – 
Translational Research Conference, School of Medicine, University College 
Cork. 2015. 
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sample. National Institute for Preventive Cardiology Conference, Galway, 
2015. 
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Sample. The Irish Cardiac Society, Athlone, 2014. 
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Supplemental table 3.5  Logistic regression results for night to day ratio and  target organ damage 
 ACR ≥ 1.1 mg/mmol 
Odds Ratio (95%CI) 
 
P-value 
ECG LVH 
Odds Ratio (95%CI) 
 
P-value 
     
Night to day ratio (+0.1) 1.6 (1.3 – 2.2) 0.000* 1.6 (1.2 – 2.3) 0.003* 
Partially adjusted 1.6 (1.2 – 2.1) 0.001* 1.4 (1.0 – 2.0) 0.03* 
Fully adjusted 1.0 (0.7 – 1.5) 0.8 1.1 (0.8 – 1.7) 0.6 
     
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; CI = Confidence interval;                                               
SBP = systolic blood pressure; DBP = diastolic blood pressure 
Adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
Fully adjusted =  sex, age, diabetes, anti-hypertensives, smoking, BMI  plus adjusted for absolute night-time systolic 
blood pressure 
* Statistically significant 
Supplemental table 3.6  Linear regression results for night to day ratio and  target organ damage 
 Log ACR 
Beta coefficient (95% CI) 
 
P-value 
Cornell product 
Beta coefficient (95%CI) 
 
P-value 
     
Night to day ratio (+0.1) 0.2 ( 0.1 – 0.2) 0.000* 120 (67 – 174) 0.000* 
Partially adjusted 0.1 (0.1 – 0.2) 0.000* 85 (30 – 140) 0.002* 
Fully adjusted - 0.03 (-0.1 – 0.05) 0.5 1 (-61 – 64) 1.0 
     
ACR = Albumin:creatinine ratio; CI = Confidence interval;                                               
ACR log transformed due to skewed data 
Adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
Fully adjusted =  sex, age, diabetes, anti-hypertensives, smoking, BMI  plus adjusted for absolute night-time systolic 
blood pressure 
* Statistically significant 
Variance inflation factors were calculated for the adjusted models and all values were under 1.7 indicating multi-
collinearity did not arise 
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Supplemental table 3.7  Logistic regression results for absolute blood pressure and  target organ damage in treated participants 
n=350 ACR ≥ 1.1 mg/mmol 
Odds Ratio (95%CI) 
 
P-value 
ECG LVH 
Odds Ratio (95%CI) 
 
P-value 
     
Night-time SBP (+10 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.4 (1.2 – 1.8) 
1.4 (1.1 – 1.8) 
1.5 (1.1 – 2.0) 
<0.001* 
0.002* 
0.01* 
1.3 (1.1 – 1.7) 
1.3 (1.0 – 1.7) 
1.6 (1.1 – 2.2) 
0.01* 
0.02* 
0.007* 
Night-time DBP (+5 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.2 (1.0 – 1.5) 
1.2 (1.0 – 1.5) 
1.3 (1.0 – 1.7) 
0.02* 
0.02* 
0.03* 
1.0 (0.8 – 1.2) 
1.0 (0.8 – 1.2) 
1.2 (0.9 – 1.5) 
0.8 
1.0 
0.3 
Daytime SBP (+10 mmHg) 
Adjusted 
Fully adjusted 
 
1.3 (1.0 – 1.6) 
1.3 (1.0 – 1.6) 
0.9 (0.7 – 1.3) 
0.02* 
0.06 
0.7 
1.1 (0.8 – 1.4) 
1.0 (0.8 – 1.4) 
0.7 (0.5 – 1.1) 
0.6 
0.7 
0.1 
Daytime DBP (+5mmHg) 
Adjusted 
Fully adjusted 
 
Twentyfour hour SBP (+10 mmHg) 
Adjusted 
 
Twentyfour hour DBP (+5 mmHg) 
Adjusted 
 
1.1 (0.9 – 1.3) 
1.1 (0.9 – 1.3) 
0.9 (0.7 – 1.2) 
 
1.5 (1.1 – 1.8) 
1.4 (1.1 – 1.8) 
 
1.2 (1.0 – 1.4) 
1.2 (1.0 – 1.4) 
 
0.2 
0.3 
0.5 
 
0.002* 
0.008* 
 
0.08 
0.1 
0.9 (0.7 – 1.1) 
0.9 (0.7 – 1.1) 
0.8 (0.6 – 1.1) 
 
1.2 (0.9 – 1.6) 
1.2 (0.9 – 1.6) 
 
0.9 (0.8 – 1.2) 
0.9 (0.7 – 1.2) 
0.2 
0.3 
0.1 
 
0.1 
0.2 
 
0.5 
0.6 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; CI = Confidence interval; SBP = systolic blood pressure;      
DBP = diastolic blood pressure 
Adjusted = sex, age, diabetes, smoking, BMI 
Fully adjusted =  sex, age, diabetes, smoking, BMI  plus daytime blood pressure further adjusted for night-time blood pressure 
and vice versa 
* Statistically significant 
2
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Supplemental table 3.8.  Logistic regression results for absolute blood pressure and  target organ damage in untreated participants 
n=670 ACR ≥ 1.1 mg/mmol 
Odds Ratio (95%CI) 
 
P-value 
ECG LVH 
Odds Ratio (95%CI) 
 
P-value 
     
Night-time SBP (+10 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.7 (1.4 – 2.0) 
1.6 (1.3 – 1.9) 
1.6 (1.2 – 2.1) 
<0.001* 
<0.001* 
0.002* 
1.3 (1.1 – 1.6) 
1.3 (1.0 – 1.6) 
1.2 (0.8 – 1.7) 
0.01* 
0.04* 
0.5 
Night-time DBP (+5 mmHg) 
Partially adjusted 
Fully adjusted 
 
1.4 (1.2 – 1.6) 
1.4 (1.2 – 1.6) 
1.3 (1.0 – 1.7) 
<0.001* 
<0.001* 
0.009* 
1.1 (0.9 – 1.3) 
1.1 (0.9 – 1.4) 
1.0 (0.8 – 1.4) 
0.6 
0.5 
0.8 
 
Daytime SBP (+10 mmHg) 
Adjusted 
Fully adjusted 
 
1.5 (1.3 – 1.7) 
1.4 (1.2 – 1.7) 
1.0 (0.7 – 1.3) 
<0.001* 
<0.001* 
0.9 
 
1.3 (1.0 – 1.6) 
1.3 (1.0 – 1.6) 
1.2 (0.8 – 1.7) 
0.02* 
0.04* 
0.5 
Daytime DBP (+5mmHg) 
Adjusted 
Fully adjusted 
 
Twentyfour hour SBP (+10 mmHg) 
Adjusted 
 
Twentyfour hour DBP (+5 mmHg) 
Adjusted 
 
1.3 (1.2 – 1.5) 
1.3 (1.1 – 1.5) 
1.1 (0.9 – 1.3) 
 
1.6 (1.3 – 1.9) 
1.5 (1.2 – 1.8) 
 
1.4 (1.2 – 1.6) 
1.4 (1.2 – 1.6) 
<0.001* 
0.001* 
0.6 
 
<0.001* 
<0.001* 
 
<0.001* 
<0.001* 
 
1.1 (0.9 – 1.3) 
1.1 (0.9 – 1.4) 
1.1 (0.8 – 1.5) 
 
1.3 (1.0 – 1.6) 
1.3 (1.0 – 1.7) 
 
1.1 (0.9 – 1.3) 
1.1 (0.9 – 1.4) 
0.5 
0.4 
0.6 
 
0.02* 
0.04* 
 
0.5 
0.4 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; CI = Confidence interval; SBP = systolic blood pressure;                 
DBP = diastolic blood pressure 
Adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
Fully adjusted =  sex, age, diabetes, anti-hypertensives, smoking, BMI  plus daytime blood pressure further adjusted for night-time 
blood pressure and vice versa 
* Statistically significant 2
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Supplemental table 3.9. Logistic regression results for dipping status and  target organ damage in treated participants 
n=350 ACR ≥ 1.1 mg/mmol 
 
n = 50 
ECG LVH 
 
n = 38 
ACR ≥ 1.1 mg/mmol 
 
OR (95%CI) 
 
 
P-value 
ECG LVH 
 
OR (95%CI) 
 
 
P-value 
 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
n  
22 
18 
7 
3 
n 
17 
12 
4 
5 
 
 
1 
1.7 (0.9 – 3.3) 
0.9 (0.4  - 2.3) 
2.7 (0.7 – 11.1) 
 
 
 
0.1 
0.9 
0.2 
 
1 
1.4 (0.6 – 3.0) 
0.7 (0.2 – 2.1) 
8.1 (2.2 – 29.3) 
 
 
0.4 
0.5 
0.001* 
Partially adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
1.6 (0.8 – 3.3) 
0.9 (0.4 – 2.2) 
2.6 (0.6 – 11.1) 
 
 
 
0.2 
0.8 
0.2 
 
1 
1.3 (0.6 – 2.9) 
0.7 (0.2 – 2.2) 
7.0 (1.8 – 26.8) 
 
 
 
0.6 
0.5 
0.005* 
 
Fully adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
1.2 (0.6 – 2.5) 
1.3 (0.5 – 3.3) 
1.0 (0.2 – 5.2) 
 
 
 
0.6 
0.6 
1.0 
 
 
1 
1.1 (0.5 – 2.7) 
0.8 (0.2 – 2.6) 
4.9 (1.0 – 23.3) 
 
 
 
 
0.8 
0.7 
0.046* 
 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; OR = Odds ratio; CI = Confidence interval 
Partially adjusted = sex, age, diabetes, smoking, BMI 
Fully adjusted = sex, age, diabetes, smoking, BMI  plus further adjusted for night-time systolic blood pressure 
* Statistically significant 
2
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Supplemental table 3.10. Logistic regression results for dipping status and  target organ damage in untreated participants 
n=670 ACR ≥ 1.1 mg/mmol 
 
n = 67 
ECG LVH 
 
n = 32 
ACR ≥ 1.1 mg/mmol 
 
OR (95%CI) 
 
 
P-value 
ECG LVH 
 
OR (95%CI) 
 
 
P-value 
 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
n 
42 
16 
7 
2 
  
 
n 
17 
6 
8 
1 
 
 
 
1 
1.2 (0.6 – 2.1) 
0.4 (0.2 – 0.9) 
1.6 (0.3 – 7.6) 
 
 
 
0.6 
0.02* 
0.6 
 
 
1 
1.1 (0.4 – 2.7) 
1.2 (0.5 – 2.8) 
1.9 (0.2 – 15.9) 
 
 
 
0.9 
0.7 
0.5 
 
Partially adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
1.0 (0.5 – 1.9) 
0.4 (0.2 – 0.8) 
1.4 (0.3 – 6.8) 
 
 
 
1.0 
0.02* 
0.7 
 
 
1 
0.8 (0.3 – 2.3) 
1.1 (0.4 – 2.7) 
1.5 (0.2 – 13.5) 
 
 
0.7 
0.9 
0.7 
Fully adjusted 
Dippers 
Non-dippers 
Extreme dippers 
Reverse dippers 
 
   
1 
0.8 (0.4 – 1.5) 
0.5 (0.2 – 1.1) 
0.5 (0.1 – 2.9) 
 
 
0.4 
0.1 
0.4 
 
 
 
1 
0.6 (0.2 – 1.8) 
1.4 (0.5 – 3.5) 
0.7 (0.1 – 7.1) 
 
 
 
 
0.4 
0.5 
0.8 
 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; OR = Odds ratio; CI = Confidence interval 
Partially adjusted = sex, age, diabetes, smoking, BMI 
Fully adjusted = sex, age, diabetes, smoking, BMI  plus further adjusted for night-time systolic blood pressure 
* Statistically significant 
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Supplemental table 3.11.  Logistic regression results for pulse pressure and  target organ damage  
n=1046 ACR ≥ 1.1 mg/mmol 
Odds Ratio (95%CI) 
 
P-value 
ECG LVH 
Odds Ratio (95%CI) 
 
P-value 
     
Night-time Pulse Pressure (+10 mmHg) 1.7 (1.4 – 2.0) <0.001* 1.7 (1.4 – 2.1) <0.001* 
Adjusted 1.6 (1.3 – 1.9) <0.001* 1.6 (1.3 – 2.1) <0.001* 
     
Daytime Pulse Pressure (+10 mmHg) 1.4 (1.2 – 1.7) <0.001* 1.5 (1.2 – 1.8) <0.001* 
Adjusted 1.3 (1.1 – 1.6) 0.006* 1.3 (1.0 – 1.7) 0.02* 
ACR = Albumin:creatinine ratio; LVH = Left ventricular hypertrophy; CI = Confidence interval; SBP = systolic blood pressure; DBP 
= diastolic blood pressure 
Adjusted = sex, age, diabetes, anti-hypertensives, smoking, BMI 
* Statistically significant 
2
1
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Appendix 4: Systematic review search strategy 
MOOSE checklist for search strategy 
 
Qualifications of searchers 
Dr. AnneMarie O’Flynn and Mr. Jamie Madden have both received training in 
systematic review methods. They both completed module PG7016 “Systematic 
Reviews for the Health Sciences” in University College Cork. Dr. O’Flynn has also 
completed the Health Research Board Cochrane course “An introduction to 
systematic reviews, the Cochrane Collaboration and the Cochrane Library”. Search 
methodology was discussed with Mr. Cathal Kerrigan, Therapies & Basic Sciences 
for Medicine Librarian, Boston Scientific Health Sciences Library, University College 
Cork. 
Search strategy 
Three medical literature databases were searched in March 2014. No filter was 
applied to the publication dates. The following search terms, combined using ‘AND’ 
or ‘OR’ according to the principles of Boolean logic, were used as text words and/or 
MESH terms: 
Circadian Rhythm [MeSH Major Topic] 
Blood Pressure Monitoring,  Ambulatory [MeSH Major Topic] 
hypertension  
(isolated OR masked) AND (nocturnal OR 'night-time' OR nighttime OR 'night time') 
AND hypertension 
(end OR target) AND organ AND (damage OR disease) 
microalbuminuria 
left AND ventricular AND hypertrophy 
left AND ventricular AND mass 
electrocardio* 
echocardio* 
arterial AND stiffness 
augmentation AND index 
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pulse AND wave AND velocity 
carotid AND ultrasound 
carotid AND intima AND media AND thickness 
cimt 
asymptomatic AND carotid AND stenosis 
ankle AND brachial AND index 
flow AND mediated AND dilat* 
endothelial AND dysfunction 
magnetic AND resonance AND imaging 
computed AND tomography 
mri 
ct 
white AND matter AND hyperintensities 
white AND matter AND lesions 
retinopathy 
retinal AND photography 
coronary AND calcium AND score 
 
These terms were further combined as follows: 
(((((isolated OR masked) AND (nocturnal OR night-time OR nighttime OR night time) 
AND hypertension)) OR (((Hypertension) AND "Blood Pressure Monitoring, 
Ambulatory") AND "Circadian Rhythm"))) AND (((((((((((((((((((((microalbuminuria) 
OR (Left AND ventricular AND hypertrophy)) OR (Left AND ventricular AND mass)) 
OR electrocardio*) OR echocardio*) OR (arterial AND stiffness)) OR (augmentation 
AND index)) OR (Pulse AND wave AND velocity)) OR (carotid AND ultrasound)) OR 
(carotid AND intima AND media AND thickness)) OR CIMT) OR (asymptomatic AND 
carotid AND stenosis)) OR (ankle AND brachial AND index)) OR (flow AND mediated 
AND dila*)) OR (endothelial AND dysfunction)) OR (((((((magnetic AND resonance 
AND imaging)) OR (computed AND tomography)) OR MRI) OR CT)) AND (((white 
AND matter AND hyperintensities)) OR (white AND matter AND lesions)))) OR 
retinopathy) OR (retinal AND photography)) OR (Coronary AND calcium AND 
score))) OR ((end OR target) AND organ AND (damage OR disease))) 
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We developed the search strategy for PubMed and adapted it for use in the other 
databases. 
Effort to include all available studies 
Studies in all languages were included 
Databases searched 
PubMed 109 titles identified (10 potentially relevant)  
EMBASE  813 titles identified (8 potentially relevant) 
Cochrane Library  32 identified (0 relevant) 
Search engine and reference manager 
Google Chrome was the web browser used to search the databases and potentially 
relevant studies were imported into the Endnote reference management software 
package.  
Use of hand searching 
The references of the included studies and those of reviews on the subject were 
examined for further potentially relevant studies. 
 
List of citations included and excluded 
Included: 
1. Li Y, Staessen JA, Lu L, Li L-H, Wang G-L, Wang J-G. Is Isolated Nocturnal 
Hypertension a Novel Clinical Entity?: Findings From a Chinese Population 
Study. Hypertension. 2007 August 1, 2007;50(2):333-9.  
 
2. Lu L, Li Y, Huang QF. [The relationship between isolated nocturnal 
hypertension and left ventricular hypertrophy]. Zhonghua nei ke za zhi 
[Chinese journal of internal medicine]. 2008 Oct;47(10):819-22. 
 
217 
3. Wijkman M, Länne T, Engvall J, Lindström T, Östgren CJ, Nystrom FH. 
Masked nocturnal hypertension—a novel marker of risk in type 2 diabetes. 
Diabetologia. 2009 2009/07/01;52(7):1258-64. 
 
4. Ogedegbe G, Spruill TM, Sarpong DF, Agyemang C, Chaplin W, Pastva A, et 
al. Correlates of Isolated Nocturnal Hypertension and Target Organ Damage 
in a Population-Based Cohort of African Americans: The Jackson Heart 
Study. Am J Hypertens. 2013 May 15. Epub 2013/05/17.  
Excluded: 
1. Endothelial-dependent flow-mediated dilation in African Americans with 
masked-hypertension. Veerabhadrappa P, Diaz KM, Feairheller DL, Sturgeon 
KM, Williamson ST, Crabbe DL, Kashem AM, Brown MD. Am J Hypertens. 
2011 Oct;24(10):1102-7 
Reason excluded:  
Didn’t assess isolated nocturnal hypertension (day and night masked hypertension 
assessed together) 
2. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, et al. Prognostic value 
of isolated nocturnal hypertension on ambulatory measurement in 8711 
individuals from 10 populations. Journal of hypertension. 2010 
Oct;28(10):2036-45.  
Reason excluded:  
Examined hard cardiovascular endpoints 
3.  Epidemiology, pathophysiology, and prognosis of isolated night - time 
hypertension. Wang J.-G. Journal of Hypertension 2012 30 SUPPL. 1 (e17) 
Reason excluded:  
Conference abstract including duplicate analysis of Chinese population 
4.  The effect of isolated masked nocturnal hypertension on arterial stiffness. 
Bakalakou E, Kyfnidis K, Kallistratos E, Tsoukas A, Hamondraka E, 
Zacharopoulou I, Kouremenos N, Chiotelis I, Koukouzeli A, Manolis A. 
European Heart Journal 2013 34 SUPPL. 1 (1050) 
218 
Reason excluded:  
Conference abstract didn’t assess isolated nocturnal hypertension (Defined masked 
nocturnal hypertension) 
5.  Night - time hypertension and target organ damage in never treated 
patients. Kyvelou S., Vyssouli G., Karpanou E., Gialernios T., Tzamou V., 
Lampropoulos K., Adamopoulos D. Stefanadis C. Journal of Hypertension 
2010 28 SUPPL. A (e81) 
Reason excluded:  
Conference abstract without a normotensive comparison group 
6.  Li LH, Li Y, Huang QF, Sheng CS, Staessen JA, Wang JG.Isolated nocturnal 
hypertension and arterial stiffness in a Chinese population. Blood Press 
Monit. 2008 Jun;13(3):157-9. 
Reason excluded:  
Duplicate study 
7.  Masked hypertension, nocturnal blood pressure and retinopathy in 
normotensive patients with type 1 diabetes. Rodrigues TC, Canani LH, 
Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Diabetes Res Clin Pract. 
2010 Feb;87(2):240-5. 
Reason excluded:  
Didn’t assess isolated nocturnal hypertension (Defined masked nocturnal 
hypertension) 
8.  Masked nocturnal hypertension and target organ damage in hypertensives 
with well-controlled self-measured home blood pressure. Hoshide S, 
Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Hypertens Res. 2007 
Feb;30(2):143-9. 
Reason excluded:  
Didn’t assess isolated nocturnal hypertension (Defined masked nocturnal 
hypertension) 
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9.  Kawano Y, Horio T, Matayoshi T, Kamide K. Masked hypertension: subtypes 
and target organ damage. Clin Exp Hypertens. 2008 Apr;30(3):289-96.  
Reason excluded:  
Review article 
Articles published in languages other than English 
The authors of the included non-English article were contacted for an English 
version. This was not available. The article was translated with an online translation 
programme and this was checked with a native Chinese speaker. 
Abstracts and unpublished studies 
Proceedings papers were considered for inclusion but none met the inclusion 
criteria for the final narrative review. 
Contact with authors 
The authors of the Lu et al article were contacted for an English version. This was 
not available. We also contacted the authors of the Wijkman et al study for further 
descriptive information on the isolated nocturnal hypertension group but this was 
also unavailable.  
Updated search February 2016 
An updated search was carried out on the 22nd of February 2016. Four new 
potential titles were identified. The abstracts of these were reviewed and 
compared to the inclusion criteria. One was excluded as it was a review article. The 
other 3 abstracts were proceedings papers. These were also excluded. One 
assessed isolated nocturnal hypertension in children attending paediatric 
nephrology units and was therefore not population based. One assessed nocturnal 
hypertension not isolated nocturnal hypertension. The source population for the 
final study wasn’t evident from the abstract. An attempt to contact the author to 
clarify this was unsuccessful. The study was therefore also excluded.  
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List of citations excluded February 2016 
Excluded 
1. Isolated nocturnal hypertension is associated with increased pulse wave 
velocity and carotid intima-media thickness in children with chronic kidney 
disease (CKD): Results from the 4C study. Duzova A., Doyon A., Kirchner M., 
Kracht D., Zeller R., Bayazit A.K., Sozeri B., Canpolat N., Karagoz T., Deveci 
M., Niemirska A., Erdem S., Kassai B., Candan C., Simonetti G., Melk A., 
Querfeld U., Schaefer F., Wühl E. Pediatric Nephrology 2015 30:9 (1552-
1553) 
Reason excluded:  
Assessed isolated nocturnal hypertension in children attending paediatric 
nephrology units and was therefore not population based. 
2.  Serum cystatin-C as a marker for left ventricular hypertrophy in isolated 
nocturnal hypertension. Androulakis E., Papageorgiou N., Chatzistamatiou 
E., Latsios G., Tsioufis C., Papaioannou S., Brili S., Antoniades C., Kallikazaros 
I., Tousoulis D. European Heart Journal 2015 36 SUPPL. 1 (675-676) 
Reason excluded:  
Source population not clear.  
3.  Correlates of isolated nocturnal hypertension and target organ damage in 
untreated hypertension. Androulakis E., Tousoulis D., Chatzistamatiou E., 
Papageorgiou N., Moustakas G., Hatzis G., Toutouzas K., Synetos A., 
Kallikazaros I., Stefanadis C. European Heart Journal 2014 35 SUPPL. 1 (31) 
Reason excluded:  
Assessed nocturnal hypertension not isolated nocturnal hypertension 
4.  Isolated nocturnal hypertension - a new clinical entity identified from 
ambulatory blood pressure monitoring. Dukát A., Mistríková L., Baláž D., 
Sabaka P., Čelovská D., Gavorník P., Gašpar L. Interni Medicina pro Praxi 
2014 16:4 (141-144) 
Reason excluded:  
Review article 
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Appendix 5: Participant information leaflet and consent form 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL 
Section A 
Protocol Number:                   Patient Name:   
 
Title of Protocol: Hypertension to Cardiovascular Disease, Can We Map the Course 
and Prevent the End-points? 
 
Doctor(s) Directing Research: Dr. AnneMarie O’Flynn  Phone: (021 
4205537) 
 
You are being asked to participate in a research study.  The doctors at University 
College Cork study the nature of disease and attempt to develop improved 
methods of diagnosis and treatment.  In order to decide whether or not you want 
to be a part of this research study, you should understand enough about its risks 
and benefits to make an informed judgment.  This process is known as informed 
consent.  This consent form gives detailed information about the research study, 
which will be discussed with you.  Once you understand the study, you will be 
asked to sign this form if you wish to participate. 
 
Section B 
I. NATURE AND DURATION OF PROCEDURE(S): 
As part of this study you will have an ultrasound scan of your carotid arteries. 
You have one carotid artery on each side of your neck. This is a painless, non-
invasive diagnostic test that uses low-power, high-frequency sound waves 
which come from an ultrasound probe through the neck and are then reflected 
back to form an image of the blood vessels. The images will be used to measure 
the thickness of the vessel wall and to check for the presence of any significant 
narrowing of the blood vessels. For the scan you will be asked to lie on a couch 
and you will have to move your head from left to right depending on which side 
is being imaged. Cold gel will be applied to the skin and the ultrasound probe 
will be moved up and down over the neck. The scan will take approximately 40 
minutes to complete. 
As part of this study you will also have an echocardiogram. This is similar to a 
carotid ultrasound scan except the sound waves are transmitted to the heart 
through the chest wall and are then reflected back to form an image of the 
heart. The images will be used to analyse the function of the heart muscle. For 
the scan you will have to lie at an angle on your side and your chest area will be 
exposed. Cold gel will be applied to the skin and the ultrasound probe will be 
moved up and down over the chest. The scan will take approximately 40 
minutes to complete.  
We may also ask you to have a 24 hour blood pressure monitor. You will already 
have had one of these when you were first seen for the Cork and Kerry Phase II 
Study (now known as the Mitchelstown Study). Similar to the last time a cuff 
will be placed on your arm which will be connected to a small box. You will be 
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asked to wear this for 24 hours. The cuff will blow up at regular intervals 
throughout the day and night to measure your blood pressure. You will also be 
asked to complete a questionnaire on your usual sleep quality and to keep a 
record of activities and sleep times while you wear the monitor.   
II. POTENTIAL RISKS AND BENEFITS: 
 There is little risk involved in an ultrasound scan. You will have to lie as 
instructed for the scan. There is a possibility that a significant abnormality may 
be detected. If this were to happen an appointment with a specialist will be 
arranged for you. The purpose of the scans is to check for early changes in your 
blood vessels and heart. Your results will be looked at with many others for an 
association with certain blood pressure patterns. If an association is identified it 
may allow doctors to identify people who may be at higher risk of developing 
heart disease and strokes in the future and treat them to prevent these events. 
You may find that the blood pressure cuff is uncomfortable and may cause you 
to have difficulty sleeping as it will blow up at intervals during the night also. 
III. POSSIBLE ALTERNATIVES: 
 You may choose not to participate. 
 
Section C                                                                    AGREEMENT TO CONSENT 
 
 The research project and the treatment procedures associated with it have 
been fully explained to me. All experimental procedures have been identified and 
no guarantee has been given about the possible results.  I have had the opportunity 
to ask questions concerning any and all aspects of the project and any procedures 
involved.  I am aware that participation is voluntary and that I may withdraw my 
consent at any time.  I am aware that my decision not to participate or to withdraw 
will not restrict my access to health care services normally available to me.  
Confidentiality of records concerning my involvement in this project will be 
maintained in an appropriate manner.  When required by law, the records of this 
research may be reviewed by government agencies and sponsors of the research. 
 I understand that the sponsors and investigators have such insurance as is 
required by law in the event of injury resulting from this research. 
 I, the undersigned, hereby consent to participate as a subject in the above 
described project conducted at the Cork Teaching Hospitals. I have received a copy 
of this consent form for my records.  I understand that if I have any questions 
concerning this research, I can contact the doctor(s) listed above. If I have further 
queries concerning my rights in connection with the research, I can contact the 
Clinical Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 
Little Hanover Street, Cork. 
 After reading the entire consent form, if you have no further questions 
about giving consent, please sign where indicated. 
 
Signature of Doctor:  _________________________________________________ 
Signature of Subject: __________________________________________________                                            
Date:                             Time:            
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Appendix 6: Short report on the reproducibility of nocturnal 
blood pressure profiles 
Background: 
The limited reproducibility of night-time blood pressure patterns is recognised (1) 
and it has been suggested that using absolute blood pressure categories rather than 
dipping status may be more reproducible. (2) However, this approach is also limited 
with just one third of those with isolated nocturnal hypertension retaining this 
pattern after 2 to 4 years in one small study. (3) This was again examined more 
recently with similar findings. (4) We therefore sought to establish the 
reproducibility of nocturnal blood pressure profiles in participants of the 
Mitchelstown Cohort Study. 
 
Methods: 
Baseline ABPM measurements were performed using the MEDITECH ABPM-05 in 
2010 and data was stored using the dabl ABPM system. The monitors were 
programmed to record the blood pressure every 30 minutes throughout the 24 
hour period. Participants kept a diary of the times they went to bed and got up. 
Diary times were used to calculate mean daytime and night-time blood pressures. 
Mean 24 hour blood pressure was calculated as the mean of all the readings 
throughout the 24 four hour period.  
Follow-up ABPM measurements were performed in 2014 using the Spacelabs 90217 
monitor. Measurements were performed every 30 minutes throughout the day and 
night. Data was stored using the Spacelabs 92506 Ambulatory Blood Pressure 
Report Management System software. Participants kept a diary of the times they 
went to bed and got up. Diary times were used to calculate mean daytime and 
night-time blood pressures. Mean 24 hour blood pressure was calculated as the 
mean of all the readings throughout the 24 four hour period. 
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Night-time ambulatory blood pressure was categorised by dipping status as follows: 
(1) Dipping pattern: 10 to 20% fall in night-time systolic blood pressure  
(2) Non-dipping pattern: < 10% fall in night-time systolic blood pressure  
(3)  Extreme dipping pattern: > 20% fall in night-time systolic blood pressure  
(4)  Reverse dipping pattern: Rise in night-time systolic blood pressure 
 
Ambulatory blood pressure was also categorised based on the absolute blood 
pressure levels into 4 groups: 
(1) Normotension: Daytime blood pressure < 135/85 mmHg and night-time blood 
pressure < 120/70 mmHg 
(2) Isolated daytime hypertension: Daytime blood pressure ≥ 135/85 mmHg and 
night-time blood pressure < 120/70 mmHg 
(3) Isolated nocturnal hypertension: Daytime blood pressure < 135/85 mmHg and 
night-time blood pressure ≥ 120/70 mmHg 
(4) Sustained day-night hypertension: Daytime blood pressure ≥ 135/85 mmHg and 
night-time blood pressure ≥ 120/70 mmHg 
 
Mean blood pressures for 2010 and 2014 were compared using a paired t-test. The 
reproducibility of night-time dipping status and absolute blood pressure patterns 
were assessed using Cohen’s kappa statistic. (5) 
 
Results: 
Fifty individuals took part in this study. We excluded 3 studies from the analysis due 
to incomplete follow-up ABPM data. Mean daytime blood pressure was 129/77 
mmHg and mean night-time blood pressure was 114/66 mmHg on follow-up ABPM. 
Overall mean blood pressures were similar in 2010 and 2014. Table 1. The 
reproducibility of blood pressure profiles categorised by dipping status was low at 
24% with a kappa statistic of -0.11 (p = 0. 89) while reproducibility based on 
categorisation by absolute blood pressure was fair at 40% with a kappa statistic of 
0.21 (p < 0.005). Tables 2 and 3. 
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Table 1. Blood pressure levels 2010 v 2014 
N =47 2010 
Mean+/-SD 
2014 
Mean+/-SD 
  
p-value 
Daytime systolic, mmHg 133+/-12 129+/-14 0.05 
Daytime diastolic, mmHg 79+/-9 77+/-8 0.2 
Night-time systolic, mmHg 117+/-15 114+/-17 0.1 
Night-time diastolic, mmHg 66+/-9 66+/-9 0.9 
Twenty four systolic, mmHg 127+/-11 123+/-14 0.05 
Twenty four diastolic, mmHg 74+/-8 73+/-8 0.3 
3 follow-up ABPM results excluded due to incomplete data 
 
Table 2. Dipping status 2010 v 2014 
N = 47 2014 
2010 Dippers Non-dippers Extreme dippers Reverse dippers Total 
Dippers  5 11 5 1 22 
Non-dippers 8 3 2 2 15 
Extreme dippers 2 3 1 0 6 
Reverse dippers 1 1 0 2 4 
Total 15 18 8 5 47 
kappa statistic = -0.11 (p = 0. 89) 
 
Discussion: 
Our findings demonstrates the limited reproducibility of night-time blood pressure 
profiles with poor reproducibility of dipping status and only fair reproducibility of 
absolute blood pressure categories despite overall similar mean blood pressures. 
The use of antihypertensive medications increased between 2010 and 2014 from 
42% (n = 21) to 61% (n = 30) which may have impacted these results. However 
when those not on medication were analysed separately the kappa statistics were -
0.2 (p = 0.9) for dipping status and 0.43 (p < 0.001) for absolute blood pressure 
Table 3. Blood pressure categories 2010 v 2014 
2010 Normotension Isolated 
daytime 
hypertension 
Isolated 
nocturnal 
hypertension 
Day/night 
hypertension 
Total 
Normotension 
 
9 0 1 0 10 
Isolated daytime 
hypertension 
4 3 1 6 14 
Isolated nocturnal 
hypertension 
7 0 4 1 12 
Day/night 
hypertension 
4 2 2 3 11 
Total 24 5 8 10 47 
kappa statistic = 0.21 (p < 0.005) 
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categories. Blood pressure is a continuous risk factor. (6) Thresholds define the 
levels where investigation and treatment have more benefit than harm, (7) and for 
this reason are important but clinicians and public health professionals need to 
recognise the limitations of thresholds and that significant numbers of events occur 
in those below definitions of normal. (8) 
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